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Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability among 
elderly. It is a multicomponent chronic disease and yet little is known about the role of ligaments 
in OA. Ligaments are the main mechanical stabilizers of the knee joint, and trauma of the ligament 
has been closely linked to OA making it a potential target for therapeutics. Cellular, matrix and 
mechanical pathology of the ligament have not been fully characterised in OA. Furthermore, 
ligament cellular complexity remains poorly understood, including identification of ligament cell 
populations and markers in healthy, non-diseased tissue. Understanding the healthy ligament is 
essential to understand the pathology of diseased OA ligaments. 
The goal of this thesis was to characterise and identify markers and mechanical properties in the 
ligaments in healthy and diseased spontaneous and post-traumatic OA murine models. Histology 
demonstrated changes in anterior cruciate ligament (ACL) and the medial collateral ligament 
(MCL) organization and cell morphology between healthy and OA ligaments. In the extracellular 
matrix (ECM) of diseased ligaments, pathology included proteoglycan and collagen type II 
(COL2) deposition. ECM pathology coincided with rounded-cell morphology and SOX9 and 
RUNX2 expression, markers of chondrogenesis, and potentially endochondral ossification. 
Changes occurred in the early stages of OA, suggesting an important role of ligaments in OA. 
Functional changes to the mechanical properties of the ligaments were explored in healthy and 
diseased OA models. Viscoelastic behaviour demonstrated a decrease in normalised strain rate 
sensitivity in both the spontaneous and post-traumatic OA ACLs. Furthermore, there was a 
decrease in stiffness and stress-relaxation in the post-traumatic OA ACL. These findings confirm 
that ligament ECM composition and viscoelastic properties are closely interrelated. 
Understanding the underlying pathways driving viscoelastic properties is imperative for OA. 
Single-cell RNA-sequencing (scRNA-seq) identified ligament cell populations and gene markers 
from healthy adult mice knee ligaments. Analysis revealed 20 distinct clusters and nine cell types, 
from which there were five fibroblast clusters. Most importantly, the smallest fibroblast cluster, 
included Aggrecan (Acan) as well as Sox9 and Col2a1 gene markers previously seen in diseased 
OA ligaments. ACAN-expressing fibroblasts were confirmed in the mid-ligament section of 
murine cruciate ligaments. The role of this novel fibroblast subpopulation in OA is unknown. 
This research introduces a deeper understanding of healthy and OA ligament, including cellular 
and fibroblast markers, ECM composition and viscoelastic properties, all which indicate that 
ligaments play a bigger role in OA than previously thought. 
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1.1 The human knee joint and ligament function 
The human tibiofemoral knee joint is a complex hinge joint made up of soft and hard connective 
tissues including bones, cartilage, menisci, ligaments, tendons, muscles and the joint capsule, each 
with their own function necessary for movement [1]. The knee is the largest joint in the human 
body, connecting the thigh bone (femur) and shin bone (tibia) [1]. The bones are maintained in 
place and stabilised by four main ligaments: the anterior cruciate ligament (ACL), the posterior 
cruciate ligament (PCL), the medial collateral ligament (MCL) and the lateral collateral ligament 
(LCL) (Figure 1.1A) [2]. In the knee joint, the ends of the bone are made up of articular cartilage 
which create a smooth protective surface [1]. Within the femorotibial joint, crescent-shaped 
menisci (lateral and medial) are found (Figure 1.1B). Menisci are fibrocartilaginous and act as 
shock absorber and stabilisers [3, 4] and are attached to the tibial surface by meniscotibial 
ligaments (Figure 1.2) [2]. In addition, the entire knee joint is surrounded by a joint capsule 
(Figure 1.1B) lined by a synovial membrane and filled with synovial fluid, which reduces friction 
and acts as a transport medium [4, 5]. Lastly, tendons link bone to muscle, providing further 
stability necessary for knee movement and gait [1]. These tissues are highly interconnected and 
together makeup the knee joint organ [6]. 
 
 
Figure 1.1 Anatomy of the human knee joint.  (A) Human knee joint are stabilised by four major ligaments, mainly the 
anterior (black arrow) and posterior cruciate ligaments (orange arrow) and the medial (green arrow) and lateral 
collateral ligaments (purple arrow). (B) Schematic of a sagittal cross-section of the knee joint organ showing the femur 
(F), tibia (T), patellar (P), synovial fluid (SF), Hoffa’s fat pad (H), anterior cruciate ligament (ACL), meniscus (M), 
posterior cruciate ligament (PCL) and synovial membrane (green). Figure B was taken from Schulze-Tanzil et al. [4]. 
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Ligaments have a unique biomechanical function in the knee joint being necessary for normal 
knee motion and homeostasis [2]. They are made up of dense connective tissue linking one bone 
to another, providing mechanical support and ensuring knee stability [2]. The ACL connects the 
lateral condyle of the femur to the medial side of the tibial intercondylar area (Figure 1.2A-B) [7] 
providing restraining force to anterior tibial displacement, preventing hyperextension [8, 9]. The 
PCL connects the posterior lateral aspect of the intercondylar area of the tibia to the medial 
condyle of the femur (Figure 1.2A-B), limiting posterior tibial displacement [10]. The cruciate 
ligaments are intra-articular and extra-synovial in humans [7]. The collateral ligaments are extra-
articular but also guide knee stability. The MCL runs along the medial side of the knee (Figure 
1.1A), providing static restraint to valgus stress (outward stress) [11]. Similarly, the LCL on the 
lateral side of the knee (Figure 1.1A) provides static restraint to varus stress (inward stress) [12].  
 
 
Figure 1.2 Anatomy of the human knee joint ligaments.  (A) Axial schematic of the human knee joint and the 
intraarticular meniscotibial ligaments: cartilage (C), anterior cruciate ligament (ACL), posterior cruciate ligament 
(PCL), medial collateral ligament (MCL), medial meniscus (MM), lateral meniscus (LM), anterior and posterior 
meniscotibial ligament (AMTL and PMTL), patellar ligament (PL), fibular head (FH), transverse genicular ligament 
(TGL) and joint capsule (JC). (B) Axial gross anatomy of the human knee joint and intraarticular ligaments. Figure 
taken from Schulze-Tanzil et al. [4]. 
 
1.2 Murine knee joint and murine models 
The anatomy of the murine knee joint is similar to that of the human knee joint [13]. The gross 
anatomy of the ACL, PCL, MCL and LCL orientation, location and insertion sites in the murine 
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knee joint is analogous to that of the human [13], suggesting similar functions to the human knee 
joint. However, the major difference is in the small size of the murine knee joint, as well as 
differences in the gait (quadruped) and mechanical distribution of the weight bearing forces [14]. 
These differences result in alterations of the mechanical function of the ligaments: the ACL of the 
murine models is the strongest knee joint ligament [13], however in humans, studies have shown 
that the PCL has higher tensile strength than the ACL [15]. Microanatomical structures of the 
murine ligaments are also similar to the human ligaments, including a fibrocartilaginous layer 
near the enthesis, aligned fibre structure, capillaries and an epiligament layer [13]. There is 
currently no literature on whether the murine cruciate ligaments are extra-synovial, however they 
are extra-synovial in the canine quadrupedal knee joint [16]. Other anatomical differences in the 
murine knee joints include thinner articular cartilage, which lack transitional and superficial 
cartilage layers compared to human articular cartilage [17]. The distinction in mechanical forces 
and cartilage thickness are important to consider in development of translational research. 
However, murine models still offer valuable advantages for testing, including the ability to assess 
disease progression at multiple time points, therapeutic interventions with a rapid outcome 
assessment and the ability to replicate consistent and repeatable injuries not possible in human 
research. Furthermore, several murine models show evidence of similar disease pathology to 
humans such as the murine STR/ort spontaneous osteoarthritis (OA) model [18], which offer a 
comparable model for the study of human knee ligament biology and translational medicine. 
 
1.3 Ligament structure and composition 
Each ligament has a distinct role and composition to match its mechanical function [19, 20], 
however they share a similar underlying matrix organisation [2]. Ligaments are composed of 
dense collagenous fibres aligned in parallel, which give them high tensile strength and facilitate 
their mechanical function [2, 21, 22]. These fibres are made up predominantly of extracellular 
material and dispersed fibroblasts [23]. The composition of the ligament ECM is two-thirds water 
and one-third dry weight [2, 23]. The dry content is primarily collagen, which makes up about 
75% of the composition [23]. Collagen type I is the main collagen type in all ligaments, making 
up over 85% of all collagen content, being slightly less than that found in tendons (~95%) [2, 23]. 
The other collagen types present in ligament are types III, V, VI, XI, and XIV [2, 24]. The exact 
amounts and arrangement will depend on the ligament [19, 20]. For example, in adult rabbits both 
cruciate ligaments are composed of 12% collagen type III from the total collagen content [25], 
18 
 
but in the adult rabbit MCLs only 5% of the total collagen is collagen type III [26]. For comparison 
in human ACLs, approximately 11-14% of total collagen content is collagen type III [27], much 
higher than the amount of collagen type III found in tendons [20]. 
The rest of the ligament ECM consists of smaller component such as proteoglycans, elastin, and 
glycolipids, each important in maintaining ligament function [2, 28]. Two groups of proteoglycans 
have been demonstrated in ligaments and tendons, mainly small leucine-rich proteoglycans 
(SLRPs) such as decorin, biglycan, fibromodulin, and lumican, and modular proteoglycans such 
as aggrecan (ACAN) and versican [29]. Modular proteoglycans such as ACAN improve water 
retention and enhance resistance to high compressive and tensile forces and are found mainly in 
the fibrocartilaginous enthesis region [30]. SLRPs, interact with the ECM and growth factors, and 
consequently play a crucial role in collagen fibrillogenesis during development [29]. Elastin 
contributes to mechanical properties of the ligament as it enhances resistance to transverse and 
shear loading [28]. A high amount of elastin (9.86% dry weight) has been reported in canine 
cruciate ligaments [31]. In contrast, in human MCLs elastin content is estimated at about 5% dry 
weight [28]. Furthermore, elastin and glycosaminoglycans (GAGs) (a component of 
proteoglycans), were more prominent in the canine ACL than in the MCL and tendons [20], 
highlighting important compositional differences between each ligament and tendon. 
Ligaments have structured subcomponents with a high degree of organisation which make up part 
of a complex hierarchical structure (Figure 1.3). At the core of the ligament structure are the 
collagen molecules composed of three left-handed helical alpha chains (Figure 1.3) [21, 32]. 
These collagen molecules are first synthesised in the form of procollagen and are modified in the 
ECM to form collagen microfibrils. Collagen microfibrils and elastin fibres are surrounded by a 
proteoglycan-water matrix, and the microfibrils are then further arranged through crosslinking 
into fibrils, fibres, fascicles and eventually the ligament/tendon unit (Figure 1.3) [2, 23]. Each 
fascicle is surrounded by connective tissue called the endoligament, and the entire ligament unit 
is enveloped by a more vascular connective tissue layer called the epiligament (Figure 1.3) [33]. 
This hierarchical structure and the intermolecular crosslinking between subunits is integral for the 





Figure 1.3 Ligament hierarchical structure.  Knee ligaments are composed of dense connective tissue with a complex 
hierarchical structure made up of fascicles, fibres, fibrils, and collagen. The main cell types, fibroblasts, are dispersed 
in the ligament matrix and in the outer vascular epiligament layer. Figure based on diagram from kastelic et al. [34]. 
 
The vasculature of ligaments provides essential nutrients and sensory information in an otherwise 
avascular fibrous connective tissue [35, 36]. The outer epiligament layer (Figure 1.3) is highly 
vascular, and in the human ACL its blood supply arrives from the middle genicular artery [33]. 
Human cruciate ligaments are also surrounded by a synovial fold from which blood vessels also 
penetrate the ligament and connect to the intraligamentous  vascular network [35]. Vascularisation 
is particularly important after ligament trauma, and in fact a lack of vascular response has been 
associated with the poor healing potential of the ACL [37]. 
Innervation of the interfascicular area of the ligament facilitates the joint and limb’s 
proprioceptive functions [38]. Sensory neurons include myelinated and unmyelinated nerves with 
articular nerve endings including free nerve endings for nociception, and mechanoreceptors such 
as Pacinian corpuscles, Golgi tendon organs, and Ruffini endings [38]. In the knee joint, these 
nerve endings can activate muscle reflexes to prevent joint distraction, reduce stress on the 
ligament and reduce build-up of force [39]. Some mechanoreceptors, such as the Pacinian 
corpuscles and the Golgi tendon organs are not found in the MCL, but are found in the ACL and 
LCL of rabbits [40]. In addition, mechanoreceptors are present in greater numbers in the ACL and 
PCL compared to the MCL and the patellar tendon [40]. The PCL in particular plays a major role 
in the sensory function of the knee joint [41]. 
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In summary, ligaments are composed of a highly dense but organised ECM with a hierarchical 
structure, which consists of a collagen molecular core which are bundled into fibre, fibrils and 
fascicles interspersed with proteoglycans, elastin and a vascular and nerve network [2]. In 
addition, ligament composition varies slightly among each ligaments due to its specific function 
[20]. This complex ECM structure and composition is maintained by the native ligament 
fibroblasts called ligamentocytes [2]. Several studies have tried to identify these cells by studying 
their cellular origin and markers during development which are outlined in Section 1.4. 
 
1.4 Ligament development and cellular markers 
The complex architectural framework of the ligament is synthesised and maintained by the 
connective-tissue cell family [42]. In ligaments, this includes mainly a type of fibroblast, called 
ligamentocytes [2], which are not well characterised. Ligamentocytes are found in the fascicles, 
the endoligament and the epiligament, and are highly organised and aligned to the thick fibres of 
collagen [25, 43]. Ligamentocytes communicate with neighbouring cells via gap junctions [44] 
and potentially also via prominent cytoplasmic extensions [2]. Other cell types found in ligaments 
include the fibrocartilaginous cells in the attachment sites, known as the enthesis [43]. These 
attachment sites are composed of a partially mineralised region, and chondrocyte-like cells with 
round cell morphology [45]. Ligament-derived stem cells have also been identified in intra-
articular ligaments [46]. 
Ligamentocyte-specific markers have yet to be identified as currently most ligament markers are 
ligament/tendon-specific. Both tissues are structurally and biochemically similar [25], but as 
mentioned previously, tendons and ligaments are unique in their composition [20] and 
transcriptome which is highly heterogeneous [47]. Cell specific markers involved in development 
of tendon and ligament tissues have been identified as scleraxis (SCX) and homeobox protein 
mohawk (MKX) [48, 49]. SCX, a helix-loop-helix transcription factor, is present in the 
SCX+/SOX9+ chondroprogenitor cells at E10.5 which differentiate into ligamentocytes and 
tenocytes, making SCX the earliest known ligament/tendon cell marker [49]. Furthermore, SCX 
regulates tenocyte differentiation from mesenchymal stem cells and characteristic gene expression 
including collagen type I, decorin, fibromodulin and tenomodulin (TNMD) [50]. Scx deletion in 
mice had a varying effect on force-transmitting tendons, ranging from tendon atrophy to ECM 




MKX, a homeobox protein transcription factor, has also been associated with ligament and tendon 
development and is further maintained in mature ligament cells [48, 52]. MKX can also drive 
mesenchymal stem cells towards tenocyte differentiation in vitro [53], and is present in regions of 
tendon progenitor cells during embryonic development, but at a later stage than SCX [48]. Mkx 
null mice have underdeveloped tendons in the form of thinning collagen fibrils and deficient 
collagen type I and TNMD production [52]. Mkx deletion had no effect on cruciate ligament 
development and effects on other ligaments’ development and composition were not reported [48, 
52]. These differences in development between ligament and tendon tissues suggest a divergent 
cell lineage. 
Growth differentiation factor 5 (GDF5), part of the bone morphogenic protein (BMP) family, is a 
marker for all synovial joint progenitor cells, prior to SCX expression [54]. All the joint tissue 
cell types from bone, cartilage and ligament are derived from a GDF5-expressing lineage [54] and 
GDF5 is maintained in cruciate ligament and meniscal cells throughout development [55]. 
Synovial joint development involves a continuous influx of cells, and GDF5-expressing cells are 
thought to regulate lineage divergence and differentiation [55]. Gdf5 null mice resulted in a lack 
of intra-articular ligaments (both cruciate ligaments), menisci and thin patellar tendons and 
collateral ligaments [56]. 
The full extent of how these markers regulate ligament development and regeneration is unclear. 
Recent studies have uncovered a complex array of markers which interact with each other, 
including early growth response factor and TNMD, which have both been directly linked to SCX 
and MKX expression [51, 57]. More importantly, many of these markers are involved in 
regulating ECM synthesis. As previously mentioned, SCX regulates collagen type I and 
proteoglycan expression in tendons [50], MKX also regulates collagen type I production [52] and 
similarly GDF5 also plays a role with upregulating collagen type I and III and matrix 
metalloproteinase (MMP)-13 amongst others [58]. These development markers are important for 
progenitor differentiation and ECM synthesis, and therefore could also be involved in disease 
pathologies that affect cellular differentiation or the ECM composition in ligaments.  
Overall, early development markers have been found such as SCX and MKX which drive 
ligament and tendon development [48]. These markers and their associated pathways are poorly 
understood, particularly in mature ligaments, in part, because of the heterogeneity of each 




1.5 Ligament mechanics 
As previously mentioned, ligament ECM composition and structure is fundamental for tissue 
function and mechanical properties [2]. Ligaments have to be both flexible and strong in resisting 
tensile loads in order to support the musculoskeletal system. The mechanical behaviour of 
ligaments is viscoelastic, meaning it exhibits both viscous and elastic behaviour when undergoing 
deformation [59]. Viscous materials display resistance to strain linearly with time when a stress 
is applied, whereas elastic materials stretch and return to their original state in a non-time 
dependant manner [59]. This behaviour, best represented in a stress-strain curve, shows an 
exponential increase in force (stress) as the material elongates (strain) and can be divided into 
three regions: the toe-region, linear-region, and failure-region (see Figure 1.4) [2, 60]. The toe-
region demonstrates non-linear and viscoelastic behaviour: non-linear due to “crimped” collagen 
fibrils [2, 60] and viscoelastic due to collagen interaction with ECM structural proteins [60, 61]. 
In the toe-region, collagen fibrils undergo “un-crimping” of their wavy structure (termed “fibrillar 
crimps”), resulting in a non-linear low stiffness behaviour [60]. The linear-region represents stiffer 
viscoelastic behaviour, due to the collagen fibril molecules stretching and the sliding of collagen 
triple helices [62]. Typically, the physiological relevant range of ligament mechanics falls within 
the toe-region, with the linear-region being the upper physiological limits of ligament mechanics 
[60, 62]. The failure-region is beyond the elastic limits of the ligament, resulting in disruption of 





Figure 1.4 Stress-strain curve of the murine anterior cruciate ligament (ACL). Viscoelastic stress-strain showing the 
non-linear (toe-region), linear and failure regions. The toe-region demonstrates non-linear viscoelastic behaviour and 
the linear region represents a stiffer viscoelastic region which can return back to its original state if the tissue does not 
pass the failure point. In the plastic failure region, there is permanent tissue failure, resulting in irreversible damage 
to the tissue structure. The ultimate load at failure, also known as maximum load, is considered a material property of 
tissue strength. Based on a diagram from Robi et al. [63]. 
 
Viscoelasticity is a time-dependant anelastic behaviour, where the response to a stimulus is 
delayed due to a loss in energy in the material [64]. The viscoelastic properties of ligament include 
strain rate sensitivity [59], stress-relaxation [59], creep [65], and hysteresis [66]. Strain rate 
sensitivity is where the stress-strain curve of ligaments is dependent on the rate at which strain is 
applied (known as strain rate) (see Figure 1.5A). In ligaments higher strain rates typically result 
in a stiffer (higher stress) response [59, 61]. Although the mechanisms of strain rate sensitivity 
are not fully understood, it has been proposed that at slow strain rates fibrils straighten before 
collagen fibrils start to glide and in faster strain rates fibrils start directly with intra-fibrillar gliding 
[67]. It has also been theorised that strain rate sensitivity is due to the viscous components of the 
ligament proteoglycan-rich matrix, where viscosity increases with strain rate [68]. This has been 
confirmed in mouse tendons, where fascicle without decorin had reduced strain rate sensitivity, 
but mutations in collagen type I did not affect the tendon strain rate sensitivity [69]. These findings 
may indicate the strain rate sensitivity is an important viscoelastic property likely affected by the 




Figure 1.5 Viscoelastic properties of ligaments. These include strain rate sensitivity (A), stress-relaxation (B), 
hysteresis (C), and creep (D). (A) Strain-rate sensitivity demonstrates different stress-strain curves dependant on the 
strain rate [59]. (B) Stress-relaxation is the relaxation of the stress over time (load-time), under a constant strain 
(extension-time) [59]. (C) Hysteresis, the area between the load and unload cycle, represents energy dissipated during 
loading-unloading [66]. (D) Similar to stress-relaxation, creep is another viscoelastic property, where ligament 
extension can increase over time (extension-time), under a constant load (load-time). Creep image was adapted from 
Thornton et al. [70]. 
 
Stress-relaxation of a viscoelastic material, such as a ligament, is the ability to reduce stress over 
time under a constant strain [59] (see Figure 1.5B). Stress-relaxation behaviour is attributable to 
ligament viscous material response and microstructure reorganising to reduce the overall stress 
[2]. Studies have shown that no changes in fibre realignment were found during stress-relaxation 
of rat tendon [71], therefore collagen structure is likely not responsible for stress-relaxation. 
Stress-relaxation is also strain dependent, and in the rabbit MCL the rate of relaxation decreased 
with increasing strain [72], which would suggest that stress-relaxation is a viscous material 
property. Stress-relaxation behaviour is in part controlled by proteoglycan composition as stress-
relaxation behaviour was found to be compromised in decorin-deficient mice tendons [73]. This 
finding was also confirmed in human MCLs which showed an increase in stress-relaxation after 
chondroitinase treatment which removes GAGs present in proteoglycans from the ligament ECM 




Similarly, creep, measures the ability of ligaments to increase their elongation (strain) over time 
under a constant force [2] (see Figure 1.5D). The mechanisms of creep behaviour include collagen 
fibre recruitment, as has been shown in rabbit MCLs during creep [75], which would suggest an 
involvement of the collagen structure. In addition, creep was found to be strain dependent in 
another study examining rabbit MCLs, similar to stress-relaxation [72], which would again 
suggest viscous behaviour. Further evidence found that an increase in hydration resulted in an 
increase in creep elongation [70]. In addition, partial GAG (a major component of all 
proteoglycans) depletion was also shown to decrease the creep rate in canine cruciate ligaments 
[61]. Therefore, creep is an important ligament viscoelastic property that can give insight not only 
on collagen fibre recruitment, but also hydration and GAG content. 
Hysteresis, another viscoelastic property, represents the amount of energy dissipated during the 
loading and unloading cycle of stress-strain [66] in a material and can be measured by the 
difference between the loading and unloading stress-strain curves [64] (see Figure 1.5C). 
Although the exact mechanisms affecting hysteresis in ligaments are unknown, it has been 
theorised that the viscous energy loss during hysteresis occurs due to rearrangement of the inter-
fibrillar ECM, such as proteoglycans [76]. In ligaments, hysteresis was shown to decrease 
significantly in the first preconditioning cycles, but not after the first 10 preconditioning cycles 
[66]. In addition, hysteresis in ligaments was shown to change with different strain rates [66]. 
Unlike some of the other viscoelastic properties, hysteresis was shown not to change in human 
MCLs with a reduction in decorin content [77], hence the role of proteoglycans has not been yet 
clearly defined in hysteresis. Importantly, freezing of ligament samples did result in significant 
differences in hysteresis compared to non-frozen ligaments, but only in the first few load-unload 
cycles [78], therefore preconditioning and storage conditions are important for when considering 
studies examining ligament mechanical properties. 
In summary ligament viscoelastic behaviour is mainly attributed to collagen structure and 
interaction with ECM structural proteins [60, 61] such as the proteoglycans, decorin and biglycan 
[79, 80], which are necessary for viscoelastic properties including strain rate sensitivity [69] and 
stress-relaxation [73]. Therefore alterations in viscoelastic properties could be an effective 
indicator of early disease pathologies such as OA where ECM structure and compositional 




1.6 Osteoarthritis (OA) 
OA is the most common form of arthritis and the leading cause of disability among the elderly 
affecting millions of people worldwide [81]. An estimated 18% of women and 10% of men 
worldwide over 60 years of age have evidence of  radiographic OA [82]. In the United Kingdom, 
incidence of OA in any joint was about 8.6/1000 overall, with a higher prevalence in women [83]. 
The risk factors for OA include ageing, obesity, exercise, genetic predisposition, trauma, 
mechanical factors and gender [6]. Knee joint OA is of particular importance as it is the most 
prevalent type of OA [84] and its incidence is expected to increase due to obesity and trauma [84]. 
Furthermore, currently there is a lack of successful treatments for knee OA, most therapies target 
symptoms or late stage knee replacement surgery [85]. There is a need to better understand the 
pathology during knee OA to create better treatments that address disease progression. 
Knee joint OA has been labelled as a ‘whole-joint’ or organ disease due to the wide range of intra-
articular tissues that are affected with this pathology [6] (Figure 1.6). In OA articular cartilage, an 
imbalance between anabolic and catabolic activity result in ECM degradation, inhibition of new 
ECM formation and consequent cartilage degradation [86-88]. In the affected periarticular bone, 
there is an increase in bone remodelling, thickening of the subchondral plate and bone attrition 
and cyst formation due to endochondral ossification [88-90]. The synovium has also shown 
significant pathological changes in OA, even before cartilage degeneration, including infiltration 
of macrophages, lining hyperplasia and fibrosis, and production of pro-inflammatory cytokines 
[91]. These catabolic and proinflammatory mediators then in turn affect adjacent cartilage by 
promoting ECM degradation [92]. Lastly, the meniscal degeneration in the form of meniscal tears 
and weakening of the structural properties is believed to be a cause [93] and consequence of OA. 
Aetiology and risk factors of OA are numerous, however some pathological changes in OA have 
been attributed to fractures, including intra-articular fractures in the cartilage [86] and 
microfractures in the subchondral bone [94], and also mechanical instability, such as meniscal 





Figure 1.6 Pathological changes in the osteoarthritic (OA) knee joint organ. Pathology includes cartilage 
degeneration, bone remodelling, subchondral bone thickening, osteophyte formation, synovial inflammation, meniscal 
and ligament degeneration [6]. All knee joint tissues are affected, suggesting that OA is a disease of the joint as an 
organ. Image adapted from Wluka et al. [96]. 
 
1.7 The link between ligament trauma and knee osteoarthritis 
Ligament injury is a major risk for knee joint OA development. Of all ligament injuries in the 
human knee joint, ACL tears are the most common [97] with a higher incidence of injury 
occurring in females compared to males [98]. Following diagnosis of an ACL injury, an average 
of 50% of patients developed OA in the 10 to 20 years following injury [99]. A high incidence, 
51%, of radiographic knee OA was also found in female soccer players, 12 years after ACL injury 
[100]. In a study of patients with symptomatic knee OA that had knee joint magnetic resonance 
imaging, 22.8% had evidence of complete ACL rupture and most could not recall any trauma that 
would explain their knee injury [101]. 
Ligament injury and OA development has also been observed in animal models which could 
provide further insight into post-traumatic knee OA [102]. The most common model used to 
examine OA in animals are surgically induced models. ACL transection (ACLT) is the earliest 
model, which was developed in large animals such as dogs (Pond-Nuki model) [103] and resulted 
in cartilage degradation, osteophyte formation and meniscal fibrillation [103, 104]. Similarly, 
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post-traumatic OA following ACLT has also been shown in mice, leading to severe joint 
instability and the marked features of OA including cartilage degeneration and osteophyte 
formation, as well as increase in MMP13 and COLX [105, 106]. The destabilisation of the medial 
meniscus (DMM) most usually performed in rodents is another common model for knee joint OA 
induction in which the medial meniscotibial ligament is transected [107]. These studies postulate 
a direct link between ACL injury and OA. It remains unclear if OA development could precede 
ACL injury and whether the ACL is an active contributor to the pathogenesis of knee OA [6]. 
 
1.7.1 Joint organ injury response and ligament pathology 
Studies on post-traumatic OA demonstrate an intricate whole joint organ response, which could 
reveal pathways and potential crosstalk between neighbouring tissues that drive OA progression. 
Whole joint response post-ligament trauma include an inflammatory response marked by 
proteoglycan deposition [108] and MMP upregulation [109, 110]. An increase of proteoglycan 
levels has been reported in the human knee joint synovial fluid following ACL or meniscal rupture 
in the initial 3-4 weeks after rupture which remained elevated for up to four years [108]. A change 
in proteoglycan composition was also observed in the healing MCL of rabbits, most notably a 
decrease in decorin content and an increase in biglycan [111]. Changes in proteoglycan 
composition, particularly decorin and biglycan, have been shown to change ligament mechanical 
function [79, 80] as previously mentioned (Section 1.5). 
MMPs are involved in the inflammation and proliferation phase of ligament healing to promote 
matrix turnover [112]. In pigs, after ACLT, MMP-1, MMP-13 and ADAMTS-4 expression were 
upregulated in the transected ligament [109]. ADAMTS-4 is another matrix degrading enzyme 
which is also expressed in cartilage in the early stages post-ligament injury driven by pro-
inflammatory markers [113]. Wright et al. tested the role of MMP-12 in MCL wound healing with 
MMP-12 deficient mice [110]. Following MCL transection, MMP-12 deficient mice had delayed 
MCL repair resulting in lower recruitment of macrophages, and lower ultimate force and stiffness 
at earlier time points but not at later time points [110]. This would suggest that MMP-12 plays a 
role in MCL post-trauma particularly at early stages by influencing the inflammatory response. 
MMPs were also involved in the early stages of spontaneous OA and ligament degeneration [114], 
which will be discussed in Section 1.8. These findings would further suggest similarities in the 
pathways affected during spontaneous and post-traumatic OA. 
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Whilst there have been many studies showing the consequential increase of proteoglycans, growth 
factors and MMPs in cartilage post injury, very few have studied the direct interaction of ligament 
with other tissues and this remains the biggest question in the role of ligament pathology in 
conditions such as OA. A recent study by Chinzei et al. has given insight into the crosstalk 
between ACL remnants and chondrocytes obtained from OA patients [115]. Periostin, an ECM 
protein expressed in many tissues, was highly expressed in torn ACLs along with MMP-13 and 
ADAMTS-4 [115]. Additionally, in a co-culture in vitro system, ACL remnants had an effect on 
the expression of anabolic and catabolic genes in chondrocytes [115]. Furthermore, transforming 
growth factor (TGF)-β1 treatment had no effect on periostin expression, meanwhile interleukin 
(IL)-1β inhibited periostin expression [115]. Hence ACL remnants can have a direct effect on 
chondrocyte matrix turnover. This research opens the gates for further studies on direct ACL 
crosstalk with cartilage and other surrounding tissue. 
The direct involvement of the ligament post-traumatic injury and in secondary OA remains poorly 
understood, though there is clear proteoglycan deposition [108] and MMP upregulation [109, 110] 
occurring in the synovial fluid following ligament injury. New research on ligament crosstalk 
revealed that ligament remnants might play a bigger role than previously expected [115]. Future 
research should focus on ligament crosstalk as well as similarities and differences between post-
traumatic and age-related spontaneous OA. 
 
1.8 OA and ligament pathology 
1.8.1 Ligament pathology in early stages of spontaneous OA 
Several studies have suggested that age-related ligament degeneration precedes cartilage 
degeneration in the early stages of spontaneous OA [114, 116]. One of the first studies in this area, 
studied the effects of collagen remodelling of the ACL in the STR/ort mouse model [114]. The 
STR/ort mouse strain is a well-recognised model for spontaneous OA [18], with similarities to 
human OA, including cartilage lesions, bone sclerosis, osteophyte formation and the presence of 
MMPs and aggrecanase [117, 118]. Collagen remodelling in the STR/ort ACLs was found to be 
present before macroscopic and radiological signs of knee joint OA, and the collagen remodelling 
was associated with higher levels of MMP-2, a metalloproteinase involved in matrix remodelling 
[114]. This study was the first to suggest that pathological and degenerative changes can occur in 
the ACL prior to OA signs in other articular tissues. 
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Early cruciate ligament degeneration was further studied in the early stages of OA in the Dunkin 
Hartley guinea pig spontaneous OA model compared to the normal Bristol strain 2 [116]. This 
OA model consistently develops cartilage degeneration in the medial tibial plateau at nine months, 
and other OA symptoms including calcification of the collateral ligaments at 22 months [119, 
120]. Quasnichka et al. measured an increase collagen turnover in the ACLs (particularly MMP-
2) which preceded both bone and cartilage pathology [116, 121]. In both of the STR/ort murine 
model and Dunkin Hartley guinea pig model, ligament collagen remodelling and ligament 
mechanical function was affected in age-related early stages of OA development. 
Naturally occurring ACL degeneration has been observed in canine breeds with a high risk of 
cruciate ligament rupture [122] leading to eventual OA development [123]. Similar to the murine 
and guinea pig spontaneous OA models [114, 116] higher pro-MMP2, immature cross-links, total 
GAGs and water content were found in ruptured cruciate ligaments compared to intact ligaments 
[122]. Following these studies, ultrastructural differences in the cruciate ligaments from high and 
low- risk canine models were also analysed [124, 125]. Canine breeds with high risk of ligament 
rupture had significantly smaller collagen fibrils [124] and intercondylar notch spaces [125] 
compared to those from low-risk breeds. Knee laxity is believed to contribute to smaller 
intercondylar notch spaces [125], resulting in impinged areas of the ACL, which had elevated 
levels of MMP-2 and sulphated GAGs [124]. Additionally, fibrocartilaginous markers were 
present in ligament and tendon enthesis and these markers had higher expression in the canine 
breeds with a low risk of ligament rupture [124] mirroring similar findings to that seen in the 
spontaneous guinea pigs [116] and mice [114]. This could suggest that the fibrocartilaginous 
markers have a protective effect on canine ligament rupture. 
Similar findings of ligament degeneration have also been observed in human knee joints. 
Hasegawa et al. analysed 120 human ACL and cartilage samples obtained from post-mortem 
tissue banks [126]. ACLs and cartilage from these joints were histologically scored for 
inflammation, chondroid metaplasia, cystic changes, collagen fibre orientation, and mucoid 
degeneration [126]. Ligament degeneration correlated with cartilage lesions and ageing and 
furthermore in a certain subset of patients ACL degradation preceded cartilage lesions [126]. 
Ligament degeneration was associated with ligament sheath (synovial membrane) inflammation, 
including hyperplasia, inflammatory cell infiltration and synovial stroma formation [126]. 
Furthermore, ECM disorganisation in the ACL occurred before synovial inflammation in some 
young donors without any history of knee trauma, and mucoid degeneration was highly prevalent 
in all ACLs [126]. Several studies have found similar results of degeneration in the PCL [127, 
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128]. These results support the findings from the animal models and suggest that age-related 
degeneration of the ACL can occur in the early stages of OA prior to articular cartilage changes 
but its contribution to the pathogenesis of knee OA is unknown. 
 
1.8.2 Ligament pathology in the late stages of OA 
Several studies have revealed several underlying cellular and extracellular changes occurring in 
the ligaments in the late stages of OA [129, 130]. In many of these studies the origin of OA (post-
traumatic or spontaneous) is unclear, however these studies present clues of potential mechanisms 
driving ligament degeneration and OA pathology. 
Hasegawa et al. characterised the cellular and ECM changes in human ACLs at all stages of OA 
development [129]. Ligament total cell density was greatly reduced in the ACL of aging donors 
but increased in the degenerated ACLs of donors with severe cartilage degeneration and OA [129]. 
This finding was due to perivascular accumulation of cells and cell aggregates in sites of 
degeneration [129]. The perivascular cells had a ‘fibroblast-like’ phenotype and had 
hematopoietic markers suggesting recruitment of bone marrow-derived fibrocytes [129]. The 
other cell aggregates had a ‘chondrocyte-like’ phenotype and expressed SCX (tendon or ligament 
marker), SOX9 (a major transcription factor in chondrogenesis) and RUNX2 (a regulator of 
chondrocyte hypertrophy) [129]. Moreover, there was increased MMP expression (MMP1, 
MMP3, and MMP13) in the degenerated OA ACLs originating from the chondrocyte-like cells as 
well as COL2 and collagen type III, and X production [129]. All of these markers increased with 
OA severity suggesting abnormal differentiation of resident ACL cells was driving irregular ECM 
production during OA. The presence of SCX and SOX9 was also confirmed in the ACL and PCL 
of OA patients in a separate study by Kumagai et al. [131]. 
MKX, another transcription factor with specificity for tendons and ligaments as previously 
described (Section 1.4) is also involved in OA progression [130]. Nakahara et al. analysed ACLs 
from OA patients greater than 60 years-old with a mild to severe grade of knee joint cartilage 
scoring and found that the presence of MKX-positive cells were significantly reduced in areas of 
collagen fibre degeneration [130]. ACL fibroblasts in vitro showed that IL-1β suppressed MKX 
expression and reduced collagen type I alpha 1 and tenascin-XB (an ECM glycoprotein which 
regulates collagen fibrillogenesis) expression and upregulated SOX9 expression [130]. These 
findings offer a potential mechanism for MKX suppression, driven in part by pro-inflammatory 
cytokines such as IL-1β. 
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BMPs, members of the TGF-β family of growth factors, are also involved in ligament 
degeneration and OA progression [132]. Ruschke et al. found significantly reduced levels of 
BMP-2 target genes ID1 and SMAD6 in fibroblasts isolated from the ACL of OA patients 
compared to non-OA fibroblasts, suggesting that OA might modify BMP-2 signalling pathways 
[132]. In addition, in the ACLs of patients undergoing knee replacement surgery there were a high 
percentage of calcium deposits in 64.4% of all ACL samples, however calcification was not 
correlated to ACL degeneration [132]. Though BMP-2 signalling is affected in OA ligaments, the 
role of BMP-2 signalling in calcium deposition and OA remains unclear. 
Other cellular changes reported in the cruciate ligaments of OA patients include loss of 
innervation [128]. Neurofilaments were absent in 40% of ACLs taken from OA patients 
undergoing knee replacement surgery [128]. In addition, nociceptive (pain) sensors in the ACL 
decreased significantly in OA patients and also following injury [133]. However, effects on 
innervation can vary based on the ligament; another study found no changes in neurofilaments in  
PCLs from OA patients compared to healthy ligaments obtained post-mortem from patients with 
no history of joint disease [134]. Loss of innervation in the PCL has been reported including 65% 
of neurovascular bundle degeneration in the PCL from OA patients undergoing knee replacement 
surgery [135]. Another study showed that nociceptive (pain) sensory innervation remained 
constant in the PCL of OA patients, even during loss of overall innervation [136]. Loss of 
innervation can occur concurrently with OA progression, however its contribution to joint disease 
progression and the driving forces in this deficiency should be explored further. 
In summary, cellular changes in the ACL in the late stages of OA included an increase in 
‘chondrocyte-like’ cells [129], reduction of MKX-positive cells [130], reduction of BMP2-
signalling [132] and reduction of neurofilaments [128]. Hence pathological changes in the ACLs 
in the late stages of OA are associated with changes in the fibroblast cell population. The cause 
of these cellular changes remains unknown as well as if these cellular changes actively contribute 
to disease progression. 
 
1.8.3 Ligament mechanics associated with OA 
Impaired mechanical properties of ligaments in the spontaneous OA animal models has been 
confirmed [114, 116]. In the spontaneous OA STR/ort mice knee joints, the ACLs had a lower 
ultimate load at failure than healthy control mice populations (CBA mice) in the early stages of 
OA [114]. In the spontaneous OA Dunkin Hartley guinea pig model, there were no significant 
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differences in the ultimate load at failure of the ACL compared to non-OA populations (Bristol 
Strain-2) [116]. However at physiologically-relevant loads, critical deformation of the ACL, a 
measure of laxity, was significantly greater than the non-OA controls before evidence of cartilage 
degeneration [116]. A study on mechanics of the ACL of dog breeds found a slightly weaker 
ultimate load to failure and significantly greater knee joint laxity in dogs at a high-risk of ligament 
rupture compared to breeds with lower-risk of ligament rupture [137]. These spontaneous OA 
animal models demonstrated early changes in the ligament mechanical properties occurring before 
cartilage degeneration and suggest that ACL mechanical properties may be important for 
spontaneous knee joint OA pathology. 
Knee ligament and joint mechanics in humans also change during OA progression. Hagena et al., 
compared ACLs and PCLs taken from patients undergoing knee replacement surgery due to OA, 
rheumatoid arthritis and ‘healthy’ non-OA and non-rheumatoid arthritis patients [138]. A decrease 
in stiffness and ultimate load at failure was found in the OA ACLs and PCLs, along with an 
increase in viscoelastic stress-relaxation [138]. This decrease in stiffness and ultimate load is 
similar to the mechanical functions of ACLs seen in the spontaneous OA animal models, and 
similarly suggests that these mechanical properties are compromised during OA progression.   
Changes in the mechanical properties of ligaments during OA varies in other knee ligaments [139, 
140]. Varus and valgus laxity, indicators of MCL and LCL laxity, measured in vivo with a 
dynamometer did not change in OA patients compared to healthy non-diseased knee joints [139]. 
However, some studies have found an increase in the stiffness of MCL and LCL, measured in situ 
in cadaveric knee joints from OA patients compared to non-OA cadaveric knee joints [140]. These 
findings indicates that changes in ligament stiffness during OA can occur in extra-articular 
ligaments and not only in the ACLs [138]. 
In summary, ligament mechanical tensile strength and viscoelastic properties are altered during 
OA progression [114, 138]. However, many of the viscoelastic properties mentioned previously 
(strain rate sensitivity, creep and hysteresis) (Section 1.5) have been largely unreported in OA 
ligaments. In addition, understanding the underlying driving factors affecting these mechanical 
changes and potential mechanotransduction pathways remain relatively unknown. For further 
understanding, both ECM composition and mechanical properties and their relationship must be 




1.8.4 Structural and signalling proteins involved in ligament function and secondary OA 
Genetically modified animal models give insight into specific ECM markers and signalling 
proteins and their role in ligament function and consequent OA development. Murine joints of 
targeted collagen V-null mice  had a phenotype similar to Ehlers-Danlos syndrome, characterised 
by joint hypermobility and premature OA formation [141]. Histological sections demonstrated 
cartilage degeneration in the lateral tibia of one-month-old mice from this model and later stages 
produced inflammation and osteophyte formation [141]. Additionally, irregular collagen fibril 
alignment in one-month-old mice resulted in fewer and larger collagen fibrils in the ACL 
midsubstance [141]. Mechanical properties of the ACLs in these mice also demonstrated 
significant decrease in elastic stiffness and modulus [141]. This study highlights the importance 
of collagen V in fibrillogenesis and of hypermobility as an initiator of OA. 
SLRPs, such as biglycan and fibromodulin, are also important in collagen fibrillogenesis of 
ligaments and tendon [142]. Biglycan and fibromodulin double knockout mice had tendons with 
smaller collagen fibrils and decreased elastic stiffness, tendon ossification and resulted in 
premature OA in the knee joint [142]. Meanwhile, fibromodulin-null mice also had greater 
incidence of OA development which manifested in the form of ligament degeneration preceding 
cartilage degeneration [143]. Ligament cell morphology in the fibromodulin-null mice was also 
altered and the cells became more ‘chondrocyte-like’ and less fibroblastic, expressing high levels 
of lumican, another SLRP [143]. No collagen fibril abnormalities were noted within the cartilage 
at the same time as the ligament changes, indicating a distinct role of fibromodulin in ligament 
homeostasis. 
The role of matricellular signalling protein NOV, also known as CCN3, was studied in NOV 
deficient mice [144]. NOV is normally expressed near the femoral enthesis of the collateral 
ligaments, as well as in the articular cartilage, menisci and synovial lining [144]. Deficiency of 
NOV resulted in OA-like pathology including joint abnormalities such as meniscal calcification, 
osteophyte formation in the lateral tibia, and articular cartilage degeneration [144]. Ligament 
degeneration was also noted, including complete degeneration of both cruciate ligaments and 
abnormal proteoglycan staining (safranin-O) possibly indicating fibrocartilage-like changes near 
the insertion sites and also in the synovium and collateral ligaments [144]. Since NOV is present 
in many tissues, it is likely a key signalling protein for the whole knee joint homeostasis, not 
specifically in the ligaments. 
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Other signalling molecules important in ligament function include hormones [82] and free radicals 
[145]. Hormones have been studied in OA development, due to the high prevalence of OA in the 
female population [82, 146] and the presence of oestrogen and progesterone receptors in the 
human ACL stroma [147]. Warden et al. tested the role of oestrogen and its receptors (ERα and 
ERβ) in the ACL and MCL of rats and mice [148]. In rats, oral gavage of ethynylestradiol, a 
synthetic oestrogen treatment, had no effect on the viscoelastic or tensile properties of the MCL 
or ACL [148]. Similar results were seen in the ERβ null mice which had no effect on the 
viscoelastic of tensile properties of the MCL or ACL [148]. These findings agreed with a similar 
study on knee ligaments of sheep where after 6 months of oestrogen administration, there was no 
difference in the mechanical strength of the ACLs [149]. Therefore, while gender may play a role 
in risk of ligament injury and OA in humans, it may not be due to oestrogen. 
Nitric oxide, a free radical and gaseous signalling molecule, has also been associated to OA due 
to its role as a mediator of inflammation that can activate MMPs [150]. In normal canine ACL 
explants, higher nitric oxide production was found than the other collateral ligaments, likely to be 
due to the greater number of inducible-nitric oxide-synthase expressing cells [145]. Additionally 
after an inflammatory stimulus (composed of IL-1, tumor necrosis factor and lipopolysaccharides) 
nitric oxide production also increased in these canine cruciate ligaments which in turn activated 
MMP production [145]. This increase in nitric oxide production was not seen in the MCL or other 
ligaments [145]. It is suggested that nitric oxide production could play an important role in the 
ACL, particularly during inflammation leading to degeneration. The protective properties of nitric 
oxide on OA development have been noted in cartilage [151], but not in ligaments. 
Understanding the role of ECM structural and signalling proteins, along with other signalling 
molecules such as oestrogen and nitric oxide and their relationship to ligament fibroblasts is 
integral to understanding ligament pathology. It is possible that these same pathways are involved 
in OA pathology. The differences and similarities in these pathways in secondary versus 
spontaneous OA could highlight important disease targets. 
 
1.9 Hypothesis and aims  
To comprehend the broader role of ligaments in OA development we must first characterise 
ligament composition and function in diseased and healthy knee joints. This thesis will address 
the hypothesis that cellular, ECM composition and mechanical properties are compromised in the 
early and late stages of OA in the cruciate knee joint ligaments of murine spontaneous and post-
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traumatic OA models. This compromised cellular and ECM composition will be evaluated in 
cellular morphology, structural organisation and presence of ECM and cellular markers. Changes 
in mechanical function will be evaluated in the ligament viscoelastic properties. Characterising 
these histopathological and mechanical properties will give insight into the microenvironments in 
which ligament fibroblasts are exposed to during OA and furthermore changes in the early stages 
of OA could reveal potential disease driving factors. In addition, using murine models, this thesis 
will address OA aetiological differences through comparison between post-traumatic and 
spontaneous OA models. Similarities and differences in the cellular markers, ECM composition 
and mechanical properties were analysed in multiple murine OA models. 
Our histopathological characterisation of ligament cellular and ECM markers was limited to 
specific markers and a currently incomplete understanding of ligament markers. To address this, 
this thesis explored the hypothesis that the ligament cellular makeup and fibroblast heterogeneity 
is more complex than has been previously demonstrated. For this hypothesis, the final goal was 
to identify specific fibroblast subpopulations and their potential roles in murine knee ligaments 
using unbiased high-resolution transcriptomics. 
To summarise, the overarching goal of this thesis was to characterise the healthy and OA ligament 
markers and mechanics. With this goal in mind, the specific aims and objective of this study were 
the following: 
• Determine changes in cellular and extracellular markers occurring in knee ligaments and 
surrounding tissues during the early and late stages of OA development in post-traumatic 
and spontaneous OA murine models. 
• Characterise the viscoelastic and material mechanical properties of the ACL in the early 
stages of OA progression in post-traumatic and spontaneous OA murine models. 
• Identify the cellular makeup, fibroblast subpopulations and their relevant markers in 
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2.1 Introduction  
In this chapter we looked at murine spontaneous and post-traumatic OA models to further explore 
meniscal and knee ligament pathology during early and late stages of OA development. The 
spontaneous OA murine model analysed was the STR/ort mouse strain [152], and the post-
traumatic OA models included a destabilisation of the medial meniscus (DMM) mouse model 
[107] and a non-invasive mechanical trauma model [153]. In addition, we also characterised knee 
OA progression in a novel spontaneous OA murine model: the CD1 mouse strain [154]. 
 
2.1.1 Spontaneous OA murine models 
In spontaneous OA models, OA develops as a natural part of the ageing process, classified as 
primary or idiopathic OA [102]. OA in these mice models mimic non-traumatic OA in humans, 
thought to be a result of aging, wear and tear and other risk factors [102]. The STR/ort mouse is 
known to exhibit early-onset spontaneous OA with high incidence and severity, and reproduces 
features of human knee OA such as proteoglycan loss, cartilage fibrillation, osteophyte formation 
and subchondral bone thickening [152, 155-159]. Meniscal and collateral ligament changes have 
been briefly reported in STR/ort mice, including ossification in the medial meniscus [152] and a 
positive association between MCL calcification and OA development [160]. In STR/ort cruciate 
ligaments, collagen remodelling and lower mechanical strength have been reported [114]. 
A new spontaneous OA mouse model (CD1) has recently been reported [154]. These mice 
develop OA-like symptoms at 1 year of age which include cartilage erosion of the medial femoral 
condyle, subchondral bone damage, osteophyte formation and meniscal degeneration [154]. There 
is currently no literature about changes to knee ligament pathology in the CD1 mice knee joint, 
and no description of pathological changes in early stages of OA development. 
 
2.1.2 Post-traumatic OA murine models 
Post-traumatic OA models offer a diverse aetiology of OA development in comparison to 
spontaneous OA models [161]. The induction of OA is well described in the murine DMM post-
traumatic model, induced by surgical transection of the meniscotibial ligament and resulting in 
moderate-to-severe lesions mainly in the medial compartment by 8 weeks post-trauma [162, 163]. 
A more novel post-traumatic OA model is the non-invasive mechanical trauma model which 
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results in a lesion in the femoral condyle and OA development within 6 weeks post-trauma [153]. 
To date, pathological changes in meniscus and knee joint ligaments are poorly described in these 
models of OA. 
 
2.1.3 Hypothesis and aims 
Past studies have shown changes in ligament function in the early stages of OA in mice [114] and 
changes in cellular phenotype in the late stages of OA in humans[129]. In this study, we 
hypothesized that changes in cellular phenotype and ECM occur in the ligament in the early stages 
of OA. To address this, the overall aim was to identify matrix and cellular pathological changes 
and biomarkers in knee ligaments and surrounding tissue during OA development. Each of these 
aims will be assessed in individual murine models of post-traumatic and spontaneous OA. 
Aim 1: Our first aim was to explore changes in knee ligament and meniscal tissue organisation 
and cell morphology during OA disease progression. To do so, we used histological staining 
techniques such as toluidine blue to look at fibre organisation, alignment, hyperplasia, cell 
morphology and general proteoglycan deposition. Picrosirius red (PR) staining was also used to 
determine collagen birefringence and fibre organisation. All these staining techniques were 
compared at different stages of OA disease progression. 
Aim 2: Our second aim was to further expose potential underlying mechanisms driving 
pathological changes using specific OA and tissue biomarkers. This was achieved using 
immunohistochemistry for specific cellular and matrix biomarkers of chondrogenesis (COL2, 
transcription factor SOX9), hypertrophy (transcription factor RUNX2), and ligament 
proteoglycan (asporin). 
Aim 3: Our third aim was to confirm if pathological changes to ligament and menisci could also 
be detected in a novel OA model. For this aim, we used a new spontaneous OA model (CD1 mice) 
and analysed ligament and meniscal pathology using histological staining, immunohistochemistry 
and micro-computed tomography (µCT) imaging. µCT imaging was used to quantify tissue 
mineralisation of the joint space during disease development. 
Aim 4: OA pathology is diverse and can originate in different ways, hence our final aim was to 
determine if diverse OA models affected meniscal and knee ligament pathologies differently or 
similarly. To do so, we compared histopathological results from murine OA models of 
spontaneous and post-traumatic OA. 
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2.2 Materials and Methods 
2.2.1 In vivo study design and tissue collection 
Murine OA models used in this study included an established spontaneous OA model (STR/ort), 
a novel spontaneous OA model (CD1), a non-invasive post-traumatic OA model (joint loading) 
and a surgically induced post-traumatic OA model (DMM) (see Table 2.1). All mice were kept in 
polypropylene cages, subjected to 12-hour light/dark cycles, at 21±2˚C and fed standard diet ad 
libitum. All procedures complied with Animals (Scientific Procedures) Act 1986 and local ethics 
committee. 
 
Table 2.1 Murine spontaneous and post-traumatic OA models used in Chapter 2. This included two spontaneous OA 
models (STR/ort and CD1) and two post-traumatic OA models (DMM and non-invasive-loading). Murine strain, 
gender, age, and control group are detailed. 
Type of OA Murine strain, 
gender 






26-week-old CBA (n=6) 




12-week-old CD1 (n=10) 
Post-traumatic 
OA 





14-week-old (n=11) 14-week-old C57BL/6J (n=8) 
 
2.2.1.1 STR/ort and CBA mice 
Male STR/ort mouse samples were provided by Professor Pitsillides at the Royal Veterinary 
College, London, UK. Two time-points of STR/ort mouse tissues were collected: 26-week-old 
(n=7) and 40-week-old (n=14) (Table 2.1). As this is a spontaneous OA model, a wider variation 
in OA severity was expected. This age range gave the full extent of OA development 
encompassing a range of severity grades of disease (OARSI score range from grades 2 to 6) [152, 
155-159]. For toluidine blue, PR and immunohistochemical staining analysis, STR/ort samples 
were categorised based on OARSI cartilage grade and compared to aged-matched healthy male 




2.2.1.2 DMM mice 
DMM mice knee joints were provided by Professor Bou-Gharios from the University of 
Liverpool. Surgical destabilisation of the medial meniscus was performed on the right knee joint 
in 10 week-old male C57CBA F1 mice (Charles River, UK; n=12) (Table 2.1) as described 
previously by Glasson et al. [107]. Anaesthesia was induced by injection of 10 μL/g of 
Hypnorm®/Hypnovel® (at a ratio of 1:1–4 parts water), the right knee joint cavity was accessed 
via a medial incision. The meniscotibial ligament was transected, resulting in the release of the 
medial meniscus from its tibial attachment. After transection, the skin was sutured and mice were 
immediately transferred to a heated post-operative recovery room. After surgery, mice received 
buprenorphine hydrochloride (Vetergesic; Alstoe Animal Health, York, UK) subcutaneously 
post-surgery and monitored daily to ensure good health. DMM knee joints were analysed at 8 
weeks post-surgery and compared to the contralateral knee joint (left leg) of the same mice (n=12) 
(Table 2.1). Procedures were approved by the local ethics committee (project license: 709047). 
 
2.2.1.3 Non-invasive mechanical loading mice 
Samples from mice following non-invasive mechanical loading mice were provided by Dr. Poulet 
(University of Liverpool). The right knee joint of eight-week-old C57BL/6J mice (Charles River, 
UK) (Table 2.1) were loaded repetitively as described previously [153], using a regime that 
induces progressive AC lesions. Axial compressive loads were applied by a servo-hydraulic 
materials testing machine (Model HC10, Dartec, UK) via custom-made cups that hold knee and 
ankle joints flexed and the tibia vertically. The loading pattern consisted of a trapezoidal wave, 
with peak 9N loads for 0.05 seconds, rise and fall times 0.025 seconds each and baseline hold 
time of 9.9 seconds at 2N. Forty cycles were applied in each loading episode, and six loading 
episodes over a period of two weeks were applied. Knee joints were collected at 4 weeks after the 
last loading episode (n=11), to determine short-term histopathological changes following OA 
initiation. C57BL/6J male mice at 14 weeks of age were used as age-matched controls (n=4 per 





2.2.1.4 CD1 mice 
Male CD1 outbred mice were purchased from Charles River, UK and then housed in the specific 
pathogen free biological services unit at the University of Liverpool, UK. These mice have been 
recently shown to develop spontaneous OA after 24-weeks of age [154]. For comparison, a 
younger (12-week-old) group was compared to an older (24-week-old) group (Table 2.1). Young 
male 12-week-old CD1 mice were euthanized upon arrival (12-week-old group, n=10) and the 
remaining were aged for 12 more weeks (24-week-old group, n=10). 
 
2.2.2 Murine tissue preparation 
At the time points mentioned above, mice were killed by cervical dislocation for immediate tissue 
collection. Firstly, skin was removed and hindlimbs were detached near the hip joint. Muscles 
surrounding the knee joint and femur and tibia were carefully trimmed and removed. Knee joints 
were fixed in neutral buffered formalin for 24 hours, washed in water and stored in 70% ethanol. 
CD1 mouse knee joints were then scanned for µCT to evaluate joint mineralisation (see Section 
2.2.5). For histological examination, STR/ort, non-invasive mechanical loading and CD1 mouse 
knee joints were decalcified with 10% formic acid (Sigma) for 1-2 weeks. DMM mouse knee 
joints were decalcified with 10% ethylenediaminetetraacetic acid (EDTA) (pH 7.4) (Sigma) for 3 
weeks. After decalcification, all samples were washed, dehydrated and processed for wax 
embedding. Knee joint samples were paraffin embedded coronally and sequentially sectioned at 
6µm across the entire joint. 
 
2.2.3 Histological staining 
2.2.3.1 Toluidine Blue 
Toluidine blue was used to assess pathophysiological changes in menisci and knee joint ligaments 
and for OARSI cartilage scoring in the CD1 mice knee joints (see Section 2.2.5). Protocol for 
Toluidine blue staining is similar to protocols previously published [153, 164, 165]. For the 
straining, a quarter of the sectioned histology slides across the joint were stained with toluidine 
blue at regular intervals (every fourth slide, about 100 µm). Slides were dewaxed and hydrated 
with xylene (5 min, x2), 100% ethanol, 90% ethanol, 70% ethanol, and distilled water (3 min each 
ethanol and water wash). Slides were then pre-conditioned with sodium acetate buffer (0.1M, pH 
5.6) for 1 minute and stained with toluidine blue (0.1% toluidine blue in 0.1M solution of acetate 
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buffer, pH 5.6) for 15 minutes. After two washes with distilled water, slides were counterstained 
with 0.2% fast green for 5 seconds. Slides were washed with distilled water, and then dehydrated 
with acetone (x2, 10 seconds) and xylene (x2, 3 minutes) before being mounted with DPX 
(Sigma). Slides were imaged with a standard brightfield microscope (Nikon Eclipse Ci). 
 
2.2.3.2 PR staining 
PR staining can be used to evaluate collagen content and birefringence [166, 167]. Paraffin 
sections were dewaxed and hydrated with xylene (x2), 100% ethanol, 90% ethanol, 70% ethanol, 
and distilled water. Sections were stained in Weigert’s haematoxylin (Stock A: 1% w/v 
hematoxylin in 95% ethanol, Stock B: 1.16% w/v ferric chloride in 1% v/v hydrochloric acid in 
distilled water, 1:1 ratio of stock A and stock B) for 8 minutes. Slides were washed with running 
water for 10 minutes. Following washing, slides were stained with PR (0.1% w/v sirius red in 
saturated aqueous picric acid, both from Sigma) for one hour and then washed with 0.5% v/v 
glacial acetic acid in distilled water for 3 minutes (x2), and dehydrated in 100% ethanol (x3) and 
xylene. Slides were then mounted in DPX (Sigma). Slides were imaged with a standard 
microscope with a polarised light analyser and an adjustable polariser (Olympus BX60), and 
images taken with brightfield for analysis of red collagen staining and with polarised light for 
analysis of collagen birefringence. 
 
2.2.4 Immunohistochemistry 
Immunohistochemistry was performed to localise expression of COL2, SOX9, RUNX2 and 
asporin (ASPN) (see Table 2.2), based on our published protocol [165]. COL2, SOX9 and 
RUNX2 markers were chosen to explore chondrogenesis and hypertrophy. As previously 
mentioned, these markers have been briefly described in human OA ACLs near ‘chondrocyte-
like’ cells [129, 168, 169]. Furthermore, SLRP ASPN was chosen as it is a known inhibitor of 
chondrogenesis in cartilage and in OA [170], and a known ligament and tendon proteoglycan 
[171]. RUNX2 and ASPN immunostaining protocol could not be validated in the DMM knee 
joints, neither were expressed in any part of the DMM knee joints. This is likely due to differences 
in the histological tissue preparation of the DMM knee joints (EDTA) (see Section 2.2.2). 
44 
 
Histology slides were dewaxed and rehydrated with two washes of xylene (5 minutes each), 
followed by washes of 100% ethanol, 90% ethanol, 70% ethanol and distilled water (3 minutes 
each). PAP pen (Thermo) barrier was quickly drawn around each individual section. 
For COL2 immunostaining, sections were preconditioned with 0.2M hydrochloric acid for 15 
minutes at 37°C and then antigen retrieval was applied with pepsin (3mg/mL in 0.02M 
hydrochloric acid) for 45 min at 37°C. No antigen retrieval steps were performed for SOX9, 
RUNX2 and ASPN. All slides were then washed with PBS-T (PBS with 0.1% Tween, Sigma) and 
blocked for endogenous peroxidase with 0.3% hydrogen peroxide (Sigma) for 15 min at 37°C. 
Next, slides were washed with PBS-T and blocked for endogenous Avidin/Biotin binding with an 
Avidin/Biotin Blocking Kit (Vector Labs, SP2001).  
Non-specific binding sites were blocked for 1 hour at room temperature with serum block of either 
mouse-on-mouse (MoM) blocking reagent (Vector Labs) (for mouse primary antibodies) or 10% 
goat serum (Vector Labs) in PBS-BSA for rabbit primary antibodies (see Table 2.2). Primary 
antibodies were incubated overnight at 4°C and included COL2 (1/100), SOX9 (1/1000), RUNX2 
(1/1000), and ASPN (1/400). Negative controls included a mouse IgG (2µg/mL, Sigma) or rabbit 
IgG (1µg/mL, Vector Labs). All antibodies were diluted in PBS. Following washing (PBS-T), 
biotinylated secondary antibody (Vector Labs) was applied for 1 hour (see Table 2.2) and then 
washed again with PBS-T. Vectastain (Vector Labs) was then applied for 30 min and washed with 
PBS. Stains were developed with DAB Substrate Kit (Preoxidase) (Vector Labs), dehydrated and 
mounted with DPX mounting medium (Sigma). 
 
Table 2.2 List of antibodies analysed with immunohistostaining. Antibody description and the corresponding antigen 
retrieval, serum block and secondary antibody used. 
Primary Antibody 
(dilution) 
Antigen Retrieval Serum Block Secondary Antibody 





MoM Block (Vector 
Labs, BMK-2202) 
Anti-Mouse IgG (Vector 
Labs, BMK-2202) 




10% goat serum  
in PBS-BSA 
(Vector Labs,  
S-1000) 
Anti-Rabbit IgG  
(Vector Labs,  
BA-1000) 
RUNX2 (1:1000),  
Rabbit polyclonal, 
(Abcam, ab23981) 





2.2.5 OARSI scoring of cartilage degradation in CD1 mouse knee joints 
CD1 mouse knee joints were graded using the OARSI cartilage scoring system [17]. Briefly, the 
scoring system is the following: grade 0 for normal articular cartilage, grade 1 for lesions in the 
superficial zone, grade 2 for lesions in the intermediate zone, grade 3 for lesions down to the 
tidemark and up to 20% of articular cartilage loss, grade 4 for 20-50% of articular cartilage loss, 
grade 5 for 50-80% of articular cartilage loss, and grade 6 for greater than 80% of articular 
cartilage loss and bone exposure [17]. Toluidine blue stained sections of the entire knee joint were 
scored for cartilage lesion severity in each knee compartment: medial tibia (MT), medial femur 
(MF), lateral tibia (LT) and lateral femur (LF). Using these calculations, the average mean and 
maximum lesion scores was calculated for each compartment and for the whole knee joint of each 
mouse. Summed scores of all the compartments were also calculated from the mean and maximum 
scores. 
Statistical analysis was completed using GraphPad Prism (version 6, USA). The data was tested 
for normality using the Shapiro-Wilk normality test. Both 24-week-old and 12-week-old OARSI 
maximum and mean score did not pass normality (p-value = 0.0002). Hence an unpaired non-
parametric Mann-Whitney test was used to compare the two separate 12-week-old and 24-week-
old groups for the maximum and mean OARSI scores. 
 
2.2.6 Micro computed tomography (µCT) for joint space mineralisation of CD1 knee 
joints  
Cadaveric knee joints of the CD1 mice were analysed with micro computed tomography (µCT) 
to quantify joint space mineralisation which has been shown to increase with OA progression 
[165]. Knee joints of CD1 mice were scanned with a 4.5µm isotropic voxel size (50kV, 200µA 
respectively, 0.5mm Aluminium filter; 0.6° rotation angle, no frame averaging) using a Skyscan 
1172 µCT scanner (Skyscan, Belgium). Hand-drawn regions of interests of the joint space 
including menisci (lateral and medial) and other mineralised tissues that were not part of the tibial 
or femoral bones. These regions of interests were analysed using 3D algorithms in CTAn 
(Skyscan, Belgium) (Figure 2.1) to provide the mineralised tissue volume (measured as Bone 
Volume on CTAn). Statistical analysis of mineralised volume comparing the different groups was 
first tested for normality using the Shapiro-Wilk normality test (GraphPad Prism). Joint 
mineralisation data for 24-week-old CD1 mice did not pass the normality test (p-value = 0.0005). 
Hence, an unpaired non-parametric Mann-Whitney test was used to compare the 12-week-old 
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CD1 mice from the 24-week-old CD1 mice. Three-dimensional models of the menisci were 




Figure 2.1 Micro computed tomography (µCT) analysis for measuring murine knee joint space mineralisation. (A) 
Region of interest around the menisci (red) was manually drawn from coronal µCT images. (B) A task list was optimized 
for processing and quantification of the region of interest. (C) The resulting menisci region of interest after thresholding 





2.3.1 Spontaneous OA STR/ort murine model 
In the spontaneous OA STR/ort murine model, knee ligament and meniscal pathology were 
assessed to identify specific changes occurring during OA progression. Histopathological analysis 
included toluidine blue and PR staining to visualise cellular and ECM changes, as well as 
immunostaining to analyse specific marker pathological changes in the ACL, MCL and medial 
menisci. The collateral ligaments and menisci were analysed as they have been previously 
reported in the STR/ort mice to exhibit calcification [152] particularly in the medial compartment 
which is most affected in the STR/ort model [117]. The ACL was also analysed for pathological 
changes as it has been previously reported to show lower ultimate strength in the STR/ort model 
compared to healthy CBA [114]. STR/ort knee ligament and menisci were categorised by OARSI 
scoring of the cartilage degeneration, and compared to healthy aged-matched CBA controls, an 
OA-resistant mouse strain. 
 
2.3.1.1 STR/ort mice anterior cruciate ligament (ACL) pathology 
2.3.1.1.1 Toluidine blue staining 
Toluidine blue staining in healthy CBA knee joints showed an organised ACL structure with 
aligned spindle-like cells and some dark-blue staining in the dense collagenous matrix of the ACL 
(Figure 2.2A). Rounded-cell morphology in the CBA ACLs was sparse and only apparent in the 
fibrocartilaginous tibial attachment region (Figure 2.2A, yellow arrow). Toluidine blue staining 
expanded as OA grade in the STR/ort mouse knee joints increased. In ACLs of STR/ort OA grade 
2 mice, toluidine blue staining was present in the mid-ligament matrix and in the tibial attachment 
site or enthesis (Figure 2.2B, red arrows). In OA grade 4 STR/ort knee joints, toluidine blue 
staining encompassed the entire ACL and loss of fibre alignment and organisation was apparent 
(Figure 2.2C). Additionally, ACL fibroblasts had a rounded phenotype potentially indicating 
hypertrophy (Figure 2.2C, yellow arrows). Lastly, in OA grade 6, toluidine blue staining covered 
most of the ACL and hypertrophic-rounded cells were present near the tibial attachment site 
extending towards the ACL (Figure 2.2D, yellow arrows). STR/ort ACLs showed changes in 
fibroblast phenotype, fibre organisation and potentially matrix changes marked by toluidine blue 




Figure 2.2 Histological staining of the anterior cruciate ligament (ACL) in STR/ort knee joints using toluidine blue. 
Representative images of: (A) Aged-matched CBA knee joints showed an organised ACL matrix and toluidine blue 
staining in the mid-ligament region. Rounded-cell morphology was only found in the fibrocartilaginous tibial enthesis 
region (yellow arrow). (B) OA grade 2 STR/ort ACL had toluidine blue staining at the tibial enthesis and the mid-
ligament region (red arrows). (C) OA grade 4 STR/ort ACL had total toluidine blue staining in all regions of the ACL 
(red arrows) and evidence of rounded-cell morphology throughout the ACL (yellow arrows). (D) OA grade 6 STR/ort 
ACL demonstrated toluidine blue staining in the mid-ligament region (red arrow) and ‘rounded’ cell morphology near 
the tibial enthesis (yellow arrows). Scale bar is 100 µm (10x) and 50 µm (40x). 
 
2.3.1.1.2 PR staining 
PR staining was used to analyse collagen content and birefringence of the ACLs in STR/ort mice. 
Brightfield microscopy confirmed an organised structure and light red collagen staining in the 
CBA ACL (Figure 2.3A), additionally spindle-cell shaped fibroblast morphology was confirmed 
in the mid-ligament region of the ACL (Figure 2.3A, green arrow). In OA grade 2 STR/ort knee 
joints, ACL structure was similar, with some red collagen stain aggregation surrounding spindle-
shaped fibroblasts in the ACL (Figure 2.3B, green arrow) and red collagen staining in the outer 
epiligament regions of the ACL. As OA grade increased, ACL fibre alignment changed and red 
collagen stain was evident in areas with rounded-cell morphology in the mid-ligament region of 
the ACL (Figure 2.3C, yellow arrows). 
Polarised light microscopy revealed green birefringence in the mid-section of the ACL, indicative 
of thin fibres, and red-yellow birefringence at the outer epiligament areas, indicative of thicker 
collagen fibres (Figure 2.3A, blue arrow). In STR/ort ACLs red birefringence was apparent in the 
outer epiligament regions of the ACL in OA grade 2 (Figure 2.3B) and extended to the mid-
ligament region at OA grade 4 (Figure 2.3C). Changes in collagen birefringence suggest thicker 
collagen fibrils in STR/ort ACLs, potentially indicative of coarser and closely packed collagens 




Figure 2.3 Histological staining of the anterior cruciate ligaments (ACL) in STR/ort knee joints using picrosirius red. 
Representative images of: (A) Aged-matched CBA knee joints had an organised ACL with light red collagen staining 
and spindle-shaped fibroblasts (brightfield, green arrow). Polarised light showed mainly green birefringence 
throughout the ACL with some red birefringence in the upper epiligament layer (polarised light, blue arrow). (B) OA 
grade 2 STR/ort ACL had sparse dark red collagen staining in the mid-ligament region and spindle-shaped fibroblasts 
(brightfield, green arrow). Red birefringence was found in the outer epiligament region of the ACL (polarised light, 
blue arrows). (C) OA grade 4 STR/ort knee joints had disorganised ACL fibre alignment and rounded-cell morphology 
in the mid-ligament region (yellow arrows). The mid-ligament region of the ACL also had dark red collagen staining 
(brightfield) and red birefringence (polarised light, blue arrows). Scale bar is 100 µm (brightfield and polarised light) 






Immunostaining confirmed changes in the ACL ECM and cellular markers in the OA STR/ort 
knee joint. We analysed immunostaining of COL2 expression in the ECM, SOX9 and RUNX2 
cellular markers, and SLRP marker ASPN. As previously mentioned, these markers were chosen 
to analyse cartilage-related markers due to the rounded-cell morphology seen in the toluidine blue 
and PR staining. 
Aged-matched CBA mice knee joints demonstrated COL2 expression in a thin layer of the 
fibrocartilaginous ACL-tibial enthesis region, as well as sparse SOX9, RUNX2 and ASPN 
expression at the ACL-tibial enthesis (Figure 2.4A, black arrows). Furthermore, in the ACL mid-
ligament region of CBA knee joint, COL2, RUNX2 and ASPN were not expressed but some 
SOX9 expression was evident within spindle-shaped ACL fibroblasts (Figure 2.5A, green 
arrows). 
In the diseased OA grade 2 STR/ort ACL-tibia enthesis, COL2 expression was evident in the 
insertion sites in similar locations to the toluidine blue staining (Figure 2.4B, black arrow). The 
ACL-enthesis also showed SOX9, RUNX2 and ASPN expression which extended from the 
enthesis to within the ACL (Figure 2.4B, black arrows). Looking further at the mid-ligament 
region of the OA grade 2 STR/ort ACL, showed no COL2, SOX9 and ASPN staining, and only 
sparse RUNX2 staining near the outer epiligament layer of the ACL (Figure 2.5B, green arrow). 
In more severe OA grade 4 STR/ort mice knee joints, the ACL had COL2 deposition surrounding 
rounded-like cells near the ACL tibial enthesis (Figure 2.4C, COL2, black arrows) and at the ACL 
mid-ligament region (Figure 2.5C, COL2, black arrows). These changes also aligned with SOX9 
and RUNX2 expression which manifested in the ‘rounded’ ligament cells throughout the 
ligament, and also ASPN expression which was mainly found in the mid-ligament region but not 
near the tibial enthesis (Figure 2.4C, Figure 2.5C). Overall, STR/ort OA ACLs showed COL2, 





Figure 2.4 Immunostaining of the anterior cruciate ligament (ACL) tibial enthesis in STR/ort knee joints of collagen 
type II (COL2), SOX9, RUNX2 and ASPN expression. Representative images of: (A) Aged-matched CBA ACL tibial 
enthesis showed COL2, SOX9, RUNX2 and ASPN expression near the fibrocartilaginous tibial enthesis. (B) OA grade 
2 STR/ort ACL showed COL2 deposition in the tibial enthesis, as well as SOX9, RUNX2 and ASPN expression. (C) OA 
grade 4 STR/ort ACL also had COL2 deposition, and SOX9 and RUNX2 expression near the tibial enthesis particularly 




Figure 2.5 Immunostaining of the anterior cruciate ligament (ACL) mid-ligament region in STR/ort knee joints of 
collagen type II (COL2), SOX9, RUNX2 and ASPN expression. Representative images of: (A) Aged-matched CBA ACL 
mid-ligament region showed no COL2, RUNX2 and ASPN expression, and sparse SOX9 expression in spindle-like cells 
(green arrows). (B) OA grade 2 STR/ort ACL mid-ligament showed no COL2, SOX9 and ASPN expression, and some 
RUNX2 expression. (C) OA grade 4 STR/ort ACL mid-ligament region showed COL2 deposition, and SOX9, RUNX2 
and ASPN expression in rounded-like cells (black arrows). Scale bar is 100 µm (10x) and 25 µm (40x). 
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2.3.1.2 STR/ort mice medial collateral ligament (MCL) pathology 
2.3.1.2.1 Toluidine blue staining 
Toluidine blue staining of the MCL in STR/ort knee joints was analysed and compared to healthy 
CBA knee joint. Toluidine blue staining of the CBA aged-matched control knee joint MCLs 
showed an organised femur-enthesis with ordered toluidine blue staining and rounded-cell 
morphology at the fibrocartilage zone (Figure 2.6A, yellow arrows), and a mid-ligament region 
with organised fibre alignment and spindle-shaped fibroblasts with little toluidine staining (Figure 
2.6A, green arrow). In STR/ort knee joints with OA grade 2 the MCL had similar fibrocartilage 
region however fibre organisation near the femoral enthesis was disrupted and hypocellular 
(Figure 2.6B, green cross). In the MCL mid-ligament region of the OA grade 2 STR/ort knee 
joints, there were a small number of rounded and potentially hypertrophic cells encircled by 
toluidine blue staining (Figure 2.6B, yellow arrows). In OA grade 4 STR/ort knee joints, the MCL 
had toluidine blue staining (red arrows) and rounded-cell morphology (yellow arrows) near the 
femoral enthesis which extended throughout the MCL mid-ligament region (Figure 2.6C). In 
severe OA grade 6 STR/ort MCL, there was a clear increase in rounded-cell morphology (yellow 
arrows), hyperplasia, abnormal tissue formation, loss of fibre alignment and organisation, and 
evidence of endochondral ossification and mineralisation throughout the MCL (Figure 2.6D). 
 
2.3.1.2.2 PR staining 
PR staining analysed collagen birefringence in healthy CBA and OA STR/ort knee joint MCLs. 
CBA mice knee joints demonstrated MCLs with red staining and rounded-cell morphology 
(yellow arrows) near the femoral enthesis and at the fibrocartilaginous region, and spindle-shaped 
cells in the mid-ligament region of the MCL (Figure 2.7A). Polarised light verified green 
birefringence throughout the entire MCL, with some red-yellow birefringence, indicating thicker 
fibres, near the femoral enthesis (Figure 2.7A). OA grade 2 STR/ort knee joint MCLs were similar 
to the healthy CBA MCL, with red staining and red birefringence near the femoral enthesis region 
and green birefringence throughout the rest of the MCL (Figure 2.7B). In OA grade 4 STR/ort 
knee joints, red collagen staining and rounded-cell morphology (yellow arrows) increased in all 
regions of the MCL (Figure 2.7B). Polarised light confirmed changes in the collagen structure, 
showing red birefringence throughout the entire MCL, including near the femoral enthesis and in 
the mid-ligament region near the meniscal attachment (Figure 2.7B, blue arrows). This finding 




Figure 2.6 Histological staining of the medial collateral ligament (MCL) in STR/ort knee joints using toluidine blue. 
Representative images of: (A) Aged-matched CBA knee joints showed an organised MCL fibre structure with spindle-
shaped fibroblasts (green arrow) and toluidine blue staining in the fibrocartilaginous region (yellow arrows). (B) In 
OA grade 2 St/ort knee joints, MCL fibre misalignment was evident and toluidine blue staining appeared in the mid-
ligament region surrounding cells with a rounded morphology (yellow arrows). (C) In OA grade 4 STR/ort knee joints, 
toluidine blue staining (red arrows) and rounded-cell morphology (yellow arrows) was present throughout the MCL. 
(D) In severe OA grade 6 STR/ort knee joints, abnormal MCL structure included complete loss of fibre alignment, 




Figure 2.7. Histological staining of the medial collateral ligament (MCL) in STR/ort knee joints using picrosirius red. 
Representative images of: (A) Aged-matched healthy CBA MCLs showed light-red collagen staining, rounded-cell 
morphology (yellow arrows) at the fibrocartilage zone, and spindle-shaped cells (green arrow) in the mid-ligament 
region. Polarised light showed green birefringence throughout the MCL with yellow-red birefringence near the femoral 
enthesis (blue arrow). (B) OA grade 2 STR/ort MCL was similar, with yellow-red birefringence near the femoral 
enthesis (blue arrow) and green birefringence in the mid-ligament region. (C) In OA grade 4 STR/ort knee joints, dark 
red collagen staining was found throughout the MCL and corresponded with rounded-cell morphology (yellow arrows) 
and red birefringence (blue arrows) near the femur attachment site and in the outer epiligament layers of the MCL mid-




Immunostaining of healthy CBA and OA STR/ort knee joint MCLs showed differences in matrix 
composition and cell marker expression. CBA MCLs had an organised COL2 expression (black 
arrow) at the fibrocartilage region of the MCL-femoral enthesis (Figure 2.8A). None of the 
markers (COL2, SOX9, RUNX2 or ASPN) were expressed in the mid-ligament region of the 
MCL in CBA mice (Figure 2.8A). In STR/ort knee joints with OA grade 2, COL2 aggregation at 
the MCL-femoral enthesis was also found in the fibrocartilaginous region, as well as some SOX9, 
RUNX2 and ASPN expression with extended from the femoral enthesis (black arrows) (Figure 
2.8B). In the mid-ligament region of the MCL, there was some SOX9 and RUNX2 expression in 
the outer epiligament layer. In OA grade 5 STR/ort knee joints, there was further expression of 
COL2, SOX9, RUNX2, and ASPN markers throughout the MCL (Figure 2.8C). This included 
expression of all markers near the MCL-femoral enthesis (black arrows) and ASPN expression in 
the outer epiligament layer near the enthesis (red arrow) (Figure 2.8C). Furthermore, there was 
COL2 deposition in the mid-ligament region near areas with rounded-cell morphology (black 
arrows) as well as SOX9, RUNX2 and ASPN expression particularly in similar rounded-cell types 
(black arrows) (Figure 2.8C). 
 
2.3.1.3 STR/ort mice medial meniscal pathology 
2.3.1.3.1 Toluidine blue staining 
The menisci of healthy CBA and OA STR/ort knee joints were also evaluated for pathological 
changes. In healthy CBA knee joints, toluidine blue staining delineated the expected ossified (O), 
hyaline cartilage (H) and fibrous region (F, red region) of the meniscus with rounded-shaped cells 
(yellow arrows) near the fibrous region (Figure 2.9A). The severity of pathological changes in the 
medial meniscus of STR/ort mice increased with AC degradation severity (Figure 2.9B-D). In OA 
grade 2 knee joints, there was an increase in the area of the fibrous region (Figure 2.9B, red region) 
which further increased with disease progression (Figure 2.9C-D). In OA grade 4 and 5, this 
fibrous region showed toluidine blue staining, rounded chondrocyte-like cells (yellow arrows) and 
formation of bone marrow cavities (black arrows) near the joint capsule (Figure 2.9C-D). Overall, 
toluidine blue staining demonstrated irregular hyperplasia, toluidine blue staining and changes in 





Figure 2.8 Immunostaining of the medial collateral ligament (MCL) in STR/ort knee joints of collagen type II (COL2), 
SOX9, RUNX2 and ASPN expression. Representative images of: (A) Aged-matched CBA knee joints had an MCL-
femoral enthesis with ordered COL2 staining in the fibrocartilaginous region, and no marker expression in the MCL 
mid-ligament region. (B) OA grade 2 STR/ort MCLs had increased COL2 expression in the fibrocartilaginous femoral 
enthesis (black arrows) and minor SOX9, RUNX2 and ASPN expression near the femoral enthesis and no marker 
expression in the MCL mid-ligament region. (C) In OA grade 5 STR/ort knee joints, COL2 expression was evident in 
the MCL femoral enthesis and in the mid-ligament region near areas with rounded-cell morphology (black arrows). 
Rounded-cells (black arrows) also corresponded with expression of SOX9, RUNX2 and ASPN. Scale is 100 µm (10x) 




Figure 2.9 Histological staining of the medial menisci in STR/ort knee joints using toluidine blue. Representative images 
of: (A) Aged-matched CBA knee joints had healthy medial menisci with hyaline cartilage layers (H), ossified central 
core (O) and an outer fibrous region (F, red region). (B) OA grade 2 STR/ort medial menisci had a slightly enlarged 
fibrous region (red zone) with rounded-cell morphology (yellow arrows) in the outer fibrous regions. (C) OA grade 4 
STR/ort medial menisci had even larger fibrous regions (red zone) with toluidine blue staining and rounded-cell 
morphology (yellow arrows) and possible bone formation (black arrows) in the fibrous region. (D) In severe OA grade 
5 STR/ort knee joints, ossification was more evident (black arrow) and toluidine blue staining and rounded-cell 
morphology expanded to upper and lower areas of the fibrous region (yellow arrows). Scale is 100 µm (10x), 50 µm 
(20x) and 25 µm (40x). 
 
2.3.1.3.2 Immunostaining 
Immunostaining of the healthy CBA and OA STR/ort medial menisci revealed several markers 
present in areas of hyperplasia. Healthy CBA medial menisci showed COL2 delineating the 
hyaline cartilage region of the murine menisci along with some ASPN expression near the fibrous 
capsular attachment (green arrows) (Figure 2.10A). In OA grade 2 STR/ort knee joints, the fibrous 
region of the capsular attachment expanded however there were no changes in the staining of 
COL2, SOX9 and ASPN (Figure 2.10B). In OA grade 5 STR/ort knee joints, meniscal hyperplasia 
was fully underway in the meniscal fibrous region and COL2 expression (black arrows) was 
present in the outer expanding meniscal attachment site surrounding areas of bone formation (red 






Figure 2.10 Immunostaining of the medial menisci in STR/ort knee joints of collagen type II (COL2), SOX9, and ASPN. 
Representative images of: (A) Aged-matched CBA knee joints had medial menisci with COL2 staining in the inner 
meniscal hyaline cartilage region and sparse SOX9 expression (black arrow) within cells in the upper fibrous region, 
and ASPN expression (green arrows) in the outer joint capsule region. (B) OA grade 2 STR/ort medial menisci had an 
expanded fibrous region but no evidence of COL2 and SOX9 staining, and only some ASPN staining (green arrows) in 
the same outer joint capsule region. (C) OA grade 5 STR/ort knee joints had medial menisci with ossification in the 
fibrous region (red arrows) showed COL2 deposition (black arrows) and SOX9 and ASPN expression (black arrows) 
in the expanding upper and lower fibrous attachment regions (red region). Scale is 100 µm (10x) and 25 µm (40x). 
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2.3.1.4 Summary of the STR/ort knee joint OA pathology 
Overall, in the STR/ort mice knee joints the ACL, MCL and medial menisci all showed structural 
changes and rounded-cell morphology in affected areas which seemed to increase with OA 
progression. More specifically, in the STR/ort ACL there were ECM matrix changes in the tibial 
enthesis and the mid-ligament region which included COL2 deposition and coincided with cellular 
changes including rounded-cell morphology with SOX9, RUNX2 and ASPN expression. The 
MCL in the OA STR/ort knee joints showed similar pathology including hyperplasia and fibre 
disorganisation and potential bone formation and rounded-cell morphology in the mid-ligament 
region. Lastly, in the medial menisci of the STR/ort knee joints, hyperplasia and bone formation 
was notable in the fibrous region of the menisci, also containing COL2 deposition and rounded-
cell morphology. These findings demonstrate that STR/ort knee ligament and menisci pathology 
was marked by structural COL2 changes potentially driven by cellular changes associated with 




2.3.2 Post-traumatic OA surgical destabilisation of the medial menisci (DMM) murine 
model 
In the post-traumatic OA model following DMM surgery in the C57CBA murine knee joint, 
pathological changes in the ACL, MCL and menisci were also determined using histological 
staining (with toluidine blue, PR staining) and immunostaining for markers of OA. DMM mice 
were categorised based on the OARSI OA cartilage score, which ranged from OA grade 2 to 6 
(mean OARSI score was 3.4 ±0.3), with OA predominant in the medial compartment as expected 
[107]. As previously mentioned, meniscal and ligament pathological changes in the DMM model 
have largely not been described. DMM post-traumatic joints were compared to the non-operated 
contralateral knee joints. 
 
2.3.2.1 DMM mice anterior cruciate ligament (ACL) pathology 
2.3.2.1.1 Toluidine blue staining 
Toluidine blue staining of the ACL in contralateral knee joints of C57CBA mice showed an 
organised ACL ECM, with the presence of toluidine blue staining in the fibrocartilaginous region 
of the tibial enthesis near cells with rounded morphology (yellow arrows) (Figure 2.11A). In the 
DMM knee joints with OA grade 4, pathological changes in the ACL included ECM 
disorganisation, fibre misalignment, toluidine blue staining near the tibial attachment site (red 
arrow) and numerous rounded hypertrophic-like cells (yellow arrows) extending from the ACL-
tibial enthesis to the ligament (Figure 2.11B). In severe OA grade 6, the ACL had toluidine blue 
staining at the fibrocartilaginous region (yellow arrows) and no cellular or fibre alignment within 
the ligament, no toluidine blue staining and abnormal tissue formation including potential 
inflammation and blood vessel formation (black arrows) (Figure 2.11C). Toluidine blue staining 
demonstrated severe pathological changes in the ECM and cellular phenotype in the ACL of the 





Figure 2.11 Histological staining of the anterior cruciate ligament (ACL) in DMM and contralateral knee joints using 
toluidine blue. Representative images of: (A) Contralateral (non-operated) knee joint had an ACL with an organised 
ECM structure and toluidine blue staining in the fibrocartilaginous tibial enthesis region (yellow arrows). (B) OA grade 
4 DMM knee joint ACL was disorganised, showed no fibre alignment and had toluidine blue staining near the 
attachment site (red arrow) and rounded-cell morphology (yellow arrows). (C) OA grade 6 DMM knee joint ACL 
showed severe misalignment and signs of inflammation including potential blood vessel formation (black arrows). Scale 
is 100 µm (10x) and 25 µm (40x). 
 
2.3.2.1.2 PR staining 
PR staining of the DMM knee joint ACL confirmed changes in the collagen matrix content and 
organisation. The ACL from the contralateral knee joints had red collagen stain and rounded-cell 
morphology (yellow arrows) at the fibrocartilaginous region of the tibial enthesis (Figure 2.12A). 
Polarised light, used to visualise collagen birefringence, in the contralateral knee joints showed 
green and orange birefringence (blue arrow) near the ACL tibial enthesis (Figure 2.12A). DMM 
OA grade 4 and 6 knee joints showed widespread red collagen staining throughout the ACL, as 
well as evidence of rounded cell morphology (yellow arrows) which extended from the 
fibrocartilaginous region to the mid-ligament region (Figure 2.12B-C). Polarised light in the ACL 
of the DMM knee joint verified extensive red birefringence (Figure 2.12B-C,). In OA grade 4 
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knee joints, green birefringence was present above the orange fibrocartilaginous region of the 
ACL (blue arrow) and orange birefringence was evident in inflamed ligament regions (blue arrow) 
(Figure 2.12B). In DMM OA grade 6 knee joints, the ACL had red birefringence from the tibial 
attachment site to the mid-ligament region (Figure 2.12C). Red birefringence would suggest 
thicker collagen fibres were prominent in the ACL of the OA grade 6 DMM knee joint. 
 
 
Figure 2.12 Histological staining of the anterior cruciate ligament (ACL) in DMM knee joints using picrosirius red. 
Representative images of: (A) Non-operated contralateral knee joint ACLs had red collagen staining near the 
fibrocartilaginous region with rounded cell morphology (yellow arrows). Polarised light showed green and orange 
birefringence (blue arrow) near the tibial enthesis. (B) The OA grade 4 DMM knee joint ACL had rounded-cell 
morphology (yellow arrows) in the fibrocartilaginous region and within the ACL. Orange birefringence (blue arrow) 
was found in the fibrocartilaginous zone and in inflamed regions of the ACL. (C) In OA grade 6 DMM knee joints, 
rounded-cell morphology (yellow arrows) extended from the ACL tibial enthesis to the mid-ligament and coincided 
with dark red collagen staining. Polarised light showed red birefringence (blue arrows) extended throughout the ACL, 




Immunostaining was used to compare COL2 staining and SOX9 expression in the DMM and 
contralateral knee joint ACLs. Contralateral knee joints had ACL with COL2 and SOX9 
expression (black arrows) in a thin and organised fibrocartilaginous region (Figure 2.13A). In 
DMM mice with OA grade 4 and 6, the fibrocartilaginous region of the ACL had expanded COL2 
expression near regions with rounded-cell morphology (black arrows), along with abundant SOX9 
expression (black arrows) which extended from the ACL tibial enthesis to the mid-ligament 
(Figure 2.13B-C). SOX9 expression correlated with areas of rounded-cell morphology noted with 
toluidine blue and PR staining. Immunostaining confirmed changes in the fibrocartilaginous 
region of the DMM knee joint ACL which included COL2 deposition, and SOX9 expression 
cellular markers extending throughout the ACL. 
 
 
Figure 2.13 Immunostaining of the anterior cruciate ligament (ACL) tibial enthesis in DMM knee joints of collagen 
type II (COL2) and SOX9 expression. Representative images of: (A) Contralateral (non-operated) knee joint ACL 
showed minor COL2 and SOX9 staining (black arrows) in the fibrocartilaginous region of the ACL tibial enthesis. (B) 
OA grade 4 DMM knee joint ACL had COL2 deposition near the ACL tibial enthesis and extensive SOX9 expression in 
all ligament cells (black arrows). (C) OA grade 6 DMM knee joints had severe ACL deformation with an increased 
fibrocartilaginous region at the tibial enthesis with COL2 deposition and extensive SOX9 expression throughout the 




2.3.2.2 DMM mice medial collateral ligament (MCL) pathology 
2.3.2.2.1 Toluidine blue staining 
Toluidine blue staining in contralateral knee joints showed an organised MCL with toluidine blue 
staining at the fibrocartilaginous region (yellow arrows) and tide mark (black arrow) of the MCL 
femoral enthesis. The MCL mid-ligament region of the contralateral knee joint, had aligned fibres 
and spindle-shaped fibroblasts (purple arrow) (Figure 2.14A). Knee joints from DMM mice with 
OA grade 4 had MCLs with faint toluidine blue staining at the MCL femoral enthesis (yellow 
arrows), and structural changes including a fibrous region (red region) parallel and adjacent to the 
MCL with evidence of toluidine blue staining (yellow arrow) (Figure 2.14B). In the DMM OA 
grade 6 knee joint there were severe structural changes to the MCL, including a lack of collagen 
fibre alignment, ECM disorganisation, hyperplasia, and potential formation of bone cavities (red 
region and red arrows) (Figure 2.14C). Despite evidence of hyperplasia and structural changes in 






Figure 2.14 Histological staining of the medial collateral ligament (MCL) in DMM knee joints using toluidine blue. 
Representative images of: (A) Non-operated contralateral knee joint MCL showed toluidine blue staining near the 
fibrocartilaginous region (yellow arrows) and a tide mark (black arrow). The mid-ligament region of the contralateral 
knee joint MCL showed fibre alignment and an organised structure with no toluidine blue staining. (B) OA grade 4 
DMM knee joint MCL showed a similar MCL structure, however near the femoral enthesis there was a fibrous 
disorganised region (red region) which extended parallel with the MCL. (C) OA grade 6 DMM knee joint MCL showed 
evident hyperplasia and no fibre alignment, no toluidine blue staining, and evidence of bone formation in the mid-
ligament region (red region, red arrows), near the medial menisci. Scale is 100 µm (4x) and 25 µm (40x). 
 
2.3.2.2.2 PR staining 
PR staining was used to analyse collagen birefringence in the DMM and contralateral knee joint 
MCLs. Contralateral knee joints demonstrated an organised MCL structure with light-red collagen 
staining (Figure 2.15A). Polarised light showed green collagen birefringence throughout the 
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contralateral knee joint MCL with yellow birefringence (blue arrows) near the MCL femoral 
attachment site and a thin layer in the epiligament of the mid-ligament region (Figure 2.15A). In 
OA grade 4 DMM knee joints, the MCL had light-red collagen staining throughout the ligament, 
with dark-red staining in the outer fibrous region (yellow region) parallel to the MCL (Figure 
2.15B). Polarised light showed yellow-orange birefringence near the MCL femoral enthesis (blue 
arrow) in the abnormal fibrous region and in the epiligament layer of the mid-ligament region 
(Figure 2.15B). The OA grade 6 DMM knee joint MCL seemed to converge with the growing 
medial meniscus and surrounding mineralisation which resulted in an MCL region with abundant 
red collagen staining, with lack of collagen fibre alignment and clear hyperplasia (Figure 2.15C). 
Polarised light showed red birefringence (blue arrows) in the MCL from OA grade 6 DMM knee 
joints (Figure 2.15C). PR staining revealed red collagen birefringence in the DMM knee joint 
MCL, which would indicate thicker collagen fibre organisation in the diseased MCL. 
 
2.3.2.2.3 Immunostaining 
Immunostaining of the MCL from contralateral and DMM murine knee joints revealed changes 
in COL2 deposition and SOX9 expression. The contralateral MCL showed a thin layer of COL2 
staining (black arrows) at the fibrocartilaginous region of the femoral enthesis along with scarce 
SOX9 staining (black arrows) also at the femoral enthesis and in spindle-shaped fibroblasts in the 
mid-ligament region (green arrow) (Figure 2.16A). MCL from OA grade 4 DMM knee joints 
showed similar COL2 staining at the MCL femoral enthesis and no COL2 and SOX9 staining in 
MCL mid-ligament region except in the outer fibrous region (black arrows) (Figure 2.16B). The 
MCL from OA grade 6 DMM knee joints, showed further COL2 and SOX9 staining (black 
arrows) at the femoral enthesis and throughout the MCL including near areas of potential bone 
formation (red arrows) (Figure 2.16C). Changes in COL2 matrix composition and SOX9 cellular 





Figure 2.15 Histological staining of the medial collateral ligament (MCL) in DMM knee joints using picrosirius red. 
Representative images of: (A) Non-operated contralateral knee joint MCL had mainly green birefringence and yellow 
birefringence (blue arrows) only near the femoral attachment site and epiligament layer of the mid-ligament region. 
(B) OA grade 4 DMM knee joint MCL showed yellow-orange birefringence (blue arrows) near the attachment site in 
the adjacent fibrous region (yellow region) and in the epiligament layer of the mid-ligament region of the MCL. (C) 
OA grade 6 DMM knee joint MCL had red birefringence (blue arrows) in all regions of the MCL, suggesting thicker 




Figure 2.16 Immunostaining of the medial collateral ligament (MCL) in DMM knee joints of collagen type II (COL2) 
and SOX9 staining. Representative images of: (A) Non-operated contralateral knee joint MCL had COL2 staining and 
sparse SOX9 expression at the fibrocartilaginous layer of the femoral enthesis and some SOX9 expression in spindle-
shaped fibroblasts (green arrow) in the mid-ligament region of the MCL. (B) OA grade 4 DMM knee joint MCL had 
COL2 staining at the femoral enthesis (black arrows), but no SOX9 or COL2 staining in other parts of the ligament, 
except in the outer fibrous region (black arrows). (C) In OA grade 6 DMM knee joints, the MCL showed a thicker 
fibrocartilaginous layer with COL2 deposition near the femoral enthesis and extensive SOX9 staining throughout the 
MCL (black arrows). COL2 and SOX9 staining was also found in the mid-ligament region (black arrows) near areas 
of potential bone formation (red arrows). Scale is 100 µm (4x, 10x) and 25 µm (40x). 
70 
 
2.3.2.3 DMM mice medial meniscal pathology 
2.3.2.3.1 Toluidine blue staining 
Toluidine blue staining of the menisci of the non-operated contralateral knee joint showed medial 
menisci within normal limits which included toluidine blue staining in the hyaline cartilage 
portion of the menisci and a clear separation between the meniscal fibrous region (red region) and 
the capsular attachment and collateral ligament (Figure 2.17A). In OA grade 4 DMM knee joints, 
the fibrous region of the medial menisci (red region) seemed to converge with the MCL and 
capsular attachment and showed hyperplasia and abnormal tissue growth including bone 
formation (black arrows), along with rounded or hypertrophic cells expanding from the hyaline 
cartilage of the medial menisci (yellow arrows) (Figure 2.17B). OA grade 6 DMM knee joints, 
showed even more pronounced changes in the medial menisci including hyperplasia and bone 
formation (black arrows) accompanied by toluidine blue staining (red arrow) and rounded-cell 
morphology (yellow arrows) (Figure 2.17C). In the inner meniscal tip also demonstrated abnormal 
tissue growth and toluidine blue staining (Figure 2.17C). 
 
2.3.2.3.2 Immunostaining 
The localisation of COL2 and SOX9 expression were determined with immunostaining of the 
contralateral and DMM knee joint medial menisci. Contralateral medial menisci had COL2 
staining near the fibrous region and SOX9 staining in the outer menisci regions (black arrows) 
(Figure 2.18A). In OA grade 4 DMM knee joints, COL2 outlined the hyaline region of the medial 
menisci and COL2 and SOX9 could also be found in the upper area of the fibrous region 
particularly near cells with a rounded morphology (black arrows) (Figure 2.18B). OA grade 6 
DMM knee joints had medial menisci with COL2 and SOX9 staining emerging in the upper and 
lower expanding fibrous region surrounding areas of mineralisation (black arrows) (Figure 
2.18C). Similar to the ACL and MCL, in the medial menisci of the DMM knee joints, COL2 and 





Figure 2.17 Histological staining of the medial menisci in DMM knee joints using toluidine blue. Representative images 
of: (A) Non-operated contralateral knee joint medial menisci showed toluidine blue staining in the inner hyaline 
cartilage regions and a small outer fibrous region (red region) separate from the collateral ligament. (B) OA grade 4 
DMM knee joints had medial menisci with enlarged fibrous region (red region) which fused with the capsular collateral 
ligament and had evidence of mineralisation (black arrows) and rounded-cell morphology and toluidine blue staining 
in the upper fibrous regions (yellow arrows). (C) OA grade 6 DMM knee joints had medial menisci with toluidine blue 
staining (red arrow) in the outer fibrous regions (red region) and clear evidence of bone formation (black arrows) and 






Figure 2.18 Immunostaining of the medial menisci in DMM knee joints of collagen type II (COL2) and SOX9 staining. 
Representative images of: (A) Non-operated contralateral knee joints had medial menisci with COL2 staining in the 
fibrous region and SOX9 staining in the hyaline cartilage areas (black arrows). (B) OA grade 4 DMM knee joints had 
medial menisci with abnormal COL2 and SOX9 staining in the outer fibrous regions near cells with rounded 
morphology (black arrows). (C) OA grade 6 DMM knee joints had medial menisci with COL2 an SOX9 staining in the 
upper and lower fibrous regions.  Scale is 200 µm (4x), 100 µm (10x), 25 µm (40x). 
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2.3.2.4 Summary of the DMM knee joint OA pathology 
The post-traumatic OA DMM knee joint demonstrated ECM and cellular changes in the ACL, 
MCL and medial menisci which corresponded with post-traumatic OA disease progression. In the 
ACL of DMM knee joints at OA grade 4 and 6, there was severe collagen fibre misalignment, 
ECM disorganisation, and evidence of inflamed or abnormal tissue growth with red collagen 
birefringence suggesting thicker collagen fibres. The MCL of OA DMM knee joints showed 
severe pathology including abnormal fibrous tissue parallel to the MCL, bone formation and red 
collagen birefringence. Ossification extended from the MCL to the fibrous region of the medial 
menisci in the OA DMM knee joints. Immunostaining showed COL2 deposition and SOX9 
expression particularly in the fibrocartilaginous zone of the ACL tibial enthesis, in the MCL 
femoral enthesis, and in the fibrous region of the medial menisci including near areas of bone 
formation. This abnormal tissue growth indicated atypical COL2 matrix composition potentially 





2.3.3 Post-traumatic OA non-invasive mechanical loading murine model 
Non-invasive mechanical loading of C57BL/6J knee joints allows for examination of OA 
development in which articular cartilage lesions in the lateral femur are induced and slowly 
progress over time [153]. OA progression in the C57BL/6J loaded knee joints was previously 
confirmed and included increased mineralisation compared to healthy non-loaded C57BL/6J knee 
joints [165]. Loaded knee joints were analysed four weeks post-trauma. Changes in the ACL and 
lateral menisci have been previously reported in CBA mice following non-invasive mechanical 
loading and briefly included meniscal ossification and ACL pathological changes [153]. Our aim 
was to describe these changes in more detail in the C57BL/6J loaded knee joints. 
  
2.3.3.1 Non-invasive mechanically loaded mice anterior cruciate ligament (ACL) pathology 
2.3.3.1.1 Toluidine blue staining 
Toluidine blue staining of the non-loaded knee joints showed healthy ACLs with collagen fibre 
alignment and some toluidine blue staining in the mid-ligament region which had mainly spindle-
shaped fibroblasts (purple arrow) and a thin layer of toluidine blue staining at the tibial enthesis 
in the fibrocartilaginous zone (yellow arrows) (Figure 2.19A). Loaded knee joints following four 
weeks post-trauma, still retained collagen fibre alignment with increased intensity in toluidine 
blue staining in the mid-ligament region and tibial enthesis (red arrows) (Figure 2.19B). 
Furthermore, in the loaded knee joints, the ACL mid-ligament region and the fibrocartilaginous 





Figure 2.19 Histological staining of the anterior cruciate ligament (ACL) in non-invasive mechanical loading knee 
joints using toluidine blue stain. Representative images of: (A) Healthy non-loaded knee joints showed an organised 
ACL with some toluidine blue staining including a thin layer at the tibial enthesis (yellow arrows) and spindle-shaped 
cells in the mid-ligament region (purple arrow). (B) In loaded knee joints four weeks post-trauma, toluidine blue 
staining was prominent throughout the ACL in the mid-ligament region and in the tibial enthesis where it surrounded 
cells with rounded-cell morphology (yellow arrows). Scale is 100 µm (10x) and 25 µm (40x). 
 
2.3.3.1.2 PR staining 
PR staining was used to analyse collagen content and birefringence in the non-invasive 
mechanically loaded OA knee joints and the non-loaded healthy knee joints. The non-loaded knee 
joints had ACLs with light red collagen staining in brightfield and spindle-shaped cells in the mid-
ligament region (green arrows) (Figure 2.20A). Polarised light showed predominantly green-
yellow birefringence in the non-loaded knee joint ACL (Figure 2.20A). The loaded knee joint had 
an ACL with red collagen staining in the mid-ligament region near areas with rounded-cell 
morphology (yellow arrows) (Figure 2.20B). Green birefringence was also present in the ACL of 
loaded knee joints along with red birefringence in the outer epiligament regions and near the tibial 
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attachment sites (blue arrows) (Figure 2.20B). Red birefringence in the loaded knee joint ACL 
was suggestive of thicker collagen composition. 
 
 
Figure 2.20 Histological staining of the anterior cruciate ligament (ACL) in non-invasive mechanically loaded knee 
joints using picrosirius red stain. Representative images of: (A) Non-loaded knee joint had ACLs with mainly light red 
collagen staining (brightfield) and green-yellow birefringence throughout the ACL and orange birefringence near the 
tibial enthesis (blue arrow). (B) Loaded knee joints four weeks post-trauma had an ACL with red collagen staining and 
rounded cell morphology (yellow arrows) and red birefringence near the tibial attachment site and the epiligament 





Non-loaded healthy knee joint had an organised ACL tibial enthesis with a small layer of COL2 
staining, sparse SOX9 and RUNX2 staining as expected in the fibrocartilaginous region, and 
ASPN expression that spread from the tibial enthesis into the ACL (black arrows) (Figure 2.21A). 
The mid-ligament region of the healthy non-loaded knee joints displayed no COL2, SOX9 and 
RUNX2 staining, and sparse ASPN expression (Figure 2.22A). In the OA knee joints that 
underwent non-invasive mechanical loading, the ACL had COL2 deposition near the tibial 
enthesis, as well as SOX9, RUNX2 and ASPN expression which extended from the 
fibrocartilaginous region further into the ACL (black arrows) (Figure 2.21B). Furthermore, ASPN 
expression was also highly expressed in the fibrous tissue adjacent to the ACL (red arrow) (Figure 
2.21B). In the mid-ligament region of the ACL of the loaded knee joints, COL2, SOX9 and ASPN 
expression were highly expressed (black arrows), including pericellular expression of ASPN in 
the mid-ligament fibroblasts (Figure 2.22B). The mid-ligament region and the tibial enthesis 
region of COL2 deposition was similar to the areas of increased toluidine blue staining (Figure 
2.19B). Immunostaining of the OA loaded knee joints confirmed changes in the ECM of the ACL 





Figure 2.21 Immunostaining of the anterior cruciate ligament (ACL) tibial enthesis in non-invasive mechanically 
loaded knee joints of collagen type II (COL2), SOX9, RUNX2 and ASPN expression. Representative images of: (A) 
Healthy non-loaded knee joints showed ACLs with COL2 staining in the fibrocartilagenous region and sparse SOX9, 
RUNX2 and ASPN staining. (B) Loaded OA knee joints had ACLs with COL2 depostion and high SOX9 and ASPN 




Figure 2.22 Immunostaining of the anterior cruciate ligament (ACL) mid-ligament region in non-invasive mechanically 
loaded knee joints of collagen type II (COL2), SOX9, RUNX2 and ASPN expression. Representative images of: (A) 
Healthy non-loaded knee joints had no COL2, SOX9 and RUNX2 staining in the mid-ligament region of the ACL and 
sparse ASPN staining. (B) OA loaded knee joints had ACLs with COL2 depostion and high SOX9 and ASPN expression 
throughout the mid-ligament region, and faint RUNX2 expression (black arrows). Scale is 100 µm (10x) and 25 µm 
(40x). 
 
2.3.3.2 Non-invasive mechanically loaded medial collateral ligament (MCL) pathology 
In the non-invasive mechanically loaded knee joint, OA cartilage degradation occurs mainly in 
the lateral compartment. However, the medial collateral ligament (MCL) was analysed to observe 
changes in the whole knee joint organ being a major stabiliser of the knee joint and the most 
injured ligament in the knee joint [172]. 
 
2.3.3.2.1 Toluidine blue staining 
Toluidine blue staining of the non-loaded knee joint showed MCLs with an organised structure 
and alignment of the collagen fibres, spindle-shaped cells in the mid-ligament region (purple 
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arrow), and a delineated toluidine blue stain at the femur attachment site near the 
fibrocartilaginous zone (black arrow) (Figure 2.23A). Loaded knee joints four weeks post-trauma 
had MCLs with loss of the toluidine blue tide mark at the femoral enthesis and toluidine blue 
staining extending from the attachment site further into the MCL, and rounded cell morphology 
near the femoral enthesis (yellow arrows) (Figure 2.23B). Toluidine blue staining at the MCL 
femoral enthesis of the OA loaded knee joint could indicate potential proteoglycan deposition. 
 
 
Figure 2.23 Histological staining of the medial collateral ligament (MCL) in non-invasive mechanically loaded knee 
joints. Representative images of: (A) Non-loaded healthy knee joints had MCLs with clear fibre and cell alignment and 
toluidine blue staining which delineated the fibrocartilage zone (black arrow), and spindle-shaped cells in the mid-
ligament region (purple arrow). (B) OA loaded knee joints had MCLs with toluidine blue staining extending from the 





2.3.3.2.2 PR staining 
PR staining of the non-invasive loaded knee joint gave further evidence of collagen composition 
and birefringence. Healthy non-loaded knee joints had an organised MCL structure with light red 
collagen staining with rounded cell morphology in the fibrocartilaginous zone (yellow arrows) 
and spindle-shaped fibroblast in the mid-ligament region (green arrow) (Figure 2.24A). Polarised 
light of the non-loaded knee joints confirmed structured green birefringence by the enthesis and 
in the mid-ligament region and orange birefringence in the fibrocartilaginous zone (blue arrow) 
(Figure 2.24A). Four weeks following non-invasive mechanical loading of the knee joint, murine 
MCLs showed evidence of hyperplasia and increased red collagen staining at the femoral enthesis 
(yellow arrow) and in the outer epiligament layer in the mid-ligament region of the MCL (Figure 
2.24B). Polarised light of these OA knee joints confirmed red birefringence near the MCL femoral 
attachment site and the outer epiligament layers in the mid-ligament region (blue arrows) (Figure 
2.24B), which would suggest thicker collagen formation at both the MCL femoral enthesis and in 
the MCL mid-ligament region.  
 
2.3.3.2.3 Immunostaining 
Immunostaining was used to analyse specific OA markers in the loaded and non-loaded knee 
joints. Non-loaded knee joints had structured COL2 staining at the MCL femoral enthesis 
fibrocartilaginous zone, with sparse SOX9 and RUNX2 expression, and ASPN expression at the 
enthesis (black arrows) (Figure 2.25A). The mid-ligament region of the MCL in the non-loaded 
healthy knee joints showed no staining of COL2, SOX9, RUNX2 and ASPN (Figure 2.25A). The 
loaded knee joints post-trauma showed COL2 encroaching from the MCL femoral enthesis and 
reaching the mid-ligament region (Figure 2.25B). Cellular expression of SOX9 and RUNX2, as 
well as pericellular expression of ASPN was increased in the MCL femoral enthesis (black 
arrows) (Figure 2.25B). Furthermore, there was SOX9 and ASPN expression in the mid-ligament 
region of the MCL (black arrows) (Figure 2.25B). Immunostaining at the MCL femoral enthesis 
in the OA loaded knee joints confirmed changes in the COL2 matrix composition and expression 






Figure 2.24 Histological staining of the medial collateral ligament (MCL) in non-invasive mechanically loaded knee 
joints using picrosirius red. Representative images of: (A) Healthy non-loaded knee joint showed light red staining in 
the MCL, with dark red staining at the fibrocartilaginous zone of the femoral enthesis (yellow arrows). Polarised light 
showed green birefringence throughout the MCL and orange birefringence near the femoral enthesis. (B) OA loaded 
knee joint showed hyperplasia near the femoral attachment site with dark red staining (yellow arrows). Polarised light 
showed red birefringence near the femoral enthesis and in the outer zone of the mid-ligament region in areas of 









Figure 2.25 Immunostaining of the medial collateral ligament (MCL) in non-invasive mechanically loaded knee joints. 
Representative images of: (A) Healthy non-loaded knee joints had an MCL with structured COL2 deposition at the 
fibrocartilaginous zone of the femoral enthesis, and sparse SOX9, RUNX2 and ASPN staining (black arrows). In the 
mid-ligament region of the hleahty MCL, no COL2, SOX9, RUNX2 and ASPN staining was found. (B) OA loaded knee 
joint MCLs showed COL2 deposition which extended from the femoral enthesis into the MCL, as well as SOX9, RUNX2 
and ASPN expression at the femoral enthesis (black arrow). The mid-ligament region also had COL2 deposition and 
SOX9 and ASPN expression (black arrows). Scale is 100 µm (10x) and 25 µm (40x). 
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2.3.3.3 Non-invasive mechanically loaded knee joint lateral menisci pathology 
OA occurs mainly in the lateral compartment of the non-invasive mechanically loaded knee joint; 
hence the lateral menisci was analysed for OA pathology. 
 
2.3.3.3.1 Toluidine blue staining 
The lateral menisci of the healthy non-loaded joints demonstrated the expected meniscal structure, 
with hyaline cartilage layers (H), a central ossified region (O, orange region) and an outer fibrous 
region (F, red region) (Figure 2.26A). In the loaded knee joints post-trauma, the lateral menisci 
showed elongation of the central ossified region (Figure 2.26B). The fibrous region of the loaded 
knee joint lateral menisci showed a structure and rounded-cell morphology (black arrow) similar 
to the non-loaded knee joint (Figure 2.26B). Toluidine blue showed evidence of elongation of the 
ossified core of the lateral menisci in the loaded knee joints. 
 
 
Figure 2.26 Histological staining of the lateral menisci in the non-invasive mechanically loaded knee joints using 
toluidine blue. Representative images of: (A) Healthy non-loaded knee joints had lateral menisci with toluidine blue 
staining the in outer hyaline cartilage layers (H) of the menisci and showed the expected ossified core (O) and fibrous 
region (F). (B) Loaded knee joints after four weeks post-trauma had lateral menisci with an expanded ossified core but 
similar toluidine blue staining. Fibrous region of the non-loaded and loaded knee joints showed similar structures with 
rounded-cell morphology only near the hyaline cartilage layers. Scale is 100 µm (10x) and 25 µm (40x). 
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2.3.3.3.2 Immunostaining  
Immunostaining of the non-loaded healthy knee joints had lateral menisci with COL2 deposition 
in the previously mentioned hyaline cartilage region and ASPN expression in the outer meniscal 
regions (Figure 2.27A). Loaded knee joints post-trauma, showed a slight increase in COL2, SOX9 
and ASPN expression in the upper fibrous region (black arrows) and also ASPN expression 
seemed to increase in the outer fibrous region near the capsular attachment (red arrow) (Figure 
2.27B). Immunostaining showed only minor changes in matrix (COL2) and marker expression 




Figure 2.27 Immunostaining of the lateral menisci in non-invasive mechanically loaded knee joints of collagen type II 
(COL2), SOX9, RUNX2 and ASPN expression. Representative images of: (A) Healthy non-loaded knee joints had 
lateral menisci with col2 and ASPN staining in the hyaline cartilage region, and no SOX9 and RUNX2 staining. (B) 
Loaded knee joint post-trauma, had lateral menisci with COL2 deposition, SOX9 and ASPN staining extending from 
the hyaline cartilage region into the upper fibrous region (black arrows). There was also ASPN staining in the outer 
fibrous region near the capsular attachment. Scale is 100 µm (10x) and 25 µm (40x). 
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2.3.3.4 Summary of the non-invasive mechanically loaded knee joint OA pathology 
In the non-invasive mechanically loaded knee joints we found structural and cellular changes in 
the ACL and MCL that emerged post-trauma. In the ACL of the mechanically loaded knee joints, 
there was toluidine blue staining, red collagen birefringence and rounded-cell morphology at the 
fibrocartilaginous zone of the ACL tibial enthesis, while the mid-ligament region also had 
toluidine blue staining and green collagen birefringence. In the MCL of the mechanically loaded 
knee joints, toluidine blue and red birefringence was present at the femoral enthesis and red 
birefringence was also present in the epiligament layer of the MCL mid-ligament region in areas 
of hyperplasia. In both the ACL and MCL of the mechanically loaded knee joints, there was COL2 
deposition near the enthesis (ACL: tibial enthesis, MCL: femoral enthesis) and mid-ligament 
region, as well as SOX9 and ASPN expressing cells in the same regions. Lastly, in the lateral 
menisci of the mechanically loaded knee joints there was elongation of the ossified meniscal core. 
Overall, pathological changes in the ACL and MCL of mechanically loaded knee joints included 







2.3.4 Confirmation of a new OA model: CD1 murine model of spontaneous OA 
As previously mentioned, CD1 mice are a novel spontaneous OA model. Briefly, CD1 OA knee 
joint pathology that has previously been described included cartilage degeneration, subchondral 
bone thickening and synovial hyperplasia mainly in the medial compartment of male 1-year-old 
CD1 mice [154]. Meniscal or knee ligament pathology in CD1 mouse knee joints have not been 
described to date. Therefore, we evaluated meniscal and knee ligament health and pathology 
during early OA development in this novel model, comparing younger 12-week-old male CD1 
mice to older 24-week-old male CD1 mice. Younger 12-week-old CD1 mice were chosen as the 
control due to the heavy bodyweight of the CD1 mouse strain. CD1 bodyweight did increase 
during ageing with 24-week-old CD1 mice being heavier (14.2% weight difference) compared to 
the younger 12-week-old CD1 mice (Figure 2.28A). 
 
2.3.4.1 Characterisation of OA in CD1 knee joints  
2.3.4.1.1 Toluidine blue OA scoring 
OA development was confirmed via the OARSI cartilage grading system and µCT quantification 
of joint space mineralisation. In the 24-week-old CD1 knee joints (n=10) there was significant 
cartilage degeneration, with cartilage lesions present in all mice and greater than 25% 
compartmental cartilage erosion (OA grade 4) occurring in 50% of the mice (Figure 2.28). This 
severe cartilage loss has not been previously reported at these time points in healthy mice knee 
joint including in CBA mice [158] and C57 mice [154, 173], but is comparable to spontaneous 
OA STR/ort mice knee scores which had cartilage erosion (OA grade 3) at 40-weeks-old [158]. 
In the 24-week-old CD1 knee joints, more cartilage lesions were seen in the medial compartment 
than in the 12-week-old CD1 knee joints (Figure 2.28C). In the medial tibial compartment, the 
maximum OA score was 0.3 ±0.2 and 3.1 ±0.6 for the 12 and 24-week-old CD1 knee joints 
respectively (Figure 2.28D). This is equivalent to no cartilage lesions in the 12-week-old knee 
joints, and up to 20% of articular cartilage loss in the 24-week-old knee joints in the medial tibial 
compartment of the CD1 mice. Furthermore, when comparing all knee compartments (whole 
joint), 50% (n=5) of the 24-week-old CD1 knee joints showed greater than 20% of articular 
cartilage loss (maximum OA score >3) (Figure 2.28F). The maximum score for the whole joint 
of the 24-week-old CD1 mice was 3.4 ±0.8 (Figure 2.28F), which is comparable to the maximum 
score of the STR/ort spontaneous OA mouse knee joint which was 2.6 ±1.1 at 26-weeks and also 
showed greater OA severity in the medial compartments [165]. Cartilage loss was not seen in the 
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CBA [153] and C57BL/6J [173] mice knee joints at 24-weeks, therefore this would suggest that 
the CD1 mice have early OA development similar to that of spontaneous OA models. 
When comparing the 12 and 24-week-old knee joints of the CD1 mice, the mean and maximum 
score of the whole joint demonstrated significant increases (p ≤0.001 and p≤0.0001 respectively) 
in the OA score of the 24-week-old CD1 mice knee joints (Figure 2.28E-F). The same was true 
for the summed mean and summed maximum OA scores of the whole joint which also confirmed 
significant increases (p ≤0.001 for both) in the OA score of the 24-week-old CD1 knee joint 
(Figure 2.28G-H). OARSI cartilage scoring confirmed that OA development in the knee joints of 
24-week-old CD1 mice was significantly higher than in the younger 12-week-old CD1 mice. 24-
week-old CD1 mice knee joints had greater variation of OA score as the maximum overall OARSI 
score varied from 0 to 1 in the 12-week-old CD1 knee joints and from 1 to 6 in the 24-week-old 
CD1s (Figure 2.28F). This variation is equivalent to healthy thick cartilage seen in most young 
CD1s (OA score 0), to minor fibrillations in the cartilage (OA score 1), to complete loss of AC 
and subchondral bone exposure (OA score 6, maximum score) in some of the older CD1 mice 
knee joints (see Figure 2.28B). Overall, OA progression was demonstrated in the 24-week-old 




Figure 2.28  Mice bodyweights and OARSI cartilage scoring of 12 and 24-week-old CD1 mice. (A) CD1 mice weights 
increased 14.2% in the 24-week-old CD1 compared to the 12-week-old CD1 mice. (B) OARSI cartilage lesion scoring 
ranged from of healthy cartilage (OA grade 0) to complete loss of articular cartilage (OA grade 6). Scale is 50 µm. (C-
D) Mean and maximum OARSI cartilage score per compartment revealed higher mean and maximum scores in the 
medial compartments (MT and MF) of the 24-week-old CD1 knee joints compared to the lateral compartments (LT and 
LF). (E-F) Mean and maximum OARSI score of the whole joint was significantly higher in the 24-week-old CD1 mice 
knee joints (p ≤0.001 and p≤0.0001 respectively). (G-H) Summed mean and maximum OARSI scores of the whole joint 
confirmed significantly higher scores in the 24-week-old CD1s (p ≤0.001 for both). Unpaired non-parametric Mann-




2.3.4.1.2 Joint space mineralisation analysis 
Quantification of joint space mineralisation using µCT was significantly increased (p ≤0.001) in 
the 24-week-old CD1 mice knee joints compared to the younger 12-week-old knee joints (Figure 
2.29A). 3D µCT images revealed increased mineralisation in the medial side of the 24-week-old 
CD1 mice (Figure 2.29B). More specifically, mineralisation can be seen in the anterior and 
posterior horn of the medial menisci (orange arrows) and in the medial collateral ligament (blue 
arrows) at both OA grade 4 and 6 (Figure 2.29B). This is similar to the findings from the OARSI 
cartilage score which increased in the medial compartment of the 24-week-old CD1 knee joints 
(Figure 2.28C-D). Joint space mineralisation has been previously associated with OA progression 
[165]. OARSI scoring and µCT joint space mineralisation confirmed OA development in the 24-
week-old CD1 mice compared to the 12-week-old mice. 
 
 
Figure 2.29 Knee joint space mineralisation in 12 and 24-week-old CD1 mice. (A) Quantification of joint space 
mineralisation showed significantly higher bone volume in the 24-week-old CD1 mice (p ≤0.001). Unpaired non-
parametric Mann-Whitney test was used for statistical analysis. (B) 3D reconstruction of µCT images of joint space 
showed mineralisation in the anterior horn of the medial and lateral menisci of the 12-week-old CD1 mice (yellow 
arrows). Increased mineralisation was visible in the OA grade 4 and 6 CD1 24-week-old medial collateral ligament 
(blue arrows) and in the medial menisci (orange arrows). 
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2.3.4.2 Knee ligament and meniscal pathology in the CD1 OA mouse model 
CD1 mice histological analysis included toluidine blue, PR and immunostaining of the ACL, 
MCL and medial menisci. The medial collateral ligaments and menisci were analysed as OARSI 
cartilage lesion severity (Figure 2.28) and µCT joint space mineralisation (Figure 2.29) was higher 
in the medial femorotibial compartments. The ligaments and menisci of the 24-week-old CD1 
knee joints were categorised based on OA score and compared to the healthy 12-week-old CD1 
mice knee joints, allowing for description of structural and cellular changes during OA 
progression. 
 
2.3.4.3 CD1 mice anterior cruciate ligament (ACL) pathology 
2.3.4.3.1 Toluidine blue staining  
Toluidine blue staining was used to analyse ACL structure and cellular morphology in 12-week-
old and 24-week-old CD1 knee joints. 12-week-old CD1 murine knee joints had an organised 
ACL structure with aligned collagen fibres and toluidine blue staining extending from the 
attachment site to the mid-ligament region (Figure 2.30A). The tibial attachment site had a 
delineated fibrocartilaginous zone (black arrow) with rounded-shaped cells (yellow arrow), and 
spindle-shaped cells (purple arrow) in the mid-ligament region (Figure 2.30A). In the 24-week-
old CD1 knee joints with OA grade 4, ACL structure and cell morphology were irregular, and 
changes included misalignment of the fibres and an increase in the ‘rounded’ cell types near the 
tibial attachment site and in the mid-ligament region (yellow arrows) (Figure 2.30B). In OA grade 
6 CD1 knee joints, the ACL had complete toluidine blue staining in all regions of the ligament, 
suggestive of substantial proteoglycan deposition, and ‘rounded’ cell types near the tibial 
attachment site (Figure 2.30C). It is worth noting that the ACL displayed better fibre alignment 
in the OA grade 6 knee joints compared to the OA grade 4 knee joints, (Figure 2.30B-C), which 





Figure 2.30 Histological staining of the anterior cruciate ligament (ACL) in CD1 mice using toluidine blue staining. 
Representative images of: (A) Healthy 12-week-old CD1 ACL had fibre alignment and some toluidine blue staining 
extending from the tibial enthesis to the mid-ligament region. The delineated fibrocartilaginous zone (black arrow) had 
rounded cell morphology (yellow arrows) and the mid-ligament region had spindle-shaped fibroblasts (purple arrow) 
and some rounded-cell types (yellow arrow). (B) CD1 OA grade 4 ACL had severe fibre misalignment, and toluidine 
blue and rounded-cell morphology in the mid-ligament region (yellow arrows). (C) CD1 OA grade 6 ACL had toluidine 
blue staining throughout the ligament, as well as cells with rounded-cell morphology at the tibial enthesis (yellow 
arrow). Scale is 100 µm (10x) and 25 µm (40x). 
 
2.3.4.3.2 PR staining 
PR staining was used to analyse collagen birefringence in the ACL of 12-week-old and 24-week-
old CD1 knee joints. CD1 12-week-old mice had an organised ACL with light red collagen 
staining and polarised light showed green birefringence throughout the ACL and yellow 
birefringence near the tibial enthesis (blue arrow) (Figure 2.31A). CD1 24-week-old OA grade 4 
knee joints had ACLs with structural changes, including extensive red collagen staining, rounded 
cell morphology (yellow arrows) and red birefringence throughout the ACL, (Figure 2.31B). In 
CD1 knee joints with OA grade 6, polarised light showed green birefringence in the mid-ligament 
region with red birefringence in the outer epiligament layers of the ACL (Figure 2.31D). Collagen 




Figure 2.31 Histological staining of the anterior cruciate ligament (ACL) in CD1 knee joints using picrosirius red. 
Representative images of: (A) Healthy 12-week-old CD1 ACL showed light red staining within the ACL and darker red 
staining near the tibial enthesis near spindle-shaped fibroblasts (green arrow). Polarised light showed mainly green 
birefringence and some yellow birefringence near the tibial attachment site (blue arrow). (B) OA grade 4 CD1 knee 
joints had ACLs with dark red collagen staining and rounded cell morphology (yellow arrows) throughout the ligament. 
Polarised light showed red birefringence throughout the ACL (blue arrows). (C) CD1 OA grade 6 ACL had light red 
collagen staining and thick fibrocartilaginous zone with rounded-shaped cells (yellow arrows). Polarised light showed 
mainly green birefringence throughout the ACL with red birefringence in the outer epiligament layer (blue arrow). 







Immunostaining was used to compare COL2 staining and SOX9, RUNX2 and ASPN expression 
in the ACLs of 12-week-old and 24-week-old CD1 knee joints. Healthy 12-week-old CD1 ACLs 
had COL2 staining in the fibrocartilaginous enthesis extending towards the ligament, along with 
sparse SOX9 and ASPN staining at the enthesis (black arrows) (Figure 2.32A). In OA grade 4 
knee joints of 24-week-old CD1 mice, there was a distinct layer of COL2 deposition at the 
fibrocartilaginous zone of the ACL tibial enthesis, along with prevalent SOX9, RUNX2 and 
ASPN expression in the same fibrocartilaginous region (black arrows) (Figure 2.32B). COL2, 
SOX9, RUNX2 expression extended to the ACL fibroblast near the tibial enthesis (purple arrow) 
(Figure 2.32B), as well as in an inflamed disorganised region adjacent to the tibial enthesis (black 
arrow) (Figure 2.32B, inflamed region). In OA grade 6 CD1 knee joints, COL2 deposition 
increased in a dense fibrocartilaginous layer at the ACL tibial enthesis (black arrow) and in 
adjacent tissue surrounding the ACL tibial enthesis (red arrow) (Figure 2.32C). Additionally, 
SOX9, RUNX2 and ASPN were only present in sparse areas near the ACL tibial enthesis (Figure 
2.32C). 
In the ACL mid-ligament region of the healthy 12-week-old CD1 knee joints, COL2 staining was 
found, however SOX9, RUNX2 and ASPN were not present (Figure 2.34A). Similarly, in OA 
grade 5 CD1 knee joints, COL2 deposition was found in the mid-ligament region of the ACL of 





Figure 2.32 Immunostaining of the anterior cruciate ligament (ACL) tibial enthesis in CD1 knee joints. Representative 
images of: (A) Healthy 12-week-old CD1 ACL showed some COL2 deposition extending from the tibial enthesis along 
with sparse SOX9 and ASPN expression. (B) OA grade 4 CD1 ACLs had a thick layer of COL2 deposition at the tibial 
enthesis as well as SOX9 and RUNX2 expression (black arrows) which extended further into the ACL ((purple arrows). 
(C) OA grade 6 CD1 ACL had a dense layer of COL2 deposition at the tibial enthesis and sparse SOX9, RUNX2 and 




Figure 2.33 Immunostaining of the anterior cruciate ligament (ACL) mid-ligament region in CD1 knee joints. 
Representative images of: (A) Healthy 12-week-old CD1 ACL showed COL2 deposition in the mid-ligament region. 
SOX9, RUNX2 and ASPN were not expressed. (B) Similarly, OA grade 5 CD1 had COL2 deposition in the ACL mid-
ligament region and no SOX9, RUNX2 and ASPN expression as well as COL2 staining in the epiligament region (purple 
arrow). Scale is 100 µm (10x) and 25 µm (40x). 
 
2.3.4.4 CD1 mice medial collateral ligament (MCL) pathology 
2.3.4.4.1 Toluidine blue staining 
Toluidine blue staining of the MCLs from CD1 mice showed changes in the 24-week-old 
experimental group compared to the 12-week-old mice. The 12-week-old CD1 MCLs showed 
organised collagen fibre alignment and some toluidine blue staining at the tibial enthesis (yellow 
arrows) (Figure 2.34A). Meanwhile, the 24-week-old CD1 knee joints had MCLs with evidence 
of hyperplasia, toluidine blue staining (red arrows) and potential ossification (red region) (Figure 
2.34B-C). OA grade 4 CD1 knee joints showed potential ossification near the MCL tibial enthesis, 
as well as some rounded-cell morphology in the MCL mid-ligament region (yellow arrow) (Figure 
2.34B). OA grade 6 CD1 MCL presented severe hyperplasia with complete loss of fibre 
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arrangement, increased ‘rounded’ cell morphology near the tibial attachment site and in the mid-
ligament region and possible bone formation in the mid-ligament region (Figure 2.34C). 
 
2.3.4.4.2 PR staining 
PR staining in the healthy 12-week-old CD1 mice had a light red staining and polarised light 
demonstrating a structured green birefringence at the MCL femoral attachment site with red 
birefringence in the upper epiligament layer (blue arrow) (Figure 2.35A). The MCL mid-ligament 
region of the 12-week-old CD1 mice had dark green birefringence (Figure 2.35A). OA grade 4 
24-week-old CD1 mice showed dark red collagen staining throughout the MCL (yellow arrows) 
which correlated to red birefringence (blue arrows) (Figure 2.35B). OA grade 6 CD1 MCLs also 
showed dark red collagen staining, and a mixture of green and red birefringence mainly in areas 
of hyperplasia (blue arrows) (Figure 2.35C). Red birefringence in the OA MCLs indicate thicker 
collagen fibres not seen in the healthy 12-week-old MCLs. 
 
2.3.4.4.3 Immunostaining 
Immunostaining of healthy 12-week-old CD1 knee joints demonstrated an MCL femoral enthesis 
with organised COL2 staining and sparse expression of SOX9, RUNX2 and ASPN (Figure 
2.36A). Additionally there was no presence of COL2, SOX9, RUNX2 or ASPN staining in the 
healthy MCL mid-ligament region. OA grade 4 CD1 knee joints had an MCL femoral enthesis 
similar to the healthy 12-week-old CD1 mice, however COL2 deposition, along with SOX9, 
RUNX2 and ASPN expression were evident in the MCL mid-ligament region (black arrows) 
(Figure 2.36B). OA grade 6 CD1 knee joints, COL2, SOX9, RUNX2 and ASPN staining was 
present near the MCL femoral enthesis and the MCL mid-ligament region, particularly in cells 
with ‘rounded’ morphology (black arrow) and in the outer epiligament layer (purple arrow) 
(Figure 2.37). Immunostaining indicates changes in COL2 deposition in the diseased MCLs of 






Figure 2.34 Histological staining of the medial collateral ligament (MCL) in CD1 knee joints using toluidine blue. 
Representative images of: (A) Healthy 12-week-old CD1 knee joints had an organised MCL with toluidine blue staining 
near the femoral enthesis (yellow arrows) and spindle-shaped fibroblasts in the mid-ligament region (purple arrow). 
(B) OA grade 4 CD1 MCLs showed rounded-cell morphology in the mid-ligament region (yellow arrow) and abnormal 
tissue growth (red region) including toluidine blue deposition (red arrow) near the tibial attachment. (C) OA grade 6 
CD1 MCLs had severe hyperplasia throughout the MCL and rounded-cell morphology and toluidine blue staining near 
the femoral enthesis which extended to the mid-ligament region (yellow arrows). CD1 OA grade 6 also had evidence 




Figure 2.35 Histological staining of the medial collateral ligament (MCL) in CD1 knee joints using picrosirius red. 
Representative images of: (A) Healthy 12-week-old CD1 MCL showed light red collagen staining with spindle shaped 
fibroblasts (green arrow) and mainly green birefringence throughout the MCL with a small zone of red birefringence 
near the femoral enthesis (blue arrow). (B) CD1 OA grade 4 had dark red collagen staining which coincided with red 
birefringence near the femoral enthesis and in the mid-ligament region. (C) CD1 OA grade 5 showed thickening of the 
MCL and red collagen staining and red birefringence mainly in the outer region of the ligament near the femoral 
enthesis. (D) CD1 OA grade 6 had clear hyperplasia in the MCL and had light red collagen staining that matched 
green birefringence in the middle regions of the ligament and red collagen staining that matched areas of red 




Figure 2.36 Immunostaining of the medial collateral ligament (MCL) in CD1 knee joints. Representative images of: 
(A) Healthy 12-week-old CD1 MCL showed some COL2 staining near the femoral enthesis and sparse SOX9, RUNX2 
and ASPN expression (black arrows). No staining was found in the MCL mid-ligament region. (B) OA grade 4 CD1 
MCLs had COL2 staining at the femoral enthesis and in the mid-ligament region. There was also SOX9, RUNX2 and 




Figure 2.37 Toluidine blue (A) and immunostaining (B) of the medial collateral ligament (MCL) in CD1 OA grade 6 
knee joints. Representative images of OA grade 6 CD1 MCLs had abundant COL2 deposition near the femoral 
attachment extending to the mid-ligament region. In these same regions SOX9, RUNX2 and ASPN were also present 
(black arrows), as well as in the epiligament layer (purple arrows). Additionally, areas of COL2 deposition seemed to 
match areas rounded-cell morphology (black arrows) and areas with toluidine blue staining (A, Tol Blue). Scale is 200 
µm (Tol Blue), 100 µm (10x) and 25 µm (40x). 
 
2.3.4.5 Medial menisci 
2.3.4.5.1 Toluidine blue staining 
Healthy12-week-old CD1 knee joints had medial menisci with the expected outer hyaline cartilage 
layers (H), central ossified region (O) and fibrous attachment (F, red region) (Figure 2.38A). At 
OA grade 4 of the 24-week-old CD1 knee joints, medial menisci showed hyperplasia of the fibrous 
region (red region), toluidine blue staining and ‘rounded’ cell morphology in the fibrous region 
(yellow arrows), as well as osteophyte formation at the anterior horn of the medial meniscus (red 
arrow) (Figure 2.38B). At OA grade 6 of the CD1 knee joint, there was further increase in 
toluidine blue staining, hyperplasia (red region), rounded-cell morphology (yellow arrows) and 
osteophyte formation (red arrow) in the medial menisci (Figure 2.38C). Toluidine blue staining 




Figure 2.38 Histological staining of the medial menisci in CD1 knee joints using toluidine blue. Representative images 
of: (A) Healthy 12-week-old CD1 medial menisci had the expected hyaline cartilage regions (H), ossified core (O) and 
outer fibrous region (F, red region). (B) OA grade 4 CD1 medial menisci had expanded fibrous areas (red region) with 
toluidine blue staining and rounded-cell morphology (yellow arrows), as well as potential osteophyte formation at the 
anterior horn (red arrow). (C) OA grade 6 CD1 medial menisci had enlarged fibrous regions (red region) with 
abundant toluidine blue staining and rounded-cell morphology (yellow arrows), and also potential osteophyte 




Immunostaining of the healthy 12-week-old CD1 menisci showed COL2 staining in the hyaline 
cartilage region as expected and sparse COL2, SOX9, RUNX2, and ASPN staining in the fibrous 
region (black arrows) (Figure 2.39A). In the enlarged fibrous region of the OA grade 4 CD1 
medial menisci, COL2, SOX9, RUNX2 and ASPN staining was more prominent or evident in the 
outer fibrous regions and corresponding to areas with ‘rounded’ cell morphology (black arrows) 
(Figure 2.39B). As OA progressed, COL2 deposition spread throughout the entire medial 
meniscus and SOX9, RUNX2 and ASPN were also present in the outer fibrous regions (Figure 
2.39C). Immunostaining of COL2 indicates a change in the ECM, meanwhile SOX9 and RUNX2 
confirm chondrogenesis and potentially hypertrophy occurring in the fibrous regions of the OA 




Figure 2.39 Immunostaining of the medial menisci in CD1 knee joints. Representative images of: (A) Healthy 12-week-
old CD1 medial menisci had a COL2 staining in the hyaline cartilage layer and sparse staining of COL2, SOX9, RUNX2 
and ASPN in the fibrous region (black arrow). (B) OA grade 4 CD1 medial menisci had COL2 which expanded into 
the fibrous region, and expression of SOX9, RUNX2 and ASPN in the same fibrous regions (black arrow). (C) CD1 OA 
grade 6 medial menisci had COL2 staining throughout the fibrous region as well as SOX9, RUNX2 and ASPN in the 
upper outer fibrous regions (black arrows). Scale is 100 µm (10x) and 25 µm (40x). 
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2.3.4.6 Summary of CD1 murine model and OA pathology 
The CD1 murine model exhibited OA features in 24-week-old CD1 male mice which were not 
present in the 12-week-old CD1 male mice knee joints. This included a significantly higher 
OARSI score and joint space mineralisation, particularly in the medial knee compartment of the 
CD1 24-week-old mice. Knee ligament and meniscal pathology in the OA 24-week-old CD1 knee 
joint revealed ECM and cellular changes which included toluidine blue staining, red collagen 
birefringence and COL2 deposition and rounded-cell morphology with SOX9, RUNX2 and 
ASPN expression. In the ACL of CD1 knee joints these pathological changes occurred mainly in 
the tibial enthesis. In the MCL of CD1 knee joints, OA pathology included hyperplasia and 
potential ossification in the MCL mid-ligament region. Lastly in the medial menisci of the CD1 
knee joints, hyperplasia was found in the fibrous region of the medial menisci.  
Overall, we found changes in the CD1 knee ligament and menisci pathology in the ECM 
composition and COL2 deposition, complemented by changes in cellular markers which included 
markers for chondrogenesis and hypertrophy. 
 
2.3.5 Summary of ligament and meniscal tissue pathology in all murine OA species 
An overview of all pathological changes found in the murine spontaneous OA ACL, MCL and 
menisci can be seen in Table 2.3. Both spontaneous OA models (Str/ort and CD1 mice) had similar 
pathological changes in all ligaments which included TB staining, red birefringence and 
chondroid-like cells with COL2 deposition as well as SOX9 and RUNX2 expression. 
Furthermore, there were similarities in the medial menisci of both spontaneous OA models, which 
had a hypertrophic outer fibrous region. Differences between the spontaneous OA models 
included more variability in ligament pathology in the CD1 mice which varied with OA grade and 
in addition CD1 mice had no ASPN expression which was present in ACL and MCL of the Str/ort 
mice. Despite difference, both spontaneous OA models demonstrated pathological change 
occurring in the knee ligaments which coincided with chondroid-like cells which could play a role 




Table 2.3 Anterior cruciate ligament (ACL), medial collateral ligament (MCL) and meniscal tissue pathology in murine 
spontaneous OA models: Str/ort mice and CD1 mice. Pathology was analysed using toluidine blue (TB) and picrosirius 





























• Mid-ACL region  
• ACL tibial enthesis 
 
OA progression: 
• Matrix disorder 
• Chondroid-like cells 
in mid-ACL region 
Found in: 
• Mid-MCL region 
• MCL femur enthesis 
 
OA progression: 
• Chondroid-like cells 
in mid-MCL 
• MCL hypertrophy 
Found in: 




• Expanding outer 
fibrous region 





• Mid-ACL region  
Red birefringence: 
• Mid-ACL region 








• All markers present 
at OA grade 2 
 
Mid-ACL: 
• All markers present 
at OA grade 4 
Mid-MCL and femur 
enthesis: 
• All markers present 
at OA grade 5 
 
Outer fibrous region: 
• COL2, SOX9 and 
ASPN expression at 










• Mid-ACL region  
• ACL tibial enthesis 
 
OA progression: 
• Chondroid-like cells 
in mid-ACL region 
• TB staining varied 
with OA grade 
Found in OA grade 6: 
• Mid-MCL region 
• MCL femur enthesis 
 
OA progression: 
• Chondroid-like cells 
• Potential ossification 
 
Found in: 
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• Mid-ACL region in 
OA grade 4 
Red birefringence: 









• COL2, SOX9, 
RUNX2 present at 
OA grade 4 
 
Mid-ACL: 
• COL2 in OA and 
12-wk-old ACLs 
Mid-MCL: 
• All markers present 
at OA grade 4 and 6 
Outer fibrous region: 
• All markers present 








Table 2.4 Anterior cruciate ligament (ACL), medial collateral ligament (MCL) and meniscal tissue pathology in murine 
post-traumatic OA models: destabilisation of the medial menisci (DMM) and non-invasive loading of the knee joint. 
Pathology was analysed using toluidine blue (TB) and picrosirius red (PR) staining and specific immunohistochemistry 
(IHC) markers which included COL2, SOX9 for the DMM mice and COL2, SOX9, RUNX2 and ASPN for the non-
invasive loaded knee joints.
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• Mid-ACL region at 
OA grade 6 
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• Throughout MCL at 






• Markers present at 
OA grade 4 
MCL-femur enthesis: 
• Markers present at 
OA grade 6 
 
Outer fibrous region: 
• Markers present at 













• Mid-ACL region  
• ACL tibial enthesis 
 
OA progression: 
• Matrix disorder 
• Chondroid-like cells 
in mid-ACL region 
Found in: 
• MCL femur enthesis 
of loaded MCL 
 
OA progression: 
• Chondroid-like cells 
OA progression: 
• Expanding ossified 






• ACL-tibial enthesis  
Red birefringence: 
• MCL-femur enthesis 







Tibial enthesis and 
mid-ACL: 
• All markers present 
in loaded ACL 
• Including COL2 in 
the mid-ACL region 
MCL-femur enthesis: 
• All markers present 
in loaded MCL 
Mid-MCL: 
• COL2, SOX9 and 
ASPN present 
Outer fibrous region: 
• COL2 and SOX9 
present in the lateral 
menisci 
 
Pathological changes in the post-traumatic OA ligaments and menisci are summarised in Error! 
Reference source not found.. Both DMM and non-invasive loaded knee joints had similar 
pathologies in the ACL that included matrix disorganisation and chondroid-like cells with COL2 
deposition and SOX9 expression as well as red collagen birefringence. However, in both post-
traumatic OA models, ACL pathological changes occurred in different micro-anatomical 
locations. The non-invasive loaded ACLs had changes in the mid-ACL region, including COL2 
deposition in the mid-ligament region which was not seen in the DMM ACLs. DMM mice had 
potential ossification occurring in the MCL and medial menisci. Both post-traumatic OA models 
had notable pathological changes to the ligaments which could indicate a compromised ligament 




This chapter has described abnormal pathology in murine knee ligaments and menisci in four 
distinct murine OA models which ranged from loss of collagen fibre alignment, hyperplasia, 
chondrogenesis and ossification, cell hypertrophy, and expression of endochondral ossification 
markers. These murine models included two post-traumatic OA models: the surgically induced 
DMM model [107] and the non-invasive mechanically loaded knee joint [153]. Additionally two 
spontaneous murine OA models were investigated: the STR/ort mice [152] and CD1 mice [154]. 
Knee ligament and meniscal pathology differed based on OA etiology. Herein we wanted to 
compare similarities and differences in OA pathology in murine knee ligament and menisci based 
on OA aetiology: spontaneous and post-traumatic. 
 
2.4.1 Comparing OA models 
2.4.1.1.1 Spontaneous OA 
The CD1 murine model was a novel spontaneous OA model with similarities and differences to 
the STR/ort mice. OA in the CD1 mice was assessed by OARSI scoring and joint space 
mineralisation. Joint space mineralisation has been previously shown to increase with OA grade 
severity in St/ort mice [165], similar to our findings in the CD1 knee joints. Additionally, both 
spontaneous murine OA models (STR/ort and CD1) demonstrated OA predominantly in the 
medial knee compartments. In the medial compartment, both the MCL and medial menisci of the 
OA STR/ort and CD1 mice had similar pathologies that included hyperplasia, abnormal tissue 
growth and in more severe grades of OA, evidence of mineralisation and bone formation. OA 
developing in the medial of the knee compartments could be due to gait and greater weight bearing 
loads in the medial side as has been shown in human knee OA patients [174].  
The ACL, MCL and medial menisci of both spontaneous OA murine knee joints, all showed 
increases in toluidine blue staining, which could suggest proteoglycan and GAG deposition [175]. 
Additionally the ACL and MCL in both spontaneous OA knee joints had increased red collagen 
birefringence particularly in the ACL mid-ligament region, indicative of collagen remodelling 
particularly thicker closely packed collagen fibres such as collagen type I [167]. Both spontaneous 
OA models showed COL2 deposition and SOX9, and RUNX2 expressing cells in areas of 
hyperplasia in the ACL tibial enthesis (Figure 2.4 and Figure 2.32), MCL enthesis and mid-
ligament and regions (Figure 2.8 and Figure 2.36), and the medial menisci fibrous regions (Figure 
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2.10 and Figure 2.39). COL2, SOX9 and RUNX2 are indicative of endochondral ossification, and 
similarities in these OA markers between both spontaneous OA models could indicate a similar 
OA pathology. 
Pathology differed in the ACL mid-ligament region, where OA STR/ort ACLs also showed COL2 
deposition, and SOX9, RUNX2 and ASPN expression (Figure 2.5), however in the OA CD1 knee 
joints, only COL2 deposition was found in the ACL mid-ligament region but no SOX9, RUNX2 
and ASPN expression (Figure 2.33). This implies that chondrogenesis and cellular hypertrophy 
driven by SOX9 and RUNX2 is not occurring in the CD1 spontaneous OA model in the mid-
ligament region potentially suggesting a different ACL pathology compared to the STR/ort ACL. 
SOX9 is not the only regulator of COL2 and does not always correlate to COL2 expression as has 
been shown in human OA cartilage [176]. 
Additionally, there were differences in the healthy control knee joints. COL2 deposition was also 
present in the ACL mid-ligament region of the younger and healthy 12-week-old CD1 knee joints 
(Figure 2.33) but not present in the healthy CBA knee joints (Figure 2.5). Expression of the gene 
encoding COL2, Col2a1 transcripts, have been previously detected in the ACL fibroblasts of both 
the STR/ort and CBA controls in all ages [177]. This would suggest that young CD1 mice are 
different to CBA mice in COL2 protein translation. The presence of COL2 in the young CD1 
ACL could in part contribute to spontaneous OA development by altering mechanical properties 
of the ligament. This could highlight a difference in the ACL pathology in the STR/ort and CD1 
knee joints but could also be due to differences in age (CD1: 24 weeks, STR/ort: 40 weeks), and 
weight. Further research is needed to better characterise the CD1 knee joints and determine 
pathological similarities and differences to the STR/ort and human OA models. 
 
2.4.1.1.2 Post-traumatic OA 
The post-traumatic OA models showed different severities of OA progression in different knee 
compartments. It is important to remember that DMM knee joints develop OA mainly in the 
medial knee compartments [107], and the non-invasive mechanically loaded knee joints in the 
lateral compartment [153]. The surgical DMM model showed severe OA pathologies including 
bone formation in the outer fibrous region of the medial menisci (Figure 2.17), however this bone 
formation did not occur in the lateral menisci of the mechanically loaded knee joints. Similarly, 
the ACL of the DMM model showed severe structural changes including collagen fibre 
misalignment, potential inflammation and red birefringence whereas the non-invasive 
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mechanically loaded knee joints retained fibre alignment and only had red birefringence near the 
ACL tibial enthesis. These findings suggest that the mechanically loaded knee joints showed less 
severe OA pathology compared to the DMM knee joints. We have previously shown that DMM 
knee joint OARSI score was 3.61 ±0.3 [165]. A previous study has also reported an OARSI score 
of 4 in CBA mice following non-invasive trauma [153]. The OARSI score of the non-invasive 
trauma on C57BL/6J mice at 6 weeks post-trauma has not been analysed, though a similar OARSI 
score between the two models would be expected.  
The differences in pathology between the two post-traumatic models (DMM and loaded knee 
joints) could be due to differences in OA risk between the medial and lateral compartments. 
Differences could also be due to the different tissues affected, in the DMM model the medial 
menisci are destabilised, meanwhile in the non-invasive loading of the murine knee joint has been 
shown to affect the ACL, even resulting in ACL rupture at higher loads [178]. Further research is 
needed to determine how changes in both post-traumatic OA models affect the whole knee joint 
stability. In addition, it is important to note that both post-traumatic OA models had different 
controls. The non-invasive loading were compared to a control mouse group of the same strain 
that did not undergo trauma, meanwhile the DMM mice were compared to the opposite 
contralateral knee joint (left leg) from the same mice that underwent DMM surgery (right leg). 
While OARSI score and joint space mineralisation was lower in the contralateral knee joint [165], 
previously studies have shown that contralateral knee joints have a high risk of concomitant 
injuries [179], indicating that they could have underlying pathologies and are not necessarily a 
disease-free control. 
Despite structural differences, both post-traumatic OA models demonstrated changes in rounded 
cell morphology. Immunostaining showed similar expression of cartilage-associated and 
chondrogenesis markers, COL2 and SOX9. In the ACL of both the DMM and the mechanically 
loaded knee joints, COL2 deposition and SOX9 expressing cells increased near the ACL tibial 
enthesis. In the mechanically loaded knee joints these markers extended further into the ACL mid-
ligament region, as well hypertrophic marker RUNX2 and ligament-tendon SLRP marker ASPN. 
Unfortunately, RUNX2 and ASPN marker expression could not be validated in the DMM knee 
joints (see Section 2.2.2). Overall, the presence of COL2 deposition and SOX9 expression in the 
knee ligament and menisci of both post-traumatic OA models suggests that they share similar 




2.4.2 Previous findings on ligament and meniscal OA mineralisation 
Meniscal hyperplasia and ossification have been briefly reported in STR/ort mice [152, 160, 180] 
and more recently in the DMM mouse model [173], however they do not describe any changes in 
the ACL and the MCL. The description of knee OA in STR/ort mice includes reports of 
heterotopic calcification [152, 160]. In particular, an increased ossification centre in the medial 
menisci [152] and a positive association between MCL calcification and OA development [160]. 
These findings agree with our histological data of meniscal ectopic mineralisation and ossified 
nodules in the collateral ligaments (Figure 2.6). Meanwhile, murine DMM medial menisci have 
been previously shown to have severe fibrillation, erosion and calcifications [173]. This also 
matches our histological results and is further strengthened by our immunostaining findings, 
which provide insight into the ECM and cellular changes involved (Figure 2.18). 
In humans, meniscal pathologies have been associated with ageing and OA [93]. Indeed, the 
meniscus commonly develops lesions in OA patients with no previous history of injury [181]. 
Although meniscal ossification is rare in humans and arises mainly from mechanical trauma [182], 
calcification is more common and found mainly in OA patients [183, 184]. In addition, aged and 
OA menisci showed changes in cellularity (with both areas of hyper- and hypocellularity), cell 
clustering and phenotype changes from fibroblast-like cells to round chondrocyte-like cells [184], 
similar to our findings in mouse OA. Similarities in meniscal pathologies between human and 
mouse OA support a favourable translatability between the species, despite clear meniscal 
structural differences. 
Pathological changes in knee ligaments in murine models are consistent with changes noted in 
human joints [185, 186] and other species [119]. As previously mentioned (Section 2.1), human 
cruciate ligaments from OA knee joints show chondroid and cartilage metaplasia, involving a 
change in ligament cell phenotype to a more chondrocyte-like round cell morphologies with 
SOX9 and RUNX2 expression and COL2 formation [168, 169]. COL2 deposition in the mid-
ligament region of the ACL in mice has, to our knowledge, never been reported, and yet it was 
evident in the spontaneous CD1 model and the non-invasive loading model. These findings are 
similar to that seen in the Dunkin Hartley guinea pigs, another spontaneous model of OA, in which 
COL2 deposition in the ACL preceded changes to the cartilage [121, 187]. Changes in COL2 
formation could be related to SOX9 expression, a transcription factor necessary for 
chondrogenesis, which binds and regulates the Col2a1 gene in chondrocytes [188] and regulates 
Acan gene promoters [189]. Further studies are needed to determine the mechanisms of 
pathological chondrogenesis in knee joint ligaments. 
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The pathological changes seen in the ligament and menisci of the OA mouse models has some 
similarities to endochondral ossification pathways. Endochondral ossification is the process by 
which cartilage mineralises and results in resorption and replacement by bone [190]. Typically 
this process begins with chondrocyte proliferation, initiated by SOX9 [188], then chondrocytes 
undergo further maturation and become hypertrophic, secreting a distinct matrix containing 
collagen type X and calcifying the matrix [190]. While chondrocytes die, due to lack of nutrients, 
they also direct surrounding stem cells to differentiate into osteoblasts which deposit the 
mineralised bone matrix [190]. RUNX2 is an important regulator at the later stages of 
endochondral ossification, promoting chondrocyte hypertrophy and controlling differentiation 
[191]. The presence of COL2, SOX9 and RUNX2, as well as evidence of bone formation in the 
OA ligament and meniscal tissue could be indicators of endochondral ossification occurring in 
these tissues. Future research should look at collagen type X secretion and mineralisation markers 
to confirm this possibility. 
The presence of ASPN in the ACL, MCL and menisci of some of the murine OA knee joints, 
suggests that it could play a role in OA development. ASPN is a known tendon and ligament 
SLRP found localised around ligament fibroblasts [171]. ASPN expression has been previously 
known to increase in the cartilage of human OA patients, inhibiting TGF-β-induced expression of 
the Col2a1 gene [170]. ASPN has also been found to increase in degenerated human intervertebral 
discs [192], yet its role is relatively unknown. ASPN deficient mice have thinner collagen fibrils 
and upregulation of collagen and other GAG [193], suggesting a role in ECM composition and 
mechanical properties. Additionally, ASPN is a negative regulator of periodontal ligament 
mineralisation, which has been shown to directly interact with BMP-2 [194]. ASPN could be 
involved in the prevention of chondrogenesis and mineralisation in the OA ligaments, though its 
effectiveness is unclear since chondrogenesis markers and bone formation were also found. 
Other factors linked to ligament ossification include Indian hedgehog, WNT and inflammatory 
cytokines signalling [185, 186, 195]. It was also reported that Col6a1 and Runx2 may be common 
susceptibility genes in ligament ossification in the spine [196, 197] and both of these genes have 
also been linked to OA [198, 199]. Growth factor signalling has also been associated to ligament 
ossification in the spine, specifically the ligamentum flavum which connects adjacent vertebrae, 
and growth factors include recombinant BMP2 in rat spines [200] and BMP2, BMP4 and BMP7 
signalling in the human spine [201]. TGF-β and BMPs are known regulators of endochondral 
ossification and fibrosis as well as being involved in OA development. Recently, epidermal 
growth factor signalling was linked to OA development comprising of ectopic chondro-osseous 
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pathologies in the ligament and meniscus [202]. Further research is needed to understand how all 
these factors interact during OA development. 
 
2.4.3 Study limitations 
There are certain limitations in the study design that could have improved the interpretation of our 
findings. In the post-traumatic OA models, the DMM surgery was performed on C57CBA mice, 
which differed from the C57BL/6 mice used for non-invasive mechanical loading. Additionally, 
tissue processing for the DMM knee joints differed from all the other OA models, which affected 
immunostaining protocols in the DMM mice. Lastly, the CD1 OA mice (24-week-old) were 
compared to their younger (12-week-old) and healthier CD1 mice which could have unknown 
pathologies, such as COL2 deposition seen in the ‘healthy’ CD1 ACL. 
The biggest limitation in this study was the lack of ligament specific cellular markers. Analysis 
of important ligament ECM components such as collagen type I, collagen type III and small 
proteoglycans such as decorin and biglycan [80] could give us further insight into ligament ECM 
health and more specific pathological changes. However, these markers could not be validated for 
immunostaining analysis in murine knee joint, likely due to antibody sensitivity. Furthermore, 
better understanding of ligament cell populations and ligament fibroblast markers is imperative to 
further analyse the changes in rounded-cell morphology and SOX9, RUNX2 and ASPN 





This study has demonstrated structural and morphological differences and similarities in knee 
joint ligaments and menisci in post-traumatic and spontaneous murine OA models. In all 
spontaneous and post-traumatic OA models, we found ECM changes in the ACL and MCL that 
included proteoglycan deposition and collagen composition. These ECM changes were 
accompanied with cellular changes, indicated by rounded-cell morphology with SOX9 expression 
and COL2 deposition, markers of chondrogenesis. Furthermore, in the spontaneous OA STR/ort 
model and the post-traumatic OA non-invasive mechanically loaded model, cellular changes 
included hypertrophy (RUNX2 expression) and ASPN expression. SOX9 and RUNX2 expression 
indicate potential endochondral ossification in the ligaments which had never before been 
reported. Furthermore, we presented a novel spontaneous OA murine model: the CD1 mice. CD1 
knee joints showed all the characteristics of OA, including joint space mineralisation, osteophyte 
formation, ossification in the MCL and medial menisci, and ACL ECM and cellular changes. 
Our findings confirm that knee ligament and menisci health was affected during OA progression 
in both the post-traumatic and spontaneous OA models. These findings confirm that OA is a whole 
joint disease affecting all tissues in the knee joint, and knee ligaments and menisci could play a 
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3.1 Introduction  
As in all matrix-rich tissue, ECM structure and function are closely related, particularly in 
ligaments. As previously mentioned, ligaments are composed of a collagen hierarchical structure 
consisting of collagen molecules, fibrils, fibres, fibre bundles and fascicles which make up the 
ligament unit [2]. Besides collagen, other structural ECM proteins such as proteoglycans, elastin 
and lysyl oxidase are also important components which interact with the fibrous collagenous 
bundles [2]. The mechanical behaviour of ligaments is viscoelastic and exhibit non-linear and 
linear behaviour when undergoing elongation (see Section 1.5, Figure 1.4) [2, 60]. Viscoelastic 
properties include strain rate sensitivity [61], stress-relaxation [59], creep [65] and hysteresis [66] 
(Figure 1.5). Viscoelastic behavior is mainly attributed to collagen interaction with ECM 
structural proteins such as proteoglycans and elastin [60, 69, 73]. Changes in the constituents of 
ligament structure can alter ligament function and mechanical behaviour which include changes 
to the ligament hierarchical structure [203] as well as collagen [141, 204], proteoglycan [205] and 
elastin content [28]. Previously, in Chapter 2, we demonstrated changes in the ligament ECM 
composition and cellular morphology during OA development in the murine knee joint. The 
consequences of the OA disease process on the mechanical behaviour of ligaments are not fully 
understood, therefore, our aim was to analyse the ligament mechanical behaviour in OA models. 
To date, there are very few studies on the mechanical and viscoelastic properties of the human 
ACL in OA patients. A study by Hagena et al, found a decrease in elastic stiffness and ultimate 
load at failure in OA ligaments, along with an increase in viscoelastic stress-relaxation [138]. 
Another study found an increase in the elastic stiffness of the MCL and LCL ligaments in OA 
patients compared to non-arthritic cadaveric ligaments [140]. Therefore, changes in the knee 
ligament elastic stiffness during OA could depend on the type of ligament, such as cruciate or 
collateral ligaments which differ in structure and function [20]. Most other studies on human OA 
patients have focused on knee joint stiffness, such as varus and valgus knee stiffness, which did 
not change in OA patients [139] and dynamic knee joint stiffness during gait which increased in 
OA patients [206]. There is a clear need to better characterise the ligament viscoelastic and 
material properties during OA, to better understand disease progression during early stages of OA 
during age-related spontaneous OA and during post-traumatic OA, something not always possible 
with human ligament samples. 
Several studies have analysed the mechanical properties of the ACL during OA development in 
different animal species, each offering deeper insight into disease pathology and ligament 
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mechanical changes. In the Dunkin Hartley guinea pig spontaneous OA model, mechanical tests 
found a decrease in the toe-region laxity of the ACLs [116]. In mice, Anderson-MacKenzie et al. 
found that STR/ort mice (spontaneous OA model) had  weaker ACLs with a lower ultimate load, 
associated with increased collagen remodelling [114]. Furthermore, in collagen V mutant mice 
with secondary OA, Sun et al. reported decreased collagen fibril numbers in the ACL, along with 
a significant decrease in ultimate load and elastic stiffness [141], further confirmed in work by 
Connizzo et al. [204]. Most of these studies on ACLs focus on material properties, but do not fully 
address the viscoelastic properties of the toe-region which is physiologically relevant [60].  
Murine models offer several advantages to study OA progression, including the ability to study 
disease progression in spontaneous OA models [114, 154] and more recently in post-traumatic 
OA [153]. The post-traumatic OA model developed by Poulet et al. [153] offers the ability to test 
the ACL mechanical properties post-trauma without invasive ACLT, which is the most common 
model of post-traumatic OA [102]. The ability to examine mechanical changes during disease 
progression in spontaneous OA will give further insight into the ACL degradation reported by 
Hasegawa et al [207] and the change in stiffness reported by Hagena et al [138]. This will elucidate 
the role of ligament function and ECM changes during OA pathology, important for future 
therapeutic applications for affected patients. 
 
3.1.1 Hypothesis and aim 
Due to our findings in Chapter 2, which included changes to the murine ACL ECM composition 
(COL2 deposition) and cell markers for chondrogenesis (SOX9 and RUNX2), we hypothesised 
there would be changes in the viscoelastic behaviour and material properties in both the murine 
spontaneous OA and post-traumatic OA ACLs. 
The overarching aim for this study was to assess the mechanical viscoelastic behaviour and 
ultimate load of the ACL in healthy and spontaneous and post-traumatic murine OA models. To 
achieve this, the first aim was to create a testing setup and protocol appropriate for murine ACLs. 
Several aspects were included in this first aim, including determining the ideal knee flexion angle 
for mechanical testing, measuring the ACL length and cross-sectional area, and protocol design. 
For mechanical analysis of the murine ACL, the aim was to analyse viscoelastic behaviour and 
material properties during OA progression in spontaneous and post-traumatic OA models. For 
viscoelastic behaviour the following properties were analysed: strain rate sensitivity, hysteresis, 
and stress-relaxation. For material behaviour, the ultimate load at failure was analysed. 
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Mechanical behaviour was compared between each OA group and appropriate control. 
Similarities and differences between the post-traumatic and spontaneous OA groups were 
discussed. 
Overall, these aims should give us further insight into the viscoelastic behaviour and ultimate load 




3.2 Materials and Methods 
3.2.1 Physiological range of murine knee flexion – Gait analysis 
Gait analysis tests to determine the physiological range of motion in the murine knee joint was 
conducted on the data provided by Mr. Marrin, Dr. D’Aout and Prof. Bou-Gharios. X-ray 
reconstruction of moving morphology was recorded using two independent 60 kW Epsilon X-ray 
generators (EMD Technologies, CA), 16 inch image intensifier tubes (Thales, FR), X-Ray Tubes 
(Varian, USA) and Phantom Miro M120 video cameras (Vision Research, USA). X-ray images 
of gait were analysed using XMALab Software (Brown University, USA) and MatLab 
(MathWorks, R2018a Version 9.4, USA). Knee joint angles during gait was measured on 
B6CBAF1 mice (n=4) (Charles River). For each mouse, two gait trials were recorded and 
analysed. X-ray generator pulsed radiographic exposures at 120 frames per second, and video was 
recorded for a run length of approximately 3 seconds (Figure 3.A). 
 
 
Figure 3.1 Setup for murine knee flexion measurements using x-ray reconstruction of moving morphology. X-ray images 
(A) were imported to XMALab software (Brown University, USA) where each anatomical point (Pt.) (B) was tracked 
at each frame during the normal mouse gait cycle. Anatomical points tracked were the following: left hip (1, LHIP), 
left knee (2, LKNEE), left ankle (3, LANK), right hip (4, RHIP), right knee (5, RKNEE), right ankle (6, RANK), and 
occiput (7, OCCI). The corresponding x,y,z location of each anatomical point was then imported to MatLab to create 
a 3D model of murine gait for the left and right hind-legs (C). Physiological knee range of motion during murine gait 
was calculated from the 3D models in MatLab (MathWorks, R2018a Version 9.4, USA). 
 
Video files were opened in XMALab software for distortion correction, calibration and point 
digitising. Mouse gait was tracked at every frame at the following points: left hip, left knee, left 
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ankle, right hip, right knee, right ankle, and occiput (Figure 3.B). The resulting locations of each 
point were exported from XMALab as a 3D csv file that was then analysed as a matrix in MatLab 
where a 3D model could be created (Figure 3.C) and knee speed and knee joint flexion was 
measured at every frame. The results from this gait analysis of physiological murine knee flexion 
were used to determine the ideal angle for mechanical testing of the femur-ACL-tibia complex. 
 
3.2.2 Experimental set-up for material testing of murine knee joints 
Clamps were specifically designed for material testing of murine ACLs, using the femur-ACL-
tibia complex. Clamp was designed based on past literature [114, 141, 204] and following advice 
from Dr. Snehal Shetye from the University of Pennsylvania. Clamps were designed using 
ProEngineer (Creo Elements/Pro, PTC, USA) with guidance from Mr. Eliasy and Mr. Janvier 
(Figure 3.2A). A 3D printed model of the clamp was manufactured in polylactic acid (Ultimaker, 
NL) for preliminary testing (Figure 3.2B). Clamps were modified to ensure ACL alignment and 




Figure 3.2 Instron clamp design and optimisation. Clamp prototypes were designed with ProEngineer (Creo 
Elements/Pro, PTC, USA) (A),a preliminary prototype was 3D printed (Ultimaker, NL) in polylactic acid (B), and then 
the final version was manufactured in medical grade steel (C) at the School of Engineering at the University of 




3.2.3 Animals and tissue collection 
3.2.3.1 Determination of sample size for material testing experiments 
Preliminary studies were conducted using C57BL/6 12-week-old male mice (n=6) for a power 
analysis to determine the sample size necessary. Preliminary data (not shown here) of the tangent 
modulus-stress curve (at 2 MPa) was measured for each sample. Measurements of tangent 
modulus for all samples was normally distributed (Shapiro-Wilk test) with a standard deviation 
of 8.34 MPa. Power and Sample Size Software (version 3.1.6, Vanderbilt University) [208] was 
used to calculate ideal sample size. The hypothetical difference of the tangent modulus between 
control and OA group was assumed to be 15%. With these assumptions, we calculated the ideal 
sample size to be 6 experimental and 6 control subjects to be able to reject the null hypothesis that 
the population means of the experimental and control groups are equal with probability (power) 
0.8 (Figure 3.3). The type I error probability associated with this test of this null hypothesis is 
0.05. Though sample size needed for analysis was 6, however we tested more (n=8 or 10) to allow 
room for error in the setup of the sample (see Section 3.3.3). 
 
 
Figure 3.3 Power and sample analysis. T-test was completed using Power and Sample Size Software (version 3.1.6, 
Vanderbilt University) [208]. By assuming a 15% difference in tangent modulus between control and OA groups, the 
predicted experimental sample size is 6. 
 
3.2.3.2 Murine animal models  
Both healthy and OA murine animal models were used in our study. Healthy ageing group were 
C57BL/6J mice at 12 and 24-weeks old. The murine OA models used in this study included a 
non-invasive post-traumatic OA model (with non-invasive loading) [153], and a novel 
spontaneous OA model (CD1 outbred mice) [154], (see Table 3.1). All mice were kept in the same 
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conditions in polypropylene cages, subjected to 12-hour light/dark cycles, at 21±2˚C and fed 
standard diet ad libitum. All procedures were performed in accordance with the UK Home Office 
guidelines and regulations under the Animals (Scientific Procedures) Act 1986 and local ethics 
committee (project license: P267B91C3). For tissue collection, all animals were euthanised by 
cervical dislocation. Murine hind legs were taken for micro-computed tomography (µCT) imaging 
analysis (see Section 3.2.4) or for ACL mechanical testing (see Section 3.2.5). The outer skin was 
removed from the murine hind legs, and samples were immediately stored in a -20C freezer until 
required for testing. Storage at -20C has been previously shown to not have effect on the 
viscoelastic and mechanical properties of ligaments in several animal models [78, 209]. 
 
3.2.3.3 Healthy ageing group (C57BL/6J mice). 
In this chapter, male 12-week-old and 24-week-old C57BL/6J mice were used to represent normal 
ageing at the same age time points of the CD1 spontaneous OA mice. This would allow for 
analysis of healthy ageing, which could be compared to CD1 mice to determine if mechanical 
changes occurred due to age or OA progression, especially since CD1 mice are a novel 
spontaneous OA model. C57BL/6J mice at 12 to 24 weeks of age are not known to develop OA 
symptoms and at 6-months of age have healthy cartilage and a low OA score [154, 173]. For this 
study, male 12 and 24-week-old C57BL/6J mice (n=8) were obtained from Charles River (UK) 
and euthanised one day after arrival (see Table 3.1). Right legs were used for ACL mechanical 
testing, and left legs for µCT ACL measurements. 
 
3.2.3.4 Spontaneous OA group (CD1 mice) 
Male CD1 outbred mice were purchased from Charles River, UK. As shown in Chapter 2, CD1 
mice develop spontaneous OA at 24-weeks of age, with significantly increased OARSI cartilage 
score and joint space mineralisation compared to the 12-week-old CD1 mice (Section 2.3.4). 
Mechanical properties of the ACL from a younger 12-week-old CD1 group was compared to an 
older 24-week-old group to determine differences within OA progression (Table 3.1). Male 12-
week-old CD1 mice were euthanised one day after arrival (12-week-old group, n=10) and the 
remaining mice were aged for 12 more weeks (24-week-old group, n=10). Right legs were used 
for ACL mechanical testing, and left legs for µCT ACL measurements. Changes between 12 and 
24-week-old ACLs in CD1 mice were briefly compared to changes between 12 and 24-week-old 
ACLs in the healthy aging group. 
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Table 3.1 Murine strain, gender, age and number for each group, including osteoarthritis (OA) and controls. Overall 
there were three main groups tested, a healthy ageing group (C57BL/6 male mice, 12 and 24-weeks-old), a spontaneous 
OA group (CD1 male mice, 24-weeks-old), and a post-traumatic OA group (C57BL/6 mice undergoing non-invasive 
loading of the knee joint). Each OA group also had a secondary healthy control: CD1 12-week-old mice previously 
shown not to develop OA (Section 2.6) and C57BL/6 non-loaded knee joint controls. 
Group Murine strain, 
gender 
Age (n) 
OA sub-group Control sub-group 
Healthy Ageing C57BL/6J, male N/A 
12-week-old (n=8) 
24-week-old (n=8) 
Spontaneous OA CD1, male 24-week-old CD1 (n=10) 12-week-old CD1 (n=10) 
Post-traumatic OA C57BL/6J male 
Non-invasive loading,  
18-week-old (n=12) 
Non-loaded,  
18-week-old (n=8)  
 
3.2.3.5 Post-traumatic OA group (Non-invasive mechanical loading of C57BL/6 mice) 
Non-invasive mechanical loading of the knee joint of C57BL/6J mice was used as a post-traumatic 
OA model. Progression of OA in this mouse model was described in Section 2.3.3 and has been 
published [153]. Non-invasive loading was performed on the right knee joints of ten-week-old 
C57BL/6J mice (Charles River, UK) (n=12), and a second group of C57BL/6J mice (n=8) which 
did not undergo treatment were used as a control group (Table 3.1). Briefly, axial compressive 
loads were applied consisting of 9N loads for forty cycles in each loading episode, and six loading 
episodes over a period of two weeks. Animals were euthanised at six weeks after the last loading 
episode, to ensure moderate OA progression. From the non-invasive loaded mice (n=12 total), 
eight of the right loaded legs were used for ACL mechanical testing (n=8), and four right loaded 
legs for µCT ACL measurements (n=4). From the non-loaded mice, right legs were used for ACL 
mechanical testing, and left legs for µCT ACL measurements. 
 
3.2.4 Cross-sectional area (CSA) and length measurements of the murine ACL 
Cadaveric knee joints for each murine group (see Table 3.1) were analysed with X-ray µCT to 
quantify the murine ACL length and cross-sectional area (CSA) at 90º knee flexion. 90º knee 
flexion was determined to be the optimal angle after gait measurements (see Section 3.3.1). For 
the healthy ageing and spontaneous OA group, ACL samples from the left knee joint (n=6) were 
scanned and analysed for CSA and length measurements. In the post-traumatic OA group, ACL 
samples from the right loaded knee joint were used (n=4), and in the healthy non-loaded control 
group ACL samples from the left knee joint were used (n=4). Previous studies have shown no 
difference in ACL measurements between left and right knee joints in humans [210], and the same 
was observed in preliminary studies on mice ACLs (data not shown here). 
124 
 
Prior to these analyses, the knee joints were defrosted and dissected under a microscope (Nikon 
SMZ-745, Japan), removing excess tissue and muscle until only the femur-ACL-tibia complex 
remained (Figure 3.4A), similar to the method previously published by Sun et al [141]. Following 
dissection, femur-ACL-tibia samples were submerged in Lipiodol contrast agent (Guerbet, FR) 
overnight at 4℃ before scanning the following day. The following day excess femur and tibia 
were removed using a scalpel (No. 11) to allow the sample to fit in a small straw holder filled with 
Lipiodol (Figure 3.4B). Dental wax (Boots, UK) and a putty adhesive (Blu Tack) (Bostik, UK) 
was used to keep the femur in place at a 90º with the ACL and tibia suspended vertically. The 
femur-ACL-tibia samples were then scanned with a 5µm isotropic voxel size (50kV, 200µA 
respectively, 0.5mm Aluminium filter; 0.6° rotation angle, no frame averaging) using a Skyscan 
1172 µCT scanner (Bruker, BE). This protocol was similar to previously published methods to 
image mouse ligaments using phosphotungstic acid [211]. 
Images of the murine femur-ACL-tibia complex were reconstructed using the NRecon software 
and inspected with the Dataviewer software (Bruker, BE) (Figure 3.4C-E). A sagittal area of 
interest showing the femoral condyles-ACL-and tibia condyles was saved for analysis of the 
murine ACL length (Figure 3.4D). The ACL length was measured using the CTan software 
(Bruker, BE). A second area of interest of the entire ACL volume was selected in the Dataviewer 
software and saved in the axial plane for analysis of the ACL CSA (Figure 3.4E). The ACL CSA 
was measured using the CTan software at the ACL midsection. For each sample length and CSA 
was measured three times to ensure accuracy, and an average ACL length and CSA was calculated 
for each mouse group. This method was chosen to measure ACL length and CSA due to the small 
size of the mouse knee joint and ACL (~1mm length). The average measurement of ACL length 
and CSA for each group was used to calculate stress-strain. This method differs from past 
mechanical studies on mouse ACLs which measured each tested ligament using a custom laser-






Figure 3.4 X-ray micro computed tomography (µCT) image analysis of the murine anterior cruciate (ACL). Length and 
cross-sectional area (CSA) were measured. (A) First the murine femur-ACL-tibia complex was dissected. (B) The 
sample was placed in a small holder submerged in Lipiodol (Guerbet, FR) contrast agent at a 90° knee flexion position. 
(C-E) Femur-ACL-tibia images were orientated in the coronal (C), sagittal (D, orange box) and axial (E, blue box) 
plane. (D) ACL length was measured in the sagittal plane (green line, yellow arrow). (E) Similarly, in the axial plane, 
the murine ACL CSA was selected (green line, yellow arrow) and measured at the mid-point of the ACL. Scale bar is 
1mm for all images. 
 
3.2.5 Sample preparation for tensile testing of the murine ACL 
Frozen (-20°C) knee joints (see Table 3.1) from the right hind leg were used for mechanical testing 
of the ACL. Samples were defrosted at room temperature for twenty minutes. Meanwhile the test 
clamp fixture was assembled and oiled (sunflower oil). Once defrosted, the murine knee joint 
samples were immediately dissected under a dissection microscope (Nikon SMZ-745, Japan) 
whilst being kept hydrated with phosphate-buffered saline (PBS) (Gibco). All soft tissue, 
including muscle and patella, were removed around the femur, tibia and knee joint until the 
collateral ligaments were visible (Figure 3.5A). The collateral ligaments and then medial and 
lateral menisci were carefully removed (dissecting at the posterior horns and then the anterior 
horns) ensuring that the cruciate ligaments stayed intact. Excess muscle was removed until both 
cruciate ligaments were the only tissue remaining at their femoral and tibial insertions. Then lastly 
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the PCL was cut from the tibial attachment site and then from the femoral condyle. The remaining 




Figure 3.5 Dissection of the murine knee joint, for preparation of the femur-anterior cruciate ligament (ACL)-tibia 
complex. (A) First surrounding tissue around the knee joint was removed, including excess muscle, patellar tendon, 
and the collateral ligaments. (B) Then the menisci were removed by dissection at the meniscal horns, and lastly the 
posterior cruciate ligament was removed, leaving only the femur-ACL-tibia complex. Dissection protocol was similar 
to past studies on murine ACL mechanical testing [4]. Scale bar is 1mm for both images. 
 
Poly(methyl methacrylate) (PMMA) (Technovit 6091) at the ratio of 1.74 g powder: 1 mL liquid 
was prepared in a fume hood and used to fix the femur and tibia samples to the clamp fixtures. A 
layer of PMMA was added to the two compartments and the sample was placed with the femur in 
the top compartment and the tibia in the bottom compartment (Figure 3.6A). The femur and tibia 
were placed at an estimated 90º angle using predefined guides in the fixture (Figure 3.6B&F), 
similar to the protocol used by Sun et al. [141]. Samples were quickly positioned, ensuring the 
ACL did not come into contact with the PMMA. Another layer of PMMA was applied to each 
compartment to ensure complete fixation of the femur and tibia. Once the PMMA hardened, the 
sample was briefly aligned under the dissection microscope (Nikon SMZ-745, Japan) to ensure a 
vertical ACL orientation (Figure 3.6C). The fixture with the sample was transferred to a dual 
column uniaxial material testing machine (Instron 3366, USA) (Figure 3.6D), the encasing outer 
plastic layer was adjusted to enclose the sample and PBS was added to ensure a hydrated ligament 
sample throughout testing (Figure 3.6E-F). Once ready, the tensile testing protocol commenced 
(Section 3.2.6). Once the tensile testing of the prepared sample was completed, a steel G-clamp 
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and a hammer were used to remove the PMMA and remaining tibia and femur sample (Figure 
3.6G).  
 
Figure 3.6 Experimental setup for mechanical testing of the murine ACL. Clamps were prepared in a fume hood (A), 
after which dissected femur-ACL-tibia complex samples were added at an approximate 90° knee flexion angle (B) and 
fixed in position using PMMA, similar to previous mechanical studies by Sun et al. [141]. ACL orientation was further 
adjusted under a microscope (C) to ensure a vertical ligament orientation. Clamps with the murine femur-ACL-tibia 
sample were transferred to a dual column uniaxial materials testing machine (Instron 3366) (D) and outer encasing 
layer was adjusted and the sample was submerged in phosphate buffered saline before mechanical testing commenced 
(E) and 90 degree knee flexion was further confirmed (F). Once the tensile testing was completed, the sample was 
forcefully removed using a G-clamp and a hammer (G). 
 
3.2.6 Mechanical testing protocol to determine viscoelastic behaviour of the murine 
ACL  
The mechanical testing protocol was chosen to determine murine ACL viscoelastic properties 
based on past literature of murine ligament mechanical properties [114, 141] and on canine cranial 
cruciate ligament mechanical testing [61]. For all mouse ACLs, the same uniaxial testing protocol 
was used in the materials testing machine (Instron 3366, USA) using a 10N load cell. Instron 
measured sample elongation and applied load. Firstly, a preload of 0.02N was applied to remove 
laxity in the ligament. Then a series of 10 preconditioning loads ensured ligaments were in a 
steady state condition [64] and removed alterations to viscoelastic behaviour due to freezing [78]. 
The 10 preconditioning load-unload cycles were applied at a strain rate of 1%/s to a maximum 
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load of 0.4N and then back to 0.02N with a resting period of 120 seconds before the next cycle 
(x10) (Figure 3.7). 
Following preconditioning, strain rate sensitivity, stress-relaxation behaviour and ultimate load at 
failure were tested (Figure 3.7). Before strain rate testing, stress-relaxation and ultimate load at 
failure there was a resting period of 300 seconds to allow the ligament to return to a stable state. 
For strain rate testing, two load-unload cycles of three different strain rates (0.1%/s, 1%/s, and 
10%/s) were followed by a 120 second rest time (Figure 3.7). Viscoelastic stress-relaxation was 
tested at 5% strain (applied strain at 1%/s) and elongation was maintained for 120 seconds (Figure 
3.7). Lastly the final ultimate load at failure was tested at a strain rate of 1%/s until ligament 
rupture (Figure 3.7). Ligament rupture occurred at the ligament mid-section and was briefly 
analysed under a microscope following testing (data not shown). Strain rates were chosen based 
on past literature which ranged from 0.1%/s [141] to 100%/s [114]. Creep was not measured in 
this study, though it is an important viscoelastic property [2]. 
 
 
Figure 3.7 Mechanical testing protocol used for viscoelastic and material behaviour of murine anterior cruciate 
ligament (ACL). Ten preconditioning cycles were applied to ensure a stretched ligament at 1%/s strain rate. Then 
viscoelastic behaviours were tested including strain rate sensitivity and stress-relaxation. Different strain rates were 
tested (x2 for each strain rate) at 0.1%/s, 1%/s and 10%/s strain rates. For stress-relaxation the sample was loaded to 
5% strain and elongation was held for 120 seconds. Lastly, the material behaviour of ultimate load to failure was tested 




3.2.7 Analysis of the viscoelastic behaviour and ultimate load of the murine ACL 
Analysis of the viscoelastic behaviour and ultimate load to failure of the murine ACLs was 
analysed using Excel (Microsoft) and GraphPad Prism (GraphPad Software, version 8.0.0). 
3.2.7.1 Stress-strain 
Stress-strain curves of each of the different strain rates was calculated from the elongation and 
applied force measurements for each strain rate (0.1%/s, 1%/s, and 10%/s) (see Figure 1.4). The 
second load-unload cycle was used for analysis [61]. Estimated CSA and length of the specific 
murine group ACL (see Section 3.3.2) were used for stress and strain calculations. Stress was 
calculated using Equation 3.1 and strain using Equation 3.2. The resulting stress-strain curve was 
then fitted to an exponential curve using the least squares method (from the root-mean-square 
error) (Equation 3.3). An exponential best-fit curve was chosen as it has been previously used to 
replicate the viscoelastic behaviour of soft-tissues [212], human ACLs [213] and more recently 
for canine cruciate ligament [61]. Stress-strain curves were plotted up to 3 MPa of stress to prevent 






   (3.1) 






   (3.2) 
Where ε is strain (mm/mm), ∆L is the change in elongation (mm) (∆L = Lt – L0), and L0 (mm) is 
the initial estimated ligament length. 
 𝜎 = a(ebε − 1)   (3.3) 
Where ‘a’ and ‘b’ are coefficients. 
 
3.2.7.2 Tangent modulus 
From the exponential best-fit curve for each strain rate, the tangent modulus (slope of the stress-
strain curve) was derived using Equation 3.4. Tangent modulus has been used to measure 
viscoelastic stiffness of the stress-strain curve for soft tissues, including the human sclera [214] 
and canine cruciate ligaments [61]. For the purposes of this study, tangent modulus was plotted 
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as a function of stress and then a best-fitted linear equation of the tangent modulus versus stress 
(Equation 3.5) was used when calculating the average tangent modulus between samples. 
 
𝐸𝑡 =  
∆𝜎
∆𝜀
  (3.4) 
Where Et is tangent modulus (MPa). 
 𝐸t(σ) =  𝑎𝑥 + 𝑏  (3.5) 
Where Et (σ) is the tangent modulus (MPa) equation as a function of stress, and ‘a’ and ‘b’ are 
coefficients. 
 
3.2.7.3 Strain rate sensitivity 
Ligaments and tendons are known to respond differently to variations in strain rate, a behaviour 
known as strain rate sensitivity [69] (see Figure 1.5A). To analyse stress-strain sensitivity, 
measurement of the stress-strain curve and tangent modulus was repeated for all the different 
strain rates. Furthermore, strain rate sensitivity was also analysed with normalised tangent 
modulus to account for deviation between samples. Normalised tangent modulus was calculated 
using the tangent modulus at 1%/s and 10%/s strain rates which was normalised to the 0.1%/s 
strain rate tangent modulus of the same sample using Equation 3.6. Normalised tangent modulus 
as a factor of stress was calculated for all samples, and an average normalised tangent modulus-
stress curve was plotted for each murine group. This is similar to previous calculations done by 
Hama Rashid et al. on canine cruciate ligaments [61]. 
 
𝐸 𝑛𝑜𝑟𝑚 =  
𝐸𝑡
𝐸0
𝑥 100 (3.6) 
Where Enorm is normalised tangent modulus (%), Et is the tangent modulus at 1%/s or 10%/s strain 
rates, and E0 is the tangent modulus at 0.1%/s strain rate. 
 
3.2.7.4 Hysteresis 
Ligaments also display hysteresis, another viscoelastic behaviour, referring to the loss of energy 
during a load and unload cycle [215]. In murine ACLs, hysteresis characterised as the area 
between the load and unload cycles (Figure 3.8), was measured using numerical integration, 
trapezoidal rule, similar to Rashid et al. [61]. Numerical integration calculated the area under the 
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curve of the load and unload cycle and the difference between the cycles was hysteresis. 
Hysteresis was measured at all strain rates (0.1%/s, 1%/s and 10%/s). 
 
Figure 3.8 Representative viscoelastic hysteresis of the murine ACL. Hysteresis as represented by the load and unload 
stress-strain curves, demonstrates a loss of energy between the two cycles, measured as the area between the two curves 
(orange region). Hysteresis area was quantified using numerical integration [61]. 
 
3.2.7.5 Stress-relaxation 
Stress-relaxation was used to measure the viscoelastic response to constant strain and the resulting 
decrease in stress (see Figure 1.5B). This nonlinear viscoelastic property has been previously 
modelled in ligaments [61, 216]. Stress-relaxation was measured when the load reached an 
estimated 5% strain (0.15N) (t=0). Stress was normalised by the peak stress at t=0 using Equation 
3.7 and plotted as a function of log time. The resulting curve was fitted into a polynomial equation 
to determine the average normalised stress for all samples (Equation 3.8). 




Where σnorm(t) is the normalised stress-time function, σt is the stress, and σ0 is the stress at t=0. 
 𝜎𝑛𝑜𝑟𝑚(𝑡) =  𝑎𝑥
3 + 𝑏𝑥2 + 𝑐𝑥 + 𝑑  (3.8) 
Where ‘a’, ‘b’, ‘c’ and ‘d’ are coefficients. 
 
3.2.7.6 Ultimate load at failure 
Lastly, ultimate load, also known as maximum load or failure load, a material property, was used 
as a measurement of maximum ligament strength [114, 141, 204] (see Figure 1.4, Failure region). 





3.2.8 Statistical analysis and normality of data testing  
Normality and statistical analysis were calculated using GraphPad Prism (GraphPad v8). 
Normality of data was tested using a Shapiro-Wilk test where a p-value ≤0.05 indicated statistical 
significance. For all other statistical analyses, a p-value ≤0.05 also indicated statistical 
significance.  
For knee flexion and murine ACL length and CSA analysis, Shapiro-Wilk test showed normally 
distributed measurements for all groups. Statistical analysis of the physiological range of murine 
knee flexion involved an unpaired t-test (two-tailed) (p≤0.05) comparing the maximum and 
minimum knee flexion angles and gait speed between the left and right knee joints. In the ACL 
CSA and length measurements, an unpaired t-test (p≤0.05) was used to compare between control 
and test groups. 
For comparison of ACL viscoelastic and material properties (stress-strain, tangent modulus, strain 
rate sensitivity, normalised strain rate sensitivity and stress relaxation), the area under the curve 
was calculated using numerical integration, trapezoidal rule [61], for each sample. Shapiro-Wilk 
test confirmed normally distributed data for the stress-strain area under the curve of the healthy 
ageing group 12-week-old and the spontaneous OA group 24-week-old ACLs. Data was not 
normally distributed for the area under the curve of the stress-strain curves for the healthy ageing 
24-week-old ACLs, in the spontaneous OA 12-week-old ACLs, and in the post-traumatic OA 
group. Therefore, for stress-strain analysis, a nonparametric statistical test was performed (Mann-
Whitney test). Lack of normality in these control samples is likely due to the standard deviation, 
potentially due to assumptions of equal ACL length and CSA. 
All other ACL mechanical properties showed normal distribution, including tangent modulus, 
normalised tangent modulus, hysteresis, stress-relaxation and ultimate load. Therefore, statistical 
analysis was completed with an unpaired t-test (two tailed) (p≤0.05). Groups compared included: 
12 versus 24-week-old ACLs in the healthy ageing group and in the spontaneous OA group, and 
non-loaded versus loaded ACLs in the post-traumatic OA group. 
Furthermore, in the strain rate sensitivity analysis compared strain rate (0.1%/s, 1%/s and 10%/s) 
differences within the same group. A nonparametric Friedman test was used when comparing the 
area under the curve of stress-strain curves at the three different strain rates, followed by a Dunn’s 
multiple comparison test (p≤0.05). Repeated measures ANOVA was used when comparing the 
area under the curve of the tangent modulus-stress curves at the same three different strain rates, 
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followed by multiple comparisons using Bonferroni post-hoc test (p≤0.05). When comparing the 
area under the curve of the normalised tangent modulus of the 1%/s and the 10%/s strain rates, a 
paired t-test (two-tailed) was used. A Friedman test, repeated measures ANOVA and paired t-test 
was possible since measurements were taken from the same ACL sample at different strain rates. 
Changes in hysteresis within the same group at different strain rates were also tested with a 
repeated measures ANOVA, followed by a post-hoc Bonferroni multiple comparisons test 
(p≤0.05). Lastly, hysteresis was also tested as a continuous variable using Pearson’s correlation 
test to determine a correlation coefficient (r). This was conducted for the hysteresis in the first 
five preconditioning cycles to measure correlation with increase in cycle in both the OA and 
control groups. 
Overall, this statistical analysis compares differences and similarities between healthy control and 






3.3.1 Physiological range of murine knee flexion – Gait analysis 
The physiological range of knee flexion in the mouse during gait was analysed to determine the 
ideal range of knee flexion for mechanical tensile testing of the ACL and CSA measurements. 
Using MatLab, a 3D model was created of the left and right hind-leg movement during gait of all 
(n=4) B6CBAF1 mice (Figure 3.9A). Knee flexion was calculated in radians and plotted at every 
frame for both legs (Figure 3.9B-C) from which the maximum and minimum angles of knee 
flexion were then calculated (Table 3.2).  
 
 
Figure 3.9 Representative images of murine knee flexion during gait. By tracking knee joint, hip, ankle and occiput 
points in each frame using XMALab (Brown University, USA) a 3D model of the left and right knee joint (A) was created 
using MatLab (MathWorks, R2018a Version 9.4, USA). From this model, knee flexion of the left (B) and right (C) knee 




Maximum knee flexion was 100.82° in the left knee joints and 100.47° in the right knee joint 
(Table 3.2). Minimum knee flexion was 56.49° and 55.61° in the left and right knee respectively 
(Table 3.2). Maximum and minimum angles of knee flexion in both the left and right knee joints 
of the B6CBAF1 (n=4) mice were similar and showed no statistically significant differences in 
the maximum (p=0.96) and minimum angle of knee flexion (p=0.67) (Table 3.2). Furthermore, 
the speed of the left and right knee joints was also analysed, average gait speed was similar for 
both legs, 136 and 139 mm/s for the left and right knee respectively (p=0.73).  
Overall, this data suggests that the physiological range of murine knee flexion during gait was 
between 55-100°. In order to remain within the physiological range, mechanical viscoelastic and 
material testing of the murine ACL was performed at 90° of knee flexion, because it allowed for 
uniform tensile testing along the axis of the ligament, similar to a previous study by Warden et al. 
[148]. 
 
Table 3.2 Angles of murine knee joint flexion and gait speed as determined by biplanar radiography. The average 
minimum (Min) and maximum (Max) knee flexion was calculated in degrees for both the left and right murine knee 
joint. Knee flexion ranged from 56.5 to 100.8° in the left knee, and 55.6 and 100.5° in the right knee joint. Relative 
standard deviation (RSD) ranged from 6.7% to 13.3%. No statistically significant differences were found between left 
and right knee in the Max knee flexion (p=0.96), Min knee flexion (p=0.67) and gait speed (p=0.73). 
 Degrees (°) Gait speed 
 Min Max Min Max (mm/s) 
 Left Knee Right Knee Left knee Right knee 
Avg. 56.5 100.8 55.6 100.5 135.6 138.7 
RSD (%) 8.8 13.3 6.7 11.5 24.3 19.1 
 
3.3.2 Micro-computed tomography (µCT) imaging and measurement of the murine 
ACL length and cross-sectional area (CSA) 
µCT imaging was used to measure the length and the CSA of the murine ACL, necessary for 
mechanical analysis. The murine ACL length for the healthy ageing 12-week-old and 24-week-
old ACLs was 1.153 ±0.053 mm and 1.174 ± 0.060 mm respectively and differences were not 
statistically significant between the two groups (p=0.414) (Figure 3.10B-C). The length of the 
spontaneous OA 12-week-old and 24-week-old ACLs was 1.207 ±0.051 mm and 1.276 ± 0.031 
mm respectively, a relative percent difference of 5.5% which was statistically significant (p=0.01) 
(Figure 3.10B-C). The ACL length of the post-traumatic OA non-loaded and loaded ACLs was 
1.144 ±0.104 mm and 1.087 ±0.091 mm respectively and were not significantly different 
(p=0.077) (Figure 3.10B-C). Only the spontaneous OA 24-week-old ACLs showed a significant 
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increase in ACL length, which was not seen in the healthy ageing control group which could 
indicate a difference in skeletal maturity in this spontaneous OA group. 
The CSA of the murine ACLs ranged between 0.097 mm2 to 0.112 mm2 based on the murine 
group (Figure 3.10A&C). When comparing the CSA between the murine groups and their 
respective controls, there were no statistically significant differences between the groups (healthy 
ageing group: p=0.648, spontaneous OA group: p=0.307, post-traumatic OA group: p=0.553). 
However, in the CSA measurements, there was relative standard deviation (RSD) which reached 
16.2% in the post-traumatic OA non-loaded ACLs. High RSD suggests high variance within the 
samples which could be a potential source of error for calculations of stress and strain used in the 
mechanical analysis. The measurements for ACL length and CSA for each specific murine group 
(Figure 3.10C) were used in the mechanical analyses of stress-strain. 
 
 
Figure 3.10 Measurement of the murine anterior cruciate ligament (ACL) length and cross-sectional area (CSA). 
Measurements were made in the healthy ageing, spontaneous and post-traumatic murine osteoarthritis (OA) groups. 
Murine ACL CSA (A) and length (B) were measured for each mouse group. Measurements of the ACL length (mm) and 
CSA (mm2), relative standard deviation (RSD) and percent difference (%diff) between each group are summarised (C). 





3.3.3 Quality control of mechanical analysis 
Preconditioning of the murine ACLs was used as a quality control step; samples that showed 
greater than 5% increased elongation during the preconditioning cycles were removed from 
analysis. All samples removed due to preconditioning can be seen in Sup Fig 1 (Appendix). In the 
healthy ageing group, two of the 24-week-old ACL samples were removed due to elongation 
increasing 6-7% (Sup Fig 1). In the spontaneous OA group, four samples were removed in the 12-
week-old ACLs (7-10% increase in elongation), and two samples were removed in the 24-week-
old group (6-7% increase in elongation) (Sup Fig 1) and an additional sample failed during 
dissection. In the post-traumatic OA group, one sample was removed from each group due to an 
increase in elongation ranging from 7-13% (Sup Fig 1). Increase in elongation was attributed to 
lack of fixation or slippage of the femur or tibia from the PMMA, resulting in increased elongation 
after every cycle. The total number of samples analysed for each group can be seen in Table 3.3. 
Representative preconditioning cycles for analysed samples can be seen in Sup Fig 2. 
 
Table 3.3 Samples mechanically tested and analysed. Samples that had a greater than 5% increase in elongation during 
preconditioning were discarded from analysis. A summary of samples tested and analysed can be seen for each murine 
group. The preconditioning cycles of the removed samples can be seen in Sup Fig 1. 
































3.3.4 Viscoelastic behaviour and ultimate load at failure of the ACLs in the healthy 
ageing group (C57BL/6J 12 and 24-week-old ACLs) 
The healthy ageing group were analysed to determine mechanical changes of the ACLs associated 
with ageing in a healthy murine group between 12 and 24-weeks-old, the same time points used 
in then CD1 spontaneous OA mice. C57BL/6J mice do not show symptoms of OA at 12-24 weeks 
of age [154, 173], hence differences within these two groups, if any, are likely to be due to ageing 




Stress-strain curves of the loading cycle at strain rates of 0.1%/s, 1%/s and 10%/s showed the 
expected exponential nonlinear viscoelastic behaviour of the ACL (Figure 3.11) [61]. When 
comparing the healthy ageing 12-week-old and 24-week-old ACLs, there were no statistically 
significant differences in the stress-strain at 0.1%/s (p=0.65), 1%/s (p=0.69) and 10%/s (p=0.69) 
strain rates. General trend at all strain rates showed a slight increase in average stress in the 24-
week-old ACLs, however this was not statistically significant. It is worth noting the large 
deviation seen in both samples, which reached up to 134% RSD in the 24-week-old ACLs and 
118% RSD in the 12-week-old ACLs at 0.1%/s strain rate. Despite this deviation, these findings 
confirm no differences in the ACL stress-strain behaviour between the two age time points of the 
healthy ageing group. 
 
 
Figure 3.11 Average stress-strain curves of the murine healthy ageing group, 12 and 24-week-old ACLs, at different 
strain rates. Strain rates tested included 0.1%/s (A), 1%/s (B) and 10%/s (C). There were no statistically significant 
differences between the 12-week-old and 24-week-old ACLs at 0.1%/s (p=0.65), 1%/s (p=0.69) and 10%/s (p=0.69) 
strain rates. This suggests there were no changes in the stress-strain behaviour in the viscoelastic region for these two 




3.3.4.1.1 Tangent modulus 
Tangent modulus-stress curves measured stiffness in the murine ACLs at different points of stress. 
Figure 3.12 showed a linear increase in tangent modulus as stress increased in the healthy ageing 
group ACLs. There were no statistically significant differences between the tangent modulus of 
the 12-week-old and 24-week-old ACLs of the healthy ageing group at any strain rate (0.1%/s: 
p=0.68, 1%/s: p=0.75, and 10%/s: p=0.98). At 0.1%/s strain rate, at 2 MPa of stress (the same 
stress used for the power and sample size analysis) the average tangent modulus was 68 ±17 MPa 
and 70 ±13 MPa for the 12 and 24-week-old ACLs respectively (Figure 3.12A). This is a higher 
standard deviation than previously calculated in preliminary studies (8 MPa) and used in sample 
size calculations (see Section 3.2.3.1) which could affect the test power. Overall, these findings 
suggest that there were no differences in the tangent modulus and stiffness behaviour of the 
healthy ageing ACLs. 
 
 
Figure 3.12 Average tangent modulus-stress curves of the murine healthy ageing group, 12 and 24-week-old ACLs, at 
different strain rates. Strain rates tested included 0.1%/s (A), 1%/s (B) and 10%/s (C). There were no statistically 
significant differences in the average tangent modulus of the 12-week-old and 24-week-old ACLs at any strain rate 
(0.1%/s: p=0.68, 1%/s: p=0.75, and 10%/s: p=0.98). Overall, stiffness did not change between the two healthy ageing 
ACL time points. 
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3.3.4.1.2 Stress-strain strain rate sensitivity 
The strain rate sensitivity, a viscoelastic property, was analysed for each of the 12 and 24-week-
old ACLs of the healthy ageing group. Generally, the average stress increased as the strain rate 
increased (Figure 3.13A-B). In the 12-week-old ACLs, when comparing the area under the curve 
of the stress-strain curves, the different strain rates were not significantly different (p=0.68). The 
same was also true in the same 24-week-old ACL at different strain rates (p=0.23). Post-hoc 
analysis (Dunn’s multiple comparisons test) found no significant differences between any of the 
strain rates at both age groups. These results suggest a lack of strain rate sensitivity in the stress-
strain curves for both healthy ageing ACLs. 
 
 
Figure 3.13 Average stress-strain curves at all strain rates (0.1%/s, 1%/s and 10%/s) to determine strain rate sensitivity 
in the murine healthy ageing group. Both 12-week-old (A) and 24-week-old ACLs (B) showed no statistically significant 
differences between strain rates (p=0.68 for 12-week-old and p=0.23 for 24-week-old). Statistical analysis would 
indicate no strain rate sensitivity in the stress-strain curves in both healthy ageing ACLs. 
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Strain rate sensitivity was further assessed in the tangent modulus-stress curves. Tangent 
modulus-stress curves showed an increase in tangent modulus in relation to the strain rate in both 
healthy ageing ACLs (Figure 3.14A-B). The difference in the tangent modulus between the 
different strain rates (0.1%/s, 1%/s and 10%/s) was statistically significant in both the 12-week-
old (p<0.01) and 24-week-old ACLs (p=0.01) (Figure 3.14A-B). Post-hoc multiple comparisons 
revealed statistically significant differences between the 0.1%/s and 10%/s strain rates in both the 
12-week-old (p<0.01) and 24-week-old ACLs (p<0.01). There were also statistically significant 
differences between the 1% and 10% strain rates in the 12-week-old ACLS (p=0.03) and in the 
24-week-old ACLs (p=0.04). However, no statistically significant differences were found in 
average tangent modulus between the 0.1%/s and 1%/s strain rates in both ACLs (12-week-old: 
p=0.31, 24-week-old: p=0.25). Results from the tangent modulus-stress curves suggest strain rate 
sensitivity in both healthy ageing ACLs. 
Strain rate sensitivity was further analysed in the normalised tangent modulus-stress curves 
(normalised to the 0.1%/s strain rate of each sample, see Section 3.2.7.3). In the 12-week-old 
ACLs, the difference between the 1%/s and 10%/s strain rates were statistically significant 
(p<0.01) (Figure 3.14C). The same was also true in the 24-week-old ACLs, where the difference 
in the normalised tangent modulus between the two strain rates was also statistically significant 
(p<0.01) (Figure 3.14D). Overall, this would suggest that at both ACLs of the healthy ageing 
group, the stress-strain, tangent modulus and normalised tangent modulus showed significant 
strain rate sensitivity, indicative that at these ageing time points there were no changes to 





Figure 3.14 Average tangent modulus and normalised tangent modulus-stress curves comparing different rates (0.1%s, 
1%/s and 10%/s) in the murine healthy ageing group to determine strain rate sensitivity. Average tangent modulus-
stress curves of the 12-week-old (A) and 24-week-old (B) ACLs showed an increase in tangent modulus with increasing 
strain rate, both were statistically significant (p≤0.01 for both)). Normalised tangent modulus-stress curves of the 1%/s 
and 10%/s strain rates (normalised to the 0.1%/s strain rate) in the 12-week-old (C) and 24-week-old ACLs (D) also 
showed an increase in the 10%/s strain rate, which was statistically significant in both ACLs (p<0.01 for both). This 
would indicate strain rate sensitivity in both ACLs of the healthy ageing group. 
 
3.3.4.2 Hysteresis 
Viscoelastic hysteresis, a measurement of the energy lost during the load-unload cycle, was 
assessed at different strain rates (0.1%/s, 1%/s and 10%/s). When comparing the healthy ageing 
12-week-old and 24-week-old ACLs, hysteresis was not statistically significant different at 0.1%/s 
(p=0.20), 1%/s (p=0.14) and 10%/s strain rates (p=0.26) (Figure 3.15). Additionally, at the 10%/s 
strain rate, hysteresis was negative for both healthy ageing ACLs, which would mean that the 
ligament released more energy than it stored, which is not possible. Negative hysteresis has 
previously been reported in human tendons [217, 218] often attributed to methodological 
inaccuracies. Overall, results suggested no differences in the hysteresis at different strain rates in 
the healthy ageing 12 and 24-week-old ACLs. 
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3.3.4.2.1 Hysteresis strain rate sensitivity 
Hysteresis strain rate sensitivity was analysed in each of the healthy ageing ACLs (Figure 3.15). 
In the 12-week-old ACLs, strain rates had statistically significant differences (p<0.01). Post-hoc 
multiple comparisons also found significant differences between the 0.1%/s and 10%/s strain rates 
(p<0.01) and between the 1%/s and 10%/s strain rates (p<0.01), however no statistically 
significant difference was found between the 0.1%/s and 1%/s strain rates (p>0.99). Similarly, in 
the 24-week-old ACLs, strain rates were significantly different (p<0.01), and the same post-hoc 
analysis showed differences between the 0.1%/s and 10%/s strain rates and 1%/s and 10%/s strain 
rates (p<0.01 for both), but no differences between the 0.1%/s and 1%/s strain rates (p>0.99). In 
both healthy ageing ACLs, strain rate sensitivity was similar and did not change despite the 
different age points. 
 
 
Figure 3.15 Hysteresis in the murine healthy ageing group, 12 and 24-week-old ACLs at different strain rates. Strain 
rates tested included: 0.1%/s, 1%/s and 10%/s. The average hysteresis and standard deviation increased in the 12-
week-old ACLs compared to the 24-week-old ACLs, however this difference was not statistically significant at different 
strain rates. Furthermore, strain rate sensitivity analysis determined statistically significant differences between the 
strain rates at both the 12 and 24-week-old ACLs (p<0.01). This suggests similar hysteresis behaviour in both healthy 
ageing ACLs. 
 
3.3.4.3 Stress Relaxation 
Stress-relaxation was analysed with the average normalised stress (normalised to stress at t=0). 
Stress-relaxation showed no significance difference between the healthy ageing 12-week-old and 
24-week-old ACLs (p=0.69) (Figure 3.16). Although there were no statistical differences between 
144 
 
the two age groups, the 24-week-old ACLs had slightly higher average normalised stress (Figure 
3.16). Overall, similar stress-relaxation behaviour in both of these ACLs suggests that the age 
differences did not affect this viscoelastic behaviour. 
 
 
Figure 3.16 Normalised stress-log time curves of the healthy ageing 12 and 24-week-old ACLs to determine the 
viscoelastic stress-relaxation behaviour. Average normalised stress (normalised to stress at t=0) had no statistically 
significant differences between the 12 and 24-week-old ACLs (p=0.69). This would indicate that age differences in the 
ACLs did not result in changes to the viscoelastic stress-relaxation behaviour. 
 
3.3.4.4 Ultimate load at failure  
The ultimate load at failure was analysed as a measurement of overall ligament strength at forces 
above the normal physiological range. The ultimate load was 5.49 ±0.92 N and 5.08 ±1.62 N for 
the 12 and 24-week-old ACLs respectively, and both groups were not statistically different 
(p=0.58) (Figure 3.17). Furthermore, in the 24-week-old ACLs there was higher deviation 
equivalent to 32% RSD, almost double the 17% RSD of the 12-week-old ACLs. Overall, this data 





Figure 3.17 Ultimate load (N) at failure of the healthy ageing group ACLs. Load to failure, also known as maximum 
load, was applied at 1%/s to 12 and 24-week-old ACLs until ligament failure. The average ultimate load applied was 
5.49 ±0.92 N in the 12-week-old ACLs and 5.08 ±1.62 in the 24-week-old ACLs (A-B). Statistical analysis found no 
differences between the two age groups (p=0.575) (B). This would indicate similar material properties in the murine 
ACL at these two time points. 
 
3.3.5 Viscoelastic behaviour and ultimate load at failure of the ACL in the spontaneous 
OA group (CD1 12 and 24-week-old ACLs) 
In the spontaneous OA CD1 mice, we previously showed significantly higher OA cartilage scores 
and joint space mineralisation in the 24-weeks-old compared to the 12-week-old knee joints (see 
Chapter 2). For this spontaneous OA model, the material and viscoelastic properties of the CD1 
12-week-old ACLs were compared to those of the 24-week-old ACLs, to analyse changes in the 
ligament mechanics during OA progression. 
 
3.3.5.1 Stress-strain 
The stress-strain curves showed the expected nonlinear exponential behaviour expected at the 
viscoelastic toe-region (Figure 3.18). For the 0.1%/s, 1%/s and 10%/s strain rates, there were no 
statistically significant differences between the 12 and 24-week-old ACLs (p=0.39 for 0.1%/s, 
p=0.36 for 1%/s and 10%/s) (Figure 3.18A-C). Overall, this indicates no difference in the stress-
strain curves at the two CD1 age groups, despite increased spontaneous OA in the 24-week-old 




Figure 3.18 Average stress-strain curves of the murine spontaneous OA group, 12 and 24-week-old ACLs, at different 
strain rates. Strain rates tested included 0.1%/s (A), 1%/s (B) and 10%/s (C). There was no significant difference in the 
spontaneous OA group between the 12 and 24-week-old ACLs at 0.1%/s (p=0.39), 1%/s and 10%/s (p=0.36 for both). 
This would indicate that there were no changes between the 12 and 24-week-old spontaneous OA ACLs in the stress-
strain behaviour. 
 
3.3.5.1.1 Tangent modulus  
Tangent modulus-stress curves demonstrated the expected increase in tangent modulus with 
increasing stress in the spontaneous OA ACLs (Figure 3.19). Average tangent modulus showed a 
general decrease in the 24-week-old ACLs compared to the 12-week-old ACLs, however the 
decrease in the 24-week-old ACLs was not statistically significant at 0.1%/s (p=0.38), 1%/s 
(p=0.50), and 10%/s (p=0.53) (Figure 3.19). Notably, the CD1 ACLs had high standard deviation 
at both age groups which could affect results; standard deviation reached 22 MPa and 20 MPa in 
the 12 and 24-week-old ACLs at 2 MPa of stress, which was higher than the expected standard 
deviation seen in the preliminary studies (8 MPa). Overall, this would confirm no change in 
stiffness between the 12-week-old and 24-week-old ACLs in the spontaneous OA group. This was 
similar to the tangent modulus-stress curves of the healthy ageing group which also found no 




Figure 3.19 Tangent modulus-stress curves of the murine spontaneous OA group, 12 and 24-week-old ACLs, at different 
strain rates. Strain rates tested included 0.1%/s (A), 1%/s (B) and 10%/s (C) strain rates. Overall, the 24-week-old 
ACLs showed a decrease in average tangent modulus after 1 MPa of stress, however this decrease was not significantly 
different at 0.1%/s (p=0.38), 1%/s (p=0.50), and 10%/s (p=0.53). This indicates no changes in the stiffness behaviour 
at the toe-region of the ACL in the spontaneous OA group. 
 
3.3.5.1.2 Stress-strain strain rate sensitivity  
The stress-strain curves demonstrated a general increase in stress with increasing strain rate in the 
spontaneous OA 12 and 24-week-old ACLs (Figure 3.20A-B), however this was not statistically 
significant in both 12 (p=0.43) and 24-week-old (p=0.14) ACLs. Post-hoc multiple comparisons 
confirmed no significant differences between any strain rate for both age time points. This is 
similar to the findings seen in the healthy ageing group, which also found a lack of strain rate 





Figure 3.20 Average stress-strain curves of the murine spontaneous OA ACLs comparing all strain rates (0.1%/s, 1%/s 
and 10%/s) to determine strain rate sensitivity. Stress-strain showed a general stress increase with strain rate increase 
in the 12-week-old ACLs (A) and 24-week-old ACLs (B). However this increase was not statistically significant in the 
12 (p=0.43) and 24-week-old ACLs (p=0.14). This would indicate a lack of strain rate sensitivity in both time points of 
the spontaneous OA ACLs. 
 
Strain rate sensitivity was also assessed in the tangent modulus-stress curves of the spontaneous 
OA ACLs. The tangent modulus in the 12 and 24-week-old ACLs showed an increase in the 
average tangent modulus associated to an increase in strain rate (Figure 3.21A-B). In both the 12 
and 24-week-old ACLs, strain rate differences were statistically significant (p=0.02 for 12-week-
old ACLs, and p=0.01 for 24-week-old ACLs) (Figure 3.21A-B). Post-hoc multiple comparisons 
showed significant differences only between the 0.1%/s and 10%/s strain rates in both the 12-
week-old and 24-week-old ACLs (p=0.01 for both). There was no significant difference between 
the 0.1%/s and 1%/s strain rates, as well as the 1%/s and 10%/s strain rates in both spontaneous 
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OA ACL age groups. This differs from the healthy ageing group ACLs where post-hoc analysis 
found significant differences between the 1%/s and 10%/s strain rates in both healthy ageing 
ACLs (Section 3.3.4.1.2). This would indicate a change in strain rate sensitivity at higher strain 
rates in the diseased spontaneous OA ACLs.  
 
 
Figure 3.21 Average tangent modulus and normalised tangent modulus-stress curves comparing different rates (0.1%s, 
1%/s and 10%/s) in the murine spontaneous OA group to determine strain rate sensitivity. Average tangent modulus-
stress curves of the 12 (A) and 24-week-old ACLs (B) increased with strain rate, and differences between strain rates 
were statistically significant (12-week-old: p=0.02, 24-week-old: p=0.01), implying strain rate sensitivity in both ACLs. 
Normalised strain rate at 1%/s and 10%/s showed statistically significant differences in the 12-week-old ACLs (C) 
(p=0.02) but not in the 24-week-old ACLs (D) (p=0.11), indicative of a lack of strain rate sensitivity in the older 24-
week-old ACLs of the spontaneous OA group. 
 
Strain rate sensitivity was further analysed with normalised tangent modulus, which was 
compared between the 1%/s and 10%/s strain rates. In the spontaneous OA 12-week-old ACLs, 
differences in the 1%/s and 10%/s strain rates were statistically significant (p=0.02) (Figure 
3.21C). In the spontaneous OA 24-week-old ACLs, differences in the 1%/s and 10%/s strain rates 
were not statistically significant (p=0.11) (Figure 3.21D). Normalised tangent modulus suggests 
a lack of strain rate sensitivity in the spontaneous OA 24-week-old ACLs, which was not seen in 
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the 12-week-old younger ACLs. This was different than the results of the healthy ageing group, 
which found strain sensitivity at both the 12 and 24-week-old ACLs (Figure 3.14) which could 
suggest that the lack of strain rate sensitivity in the normalised tangent modulus between the 1%/s 
and 10%/s strain rates could have occurred due to OA progression and not differences in age. 
 
3.3.5.2 Hysteresis  
Viscoelastic hysteresis was analysed at different strain rates (0.1%/s, 1%/s and 10%/s) in the 
spontaneous OA ACLs. There were no statistically significant differences between spontaneous 
OA 12 and 24-week-old ACLs at different strain rates (0.1%/s: p=0.82, 1%/s: p=0.93, 10%/s: 
p=0.80) (Figure 3.22). Furthermore, there was negative hysteresis in both CD1 age groups at the 
10%/s strain rate, similar to the healthy ageing group and likely due to inaccuracies in the testing 
method [217, 218]. The lack of significant differences could be due to the high standard deviation 
in both spontaneous OA ACLs which was 91.2% and 74.2% RSD at 0.1%/s strain rate for the 12 
and 24-week-old ACLs respectively. Overall, results suggest no changes in the viscoelastic 
hysteresis in the spontaneous OA group between the 12 and 24-week-old ACLs. This is similar to 
the healthy ageing ACLs, which also found no significant differences in the hysteresis at different 
strain rates (Figure 3.15). 
 
 
Figure 3.22 Viscoelastic hysteresis at different strain rates (0.1%/s, 1%/s and 10%/s) in the spontaneous OA 12 and 
24-week-old ACLs. The average hysteresis was similar in both the 12 and 24-week-old ACLs, and the difference between 
the two groups was not significant at the different strain rates. Furthermore, hysteresis strain rate sensitivity showed 
significant differences between strain rates in the 12 and 24-week-old ACLs. This would suggest similar viscoelastic 
hysteresis in both ACLs in the spontaneous OA group. 
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3.3.5.2.1 Hysteresis strain rate sensitivity  
Hysteresis strain rate sensitivity was analysed in the spontaneous OA ACLs (Figure 3.22). In the 
12 and 24-week-old ACLs, strain rates were significantly different (p<0.01 for both). Post-hoc 
comparisons also determined significant differences between the 0.1%/s and 10%/s strain rates 
and between the 1%/s and 10%/s strain rates (p<0.01 for both). No statistically significant 
difference was found between the 0.1%/s and 1%/s strain rates (p>0.99 for both). Hysteresis strain 
rate sensitivity was found in both ACLs of the spontaneous OA group, similar to the findings of 
the healthy ageing group (Figure 3.15). 
 
3.3.5.3 Stress-relaxation  
The average normalised stress in the CD1 24-week-old ACLs seemed to decrease over time 
compared to the CD1 12-week-old ACLs, however this difference was not statistically significant 
(p=0.60) (Figure 3.23). This confirms that there were no significant changes to the stress-
relaxation viscoelastic behaviour in the spontaneous OA group. This is similar to the stress-
relaxation in the healthy ageing group ACLs, which also demonstrated no differences between the 
two healthy age groups (Figure 3.16). 
 
 
Figure 3.23 Normalised stress-log time curves of the spontaneous OA 12 and 24-week-old ACLs to determine 
viscoelastic stress-relaxation behaviour. The spontaneous OA 24-week-old ACLs had a lower normalised stress 
compared to the 12-week-old ACLs, however this decrease was not statistically significant (p=0.60). This would 
indicate no changes in the stress-relaxation behaviour in the spontaneous OA group. 
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3.3.5.4 Ultimate load at failure 
The ultimate load at failure was similar in both the spontaneous OA group in the 12 and 24-week-
old ACLs. The ultimate load in the ACLs was 6.98 ±1.18 N and 6.92 ±1.64 N in the 12 and 24-
week-old ACLs respectively (Figure 3.24A-B). There were no statistically significant differences 
between the two groups (p=0.96). Overall, there were no differences in the ultimate load material 
property in the spontaneous OA group. This was similar to the ultimate load of the healthy ageing 
group which also had no difference in the ultimate load in both age groups (Figure 3.17). 
 
 
Figure 3.24 Ultimate load (N) at failure of the spontaneous OA CD1 12 and 24-week-old ACLs. The average ultimate 
load at failure, also known as maximum load, was similar for both ACLs: 6.98 ±1.18 N in the 12-week-old ACLs and 
6.92 ±1.64 in the 24-week-old ACLs (p=0.962). This would suggest no change to the material strength of the 
spontaneous OA ACLs. 
 
3.3.6 Viscoelastic behaviour and ultimate load at failure of the ACL in the post-
traumatic OA group. 
Non-invasive loading of the murine C57BL/6J knee joint is an established post-traumatic OA 
model [27]. In this post-traumatic OA group, ACLs from loaded knee joints (i.e. loaded ACLs) 





Stress-strain curves at strain rate 0.1%/s, 1%/s and 10%/s showed exponential viscoelastic 
behaviour in the non-loaded ACL controls and a decreased stress-strain curve in the loaded ACLs 
(Figure 3.25). Despite this average stress decrease, statistical analysis found no significant 
differences at the 0.1%/s, 1%/s and 10%/s strain rates (p=0.38 for 0.1%/s, p=0.45 for 1%/s, p=0.48 
for 10%/s) (Figure 3.25). This could be potentially due to the large standard deviation which was 
equivalent to 122% RSD in the non-loaded ACLs and 103% RSD in the loaded ACLs at 0.1%/s 
strain rate. Overall, these findings suggest there were no differences between the stress-strain 
curves of the healthy non-loaded and post-traumatic OA loaded ACLs. 
 
 
Figure 3.25 Average stress-strain curves of the healthy non-loaded and post-traumatic OA loaded ACLs at different 
strain rates.Strain rates included 0.1%/s (A), 1%/s (B) and 10%/s (C). Viscoelastic stress-strain behaviour showed a 
general decrease in the average stress of the loaded knee joint ACLs compared to the non-loaded ACLs, however this 
difference was not statistically significant at any strain rate (p=0.38 for 0.1%/s, p=0.45 for 1%/s, p=0.48 for 10%/s). 
This would indicate no changes in the viscoelastic stress-strain behaviour in the post-traumatic loaded ACLs. 
 
3.3.6.1.1 Tangent modulus 
Tangent modulus-stress curves of the loaded and non-loaded control ACLs showed a decrease in 
average tangent modulus in the loaded ACLs (Figure 3.26). Statistical analysis confirmed 
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significant reduction in the tangent modulus of the post-traumatic loaded ACLs at the 0.1%/s 
(p=0.03), 1%/s (p=0.02), and 10%/s (p=0.02) strain rates. Overall, this would suggest a significant 
reduction in the tangent modulus and stiffness of the post-traumatic OA loaded ACL compared to 
the healthy non-loaded ACL. 
 
 
Figure 3.26 Tangent modulus-stress curves of the murine healthy non-loaded and post-traumatic OA ACLs, at different 
strain rates. Strain rates tested included 0.1%/s (A), 1%/s (B) and 10%/s (C). Overall, the loaded ACLs showed a 
significantly decreased average tangent modulus at the 0.1%/s (p=0.03), 1%/s (p=0.02), and 10%/s (p=0.02) strain 
rates. This indicates a decrease in stiffness in the viscoelastic toe-region of the post-traumatic OA ACLs. 
 
3.3.6.1.2 Stress-strain strain rate sensitivity  
Strain rate sensitivity was analysed in the stress-strain curves, the tangent modulus-stress curves 
and the normalised tangent modulus-stress curves. In the non-loaded and loaded ACLs, the stress-
strain curves showed no statistical difference between the different strain rates in the non-loaded 
ACLs (p=0.74) and in the loaded ACLs (p=0.30) (Figure 3.27A-B). This would suggest a lack of 
strain rate sensitivity in both ACLs. Post-hoc analysis also confirmed no significant differences 
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between any of the strain rates. Overall, stress-strain behaviour found no strain rate sensitivity in 
both healthy and OA ACLs. 
 
 
Figure 3.27 Average stress-strain curves of the murine healthy non-loaded and post-traumatic OA ACLs comparing all 
strain rates (0.1%/s, 1%/s and 10%/s) to determine strain rate sensitivity. Overall, there was no statistical significance 
in both the non-loaded (A) (p=0.74) and loaded (B) (p=0.30) knee joint ACLs. This would suggest no strain rate 
sensitivity in both the non-loaded and the post-traumatic OA loaded ACLs. 
 
The tangent modulus-stress curve was another measure of strain rate sensitivity. In both the non-
loaded control and loaded knee joint ACLs, the average tangent modulus increased as strain rate 
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increased (Figure 3.28). In the non-loaded control ACLs, strain rate differences were statistically 
significant (p<0.01) (Figure 3.28A). Post-hoc multiple comparisons further confirmed further 
significant differences between all of the strain rates, including between 0.1%/s and 1%/s, 0.1%/s 
and 10%/s and between 1%/s and 10%/s (p<0.01 for all) suggesting high strain rate sensitivity for 
the non-loaded ACLs. In the post-traumatic loaded ACLs, differences between strain rates were 
also statistically significant (p<0.01) (Figure 3.28B). However, post-hoc multiple comparisons 
reveals only statistically significant differences between the 0.1%/s and 10%/s strain rates 
(p<0.01), but no differences between the 0.1%/s and 1%/s and the 1%/s and 10%/s strain rates 
(p=0.13 for both). Therefore, tangent modulus-stress curves revealed a partial decrease in strain 
rate sensitivity for some of the strain rates of the post-traumatic OA loaded ACLs. 
Tangent modulus was normalised for further analysis of the strain rate sensitivity. In the non-
loaded control ACLs, the normalised tangent modulus of the 1%/s and 10%/s strain rates were 
significantly different (p<0.01) (Figure 3.28C). Meanwhile in the post-traumatic loaded ACLs, 
the normalised tangent modulus differences between the 1%/s and 10%/s strain rates were not 
statistically significant (p=0.08) (Figure 3.29D). These findings suggest that the normalised 
tangent modulus shows a lack of strain rate sensitivity in the post-traumatic loaded ACLs, 





Figure 3.28 Average tangent modulus and normalised tangent modulus-stress curves comparing different rates (0.1%s, 
1%/s and 10%/s) in the murine healthy and post-traumatic OA ACLs to determine strain rate sensitivity. Strain rates 
were significantly different in the tangent modulus of both the non-loaded (A) and loaded (B) knee joint ACLs (p<0.01 
for both), suggesting strain rate sensitivity. In the normalised tangent modulus-stress curves, strain rate differences 
between the 1%/s and 10%/s strain rates were statistically significant in the non-loaded ACLs (C) (p<0.01) but were 
not in the loaded ACLs (D) (p=0.08). This would suggest a lack of strain rate sensitivity in the post-traumatic loaded 
ACLs at higher strain rates. 
 
3.3.6.2 Hysteresis  
Hysteresis was assessed at different strain rates (0.1%/s, 1%/s and 10%/s). When comparing the 
hysteresis between the non-loaded and loaded ACLs, the average hysteresis increased at all strain 
rates in the loaded ACLs (Figure 3.29). Although the average hysteresis increased in the loaded 
ACLs, the difference between the two groups was not statistically significant at 0.1%/s (p=0.09), 
1%/s (p=0.08) and 10%/s (p=0.88). Like in the previous mouse groups, negative hysteresis was 
found in the 10%/s strain rate for both the non-loaded and loaded knee joint ACLs (Figure 3.29), 
possibly due to the low measurements and inaccuracies in the methodology [217, 218]. Overall, 
this data suggests, that there were no changes in hysteresis in the post-traumatic OA loaded ACLs 
at different strain rates. 
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3.3.6.2.1 Hysteresis strain rate sensitivity 
Strain rate sensitivity was analysed in the hysteresis of non-loaded and post-traumatic loaded 
ACLs (Figure 3.29). Both the non-loaded and the loaded ACLs showed similar behaviour in strain 
rate sensitivity. Statistical analysis calculated significant differences between the strain rates in 
both the non-loaded and loaded ACLs (p<0.01). Post-hoc multiple comparison analysis also found 
significant differences between the 0.1%/s and 10%/s strain rates, as well as the 1%/s and 10%/s 
strain rates for both the non-loaded and loaded ACLs (p<0.01). This would suggest no changes in 
strain rate sensitivity behaviour of viscoelastic hysteresis in the post-traumatic OA loaded ACLs. 
 
 
Figure 3.29 Viscoelastic hysteresis at different strain rates (0.1%/s, 1%/s and 10%/s) in the healthy non-loaded and 
post-traumatic loaded OA ACLs. The average hysteresis and standard deviation increased in the loaded ACLs 
compared to the non-loaded ACLs, however this difference was not significant at the different strain rates (0.1%/s: 
p=0.09, 1%/s: p=0.08, 10%/s: p=0.88). Furthermore, strain rate sensitivity analysis determined statistically significant 
differences between the strain rates at both the non-loaded control ACLs and post-traumatic loaded ACLs (p<0.01). 
This would suggest no changes to the viscoelastic hysteresis behaviour in the post-traumatic OA loaded ACLs. 
 
3.3.6.3 Stress Relaxation  
Stress-relaxation curves showed a decrease in the normalised stress in the loaded ACLs compared 
to the non-loaded control ACLs (Figure 3.30). Statistical analysis confirmed a significant 
difference between the non-loaded and loaded stress-relax curves (p=0.04). This data indicates 
that there was a reduction in the stress-relaxation response of the post-traumatic loaded ACLs 




Figure 3.30 Normalised stress-log time curves of the healthy non-loaded and post-traumatic OA ACLs to determine 
viscoelastic stress-relaxation behaviour. Overall the loaded ACLs had a lower normalised stress compared to the non-
loaded ACLs. This decrease was statistically significant (p=0.04) and would suggest a reduction in the stress-relaxation 
behaviour of the post-traumatic loaded ACLs. 
 
3.3.6.4 Ultimate load at failure  
The ultimate load was similar in both the non-loaded controls and loaded ACLs. The ultimate load 
for the non-loaded control ACLs was 6.17 ±1.91 N and for the loaded ACLs the ultimate load was 
6.10 ±2.51 N (Figure 3.31A-B). The small differences between the two groups were not 
statistically significant (p=0.96) (Figure 3.31B). In addition, both ACLs had high standard 
deviation equivalent to 41% and 31% RSD, for the loaded and non-loaded ACLs respectively. 
Overall, this data suggests no statistically significant differences in the ultimate load and material 





Figure 3.31 Ultimate load (N) at failure of the healthy non-loaded and post-traumatic OA ACLs. The average ultimate 
load, also known as maximum load, was 6.17 ±1.91 N in the non-loaded ACLs and 6.10 ±2.51 in the loaded ACLs. 
There was little difference between the two ACLs, and statistical analysis confirmed no significant differences 
(p=0.955). This would suggest no changes in the ultimate load and material strength of the post-traumatic loaded 
ACLs. 
 
3.3.7 Summary of results 
In summary, viscoelastic strain rate sensitivity decreased during OA progression in both the 
spontaneous and post-traumatic OA group. More specifically, strain rate sensitivity was not 
significantly different between the higher strain rates (1%/s vs 10%/s) in the normalised tangent 
modulus-stress (normalised to the 0.1%/s strain rate) in the 24-week-old ACLs of the spontaneous 
OA group and in the post-traumatic loaded ACLs (Table 3.4). This lack of normalised strain rate 
sensitivity was not seen in the 24-week-old ACLs from the healthy aging group, indicating that 
this loss of strain rate sensitivity was due to OA progression. Most viscoelastic properties, such 
as stress-strain, tangent modulus, hysteresis and stress-relaxation and material properties (ultimate 
force at failure) were not significantly different between the 12 and 24-week-old in the healthy 
ageing group and in the spontaneous OA group (Table 3.4). In the post-traumatic OA group, 
comparing healthy non-loaded to post-traumatic loaded knee joint ACLs, there were significant 
difference in the viscoelastic tangent modulus and stress-relaxation, indicating further viscoelastic 





Table 3.4 Summary of ACL viscoelastic and mechanical tests and results for each murine group. Murine groups 
included the healthy ageing group, the spontaneous OA group (both with 12 versus 24-week-old ACLs), and the post-
traumatic OA group (non-loaded vs loaded ACL). Viscoelastic and mechanical properties measured included stress-
strain, tangent modulus, hysteresis, stress-relaxation, ultimate load at failure and strain rate sensitivity. 



















Significance? (p value) 
Stress-strain No No No 
Tangent modulus No No Yes (p=0.02 for 1%/s) 
Stress-strain strain rate 
sensitivity 














strain rate sensitivity 





























Hysteresis No No No 
Hysteresis strain rate 
sensitivity 













Stress-relaxation No (p=0.69) No (p=0.60) Yes (p=0.04) 






We hypothesized a change in the viscoelastic behaviour of the post-traumatic and spontaneous 
OA ACLs. This hypothesis was partially proven correct, as statistically significant differences 
were found in the normalised tangent modulus-stress strain rate sensitivity of the spontaneous OA 
ACLs, and in the normalised tangent modulus-stress strain rate sensitivity, tangent modulus and 
stress-relaxation of the post-traumatic OA ACLs. There were no changes in the viscoelastic 
behaviour between the aged ACLs of the healthy ageing group, confirming that the viscoelastic 
changes seen in the spontaneous OA model are involved in OA progression and not differences 
in ageing. 
 
3.4.1 Age-related ACL mechanics 
In the healthy ageing group, there were no statistically significant differences in the viscoelastic 
behaviour and ultimate load in the ACLs between the 12 and 24-week-old mice, implying that at 
these age time points, there were no changes to the viscoelastic or material properties of murine 
ACLs. 
Reports of viscoelastic behaviour of ligament or tendons change with age vary, and likely depend 
on the specific ligament and age differences [205, 219, 220]. Connizzo et al. found minimal 
differences in the viscoelastic properties with age in murine supraspinatus tendons, including no 
changes in the midsubstance moduli of 90, 300 and 570 day-old tendons [205]. Other studies have 
shown that age can affect ligament and tendon mechanical behaviour. In pig tendons, mature 
tendons had an increase in tensile strength and stiffness compared to newborn pigs [221]. In rat 
tail tendons, ultimate load and elastic stiffness were highest in the 12-month-old rats compared to 
the 1, 2 and 4-month-old rats and viscoelastic hysteresis decreased with age [220]. In rabbit medial 
collateral ligaments, increased stress-relaxation was evident in the 3-month-old rabbit ligaments 
and no differences were noted in the 6, 9 and 12-month-old rabbits [219]. 
Clinical research studies in humans have also reported age-related changes in ligament mechanical 
behaviour and properties [15, 222]. A general decrease in ligament strength has been reported by 
Woo et al., including a decrease in linear stiffness and ultimate load in the ACL of middle and 
older age adults compared to younger adults [15]. Meanwhile, in the Achilles’ tendon, mechanical 
strength and elastic stiffness were shown to increase during childhood [222]. Both of these human 
studies showed an increase in linear-elastic stiffness in ligament and tendon but did not measure 
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viscoelastic stiffness or behaviour. Together, all these findings suggest that age-related 
mechanical changes could be species-dependant and ligament-specific, as well as being based on 
tissue maturation and age difference.  
Our results indicate that in the healthy C57BL/6J mice ACLs there were no significant changes 
between the 12 and 24-week-old ACLs. In these mice, skeletal maturity is reached at about 4 
months (16-weeks) [223], therefore at 12-weeks-old, the ACLs are nearing skeletal maturity and 
at 24-week-old are fully matured. This potential difference in skeletal maturity did not result in 
statistically significant differences in the viscoelastic and material behaviours of the murine ACL. 
 
3.4.2 OA-related ACL mechanics 
Viscoelastic behaviour of the OA murine ACLs showed changes in the strain rate sensitivity and 
stress-relaxation properties. Specifically, there was a decrease in strain sensitivity in the 
normalised tangent modulus-stress between strain rate 1%/s and 10%/s in both the post-traumatic 
OA ACL (Figure 3.28) and spontaneous OA ACL (Figure 3.21) which was not evident in any of 
the healthy ageing group ACLs (Figure 3.14). These findings indicate similar losses in normalised 
tangent modulus-stress strain rate sensitivity at higher strain rates in both the post-traumatic and 
spontaneous OA model. Hence disease pathology in both OA models is resulting in the loss of 
viscoelastic strain rate sensitivity. Loss of strain rate sensitivity suggests a change in the ECM 
components, which, as described in Chapter 2, include COL2 and proteoglycan deposition.  
Changes in ligament viscoelasticity and ECM raises new questions on the ligament biomechanical 
response and its importance in OA disease progression. It is well documented that cells respond 
to force to the ECM and mechanical stimuli and the corresponding mechano-regulation mainly 
comprises of matrix deposition, rearrangement and removal [224]. Tendon cells in particular have 
been shown to sense and respond to mechanical stimuli, including cyclic strain which upregulates 
collagen synthesis [225] and MMP1 expression [226]. Therefore, it follows, if ligament strain rate 
sensitivity decreases and ECM changes during OA, mechanical stimuli and cellular response 
could also be affected. How cells respond to matrix viscosity is a new and emerging field of 
mechanobiology [227]. Understanding the mechanotransduction pathways of ligament fibroblasts 
is critical to comprehend the passive or active role of the ligament in OA progression. 
Additional changes in the viscoelastic behaviour were seen in the post-traumatic OA loaded ACLs 
when compared to the healthy non-loaded ACLs. These changes included a significant decrease 
in the tangent modulus (Figure 3.26) at all strain rates of the loaded ACL, implying a decrease in 
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viscoelastic stiffness in the post-traumatic ACL. Changes in ligament elastic stiffness have been 
previously associated with changes to collagen [69], which were previously seen in Chapter 2, 
including COL2 deposition (Figure 2.22) and thicker collagen birefringence (Figure 2.20). 
Biologically, it is well documented that cells can sense and respond to ECM stiffness [228], but 
how ligament cells respond to ECM stiffness in OA is unknown. As previously mentioned, tendon 
cells can adapt to mechanical stimuli to adjust the ECM stiffness [225, 226], therefore it is likely 
that ligament cells are driving this ECM stiffness change seen post-trauma. 
Furthermore, stress-relaxation curves (Figure 3.30) were significantly decreased in the post-
traumatic loaded ACLs compared to the non-loaded ACLs, which would indicate an increase in 
relaxation. and changes in viscoelastic stress-relaxation has been previously associated with GAG 
[229] and proteoglycan depletion [69]. Changes in stress-relaxation of the ECM can regulate 
scaffold remodelling and bone formation, as has been shown in rats with implanted hydrogels 
with different stress-relaxation properties [230]. Therefore, similar ECM changes in the ligaments 
could be driving the chondrogenesis and potential ossification seen in OA ligaments. Further 
research is necessary, to understand which specific ECM components are causing a loss in ECM 
stress-relaxation as well as the underlying cellular pathways. 
There are very few studies on the ligament mechanics of human knee OA patients. Changes in the 
ACL viscoelastic behaviour in human OA and rheumatoid knees, has only been reported once 
previously where Hagena et al. found an increase in relaxation during stress-relaxation [138]. 
These results in human OA ACLs are similar to our findings of stress-relaxation in the post-
traumatic OA murine model (Figure 3.30). This confirms similar viscoelastic mechanical 
pathology between murine and human OA. However, Hagena et al. also found a decrease in 
ultimate load at failure in the ACL of knee OA and rheumatoid patients [138], which was not seen 
in the murine post-traumatic (Figure 3.31) and spontaneous OA models (Figure 3.24). These 
differences could arise from different methodologies, or different time points of analysis. 
Changes in strain rate sensitivity in ACLs from OA knee joints have not been previously reported. 
A reduction in strain rate sensitivity has been previously reported in proteoglycan depleted canine 
ACLs [61], and decorin and biglycan depleted tendons [69, 73]. It is possible that changes to the 
ACL proteoglycan composition during OA could affect viscoelastic behaviour. Decorin and 
biglycan depleted mice had altered mechanical properties, including decreased strain rate 
sensitivity and increased relaxation during stress-relaxation in the mouse tail tendons [69, 73] and 
in the flexor digitorum longus tendon [80]. Hama Rashid et al. found a decrease in stress-
relaxation in GAG depleted canine cruciate ligaments [61]. The role of proteoglycans and GAG 
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on viscoelastic behaviour is still debated. We previously reported an increase in ASPN expression, 
a SLRP, in both murine OA models (see Chapter 2), however ASPN lacks GAG chains [193] 
usually associated with increased viscosity [231]. Further research is needed to fully map 
proteoglycan composition in the ACL during OA. 
It is also possible that multiple ECM components are driving this viscoelastic change, including 
COL2 deposition. Collagen is generally a determinant factor in the elastic properties of ligaments 
[69]. Furthermore, COL2 molecules are generally flexible and have a lower elastic modulus 
(stiffness) than collagen type I molecules [232]. COL2 deposition could in theory explain a 
decrease in stiffness found in the post-traumatic OA ACL. Furthermore, collagen remodelling has 
been previously shown in spontaneous OA murine models [114], and it is a known process in OA. 
Pathways driving proteoglycan and collagen deposition could be related, therefore understanding 
these biological processes is key. 
There have been a few studies on the ACL of spontaneous OA models, such as  Dunkin Hartley 
guinea pig [116] and STR/ort mice [114]. Quasnichka et al. studied the Dunkin Hartley 
spontaneous OA guinea pig model and analysed critical deformation, a measurement of the size 
of the toe-region which significantly increased in the spontaneous OA model [116]. Change in the 
toe-region critical deformation, would likely be reflected in the tangent modulus of the 
viscoelastic behaviour, however in our murine spontaneous OA model, we did not find any 
changes in the tangent modulus. Quasnichka et al. compared the Dunkin Hartley guinea pigs to 
healthy Bristol Strain 2 guinea pigs, at multiple time points from 3 to 36-week-old ACLs [116]. 
In contrast, our study on the murine spontaneous OA group focused on OA progression, 
comparing mechanical changes to a younger ACL from the same spontaneous OA strain. In the 
Dunkin Hartley guinea pig model, ACL critical deformation preceded cartilage degeneration and 
was associated with higher collagen turnover at young ages compared to the healthy Bristol strain 
2 [116]. The ACLs from STR/ort mice, a spontaneous OA model, had a decreased ultimate load 
as well as increases in MMP2, a collagenase involved in collagen turnover [114]. Similar to the 
study by Quasnichka et al [116], STR/ort mice were compared to the healthier CBA mouse strain 
[114]. Changes in the ultimate load material property of the STR/ort spontaneous OA mice were 
not found in the CD1 spontaneous OA model (Figure 3.24). This could be in part because our 
study did not compare the ultimate load of the spontaneous OA model to a healthy model. 
Further research is needed to determine age-related pathology in the CD1 murine spontaneous 
OA model. It is possible that ECM changes had already occurred in the 12-week-old CD1 ACLs 
and could explain the lack of differences in the other viscoelastic properties (hysteresis, stress-
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relaxation and tangent modulus) when comparing the CD1 12 and 24-week-old ACLs. In Chapter 
2, CD1 12-week-old ACLs showed COL2 immunostaining within the ligament mid-region, which 
was not found in the healthy ACL groups (non-loaded controls, CBA controls). It is possible that 
direct comparison with the healthy ageing group would lead to a better understanding of ligament 
mechanical properties in the early stages of spontaneous OA. 
Overall, this research is a step closer to characterising ligament viscoelastic behaviour in healthy 
and OA ligaments. This will allow for a more applicable understanding of ligament ECM 
pathology and its correlation with mechanical function. In the future mechanical properties will 
be important for OA diagnosis and for more effective tissue engineered ligament models. 
 
3.4.3 Limitations 
There are several limitations in our study design and measurements. It is important to note that 
most studies previously mentioned use slightly different testing protocols including different 
preconditioning cycles, strain rates, knee flexion angle and methods for measurement of the 
ligament length and CSA. An additional limitation in our methods, was the assumption of similar 
ACL length and CSA within groups, which could affect the accuracy of the calculations for the 
stress-strain curve. Most other studies on murine ACL mechanics measured the CSA and length 
for each individual sample [114, 141, 204], which was not feasible in our setup. These 
inaccuracies could account for the negative hysteresis we found in the faster 10%/s strain rate of 
all our murine models, but despite inaccuracies these measurements were reproducible.  
Negative hysteresis is another phenomena which has been previously reported in human tendons 
and ligaments [45, 46] as well as in canine tendons [233] but has never been entirely explained. 
As mentioned previously, most literature dismisses negative hysteresis because it implies a net 
positive energy return which should not exist and attributes it to testing inaccuracies such as 
overshoot and equipment limitations [45, 46]. Testing innacuracies are possible in the murine 
ACL due to low hysteresis measurements (~0.01 MPa) and the small ACL length (1.1-1.2 mm, 
see Figure 3.10). However, the strain rates tested in this study are well within the boundaries of 
strain rates previously tested on mice tendons [69]. Furthermore, our results showed consistent 
negative hysteresis only in the faster 10%/s strain rates (in both repeats) and at areas of high stress, 
similar to what was reported previously in the human Achilles tendon [217]. While it is possible 
that all previous studies had similar testing inaccuracies, this does not rule out the possibility that 
measurements of negative hysteresis could be amplified by underlying ligament physiology. Past 
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studies in human skin have attributed negative hysteresis to varying viscoelastic properties [234], 
the same could also apply to the ACL and differences in its ligament bundles or fascicles. 
Understanding the causes for negative hysteresis at high strain rate could give further insight into 
soft tissue mechanics and merits further investigation. 
Another limitation in mechanical testing includes the variability in testing protocols. 
Preconditioning procedures are not standardised for ligament mechanical testing. Sun et al. used 
0.1%/s to 0.04N [141], and other previous studies by Warden et al. used 1 Hz (100%/s) to 1% 
strain for preconditioning [148]. In this study, the 10 preconditioning load-unload cycles were 
applied at a strain rate of 1%/s to a maximum load of 0.4N (Figure 3.7). The 0.4 N maximum load 
was chosen during preliminary testing which showed that this load was within the elastic limits 
and showed the full ‘toe region’ of the viscoelastic behaviour of the murine ACL. 
Another potential limitation is the variability in OA progression in the spontaneous OA model. 
As previously shown (see Chapter 2), maximum OA cartilage lesion scores of the spontaneous 
OA 24-week-old knee joint ranged from a score 6 to 1 (Figure 2.28). This is equivalent to minor 
fibrillations in the cartilage (OA score 1), to complete loss of AC and subchondral bone exposure 
(OA score 6, maximum score). OA score varied greatly, as expected for a spontaneous OA model, 
and could result in large variations of the ACL mechanical properties. Analysis of OA progression 
for each sample (before or after mechanical testing) might allow for better correlation of OA and 
mechanical changes. We attempted to score cartilage after mechanical testing using Indian ink 
[175], however our results for cartilage scoring were inconclusive. The post-traumatic OA model 
offers less variability in OA score. The maximum OARSI cartilage lesion score has been reported 
to be 4 at 3-weeks post-trauma [153] and 3 at 6-weeks post-trauma [164]. It is possible that 
differences between the spontaneous and post-traumatic OA models could be due to differences 
in OA variability and progression. These factors could influence the analysis of viscoelastic 




3.5 Conclusions and future work 
Mechanical testing of the ACLs revealed that ACL function changed in OA knee joints. 
Viscoelastic strain rate sensitivity decreased in both the post-traumatic and spontaneous OA 
murine models, indicating that a change in viscoelastic ligament function occurs in both OA types. 
Changes in the strain rate sensitivity of the ACL in both OA models is, to our knowledge, a novel 
finding. There were additional viscoelastic changes in the post-traumatic OA model including a 
decrease in viscoelastic stiffness and an increase in relaxation during stress-relaxation which could 
lead to further OA progression. These findings support the theory that the ACL has an important 
role in OA progression, and that the OA is a whole joint disease affecting all surrounding tissues 
of the knee joint [6]. 
Further research is needed to determine the overall implications of how changes in the ACL 
viscoelastic properties affect knee stability and mechanics, as well as the mechanical pathological 
changes which are leading to changes in viscoelastic behaviour. Particularly, research on the 
proteoglycan compositional changes and involved pathways is necessary as it has been previously 
linked to changes to strain rate sensitivity in tendons [69, 73] and canine ACLs [61]. To do this, 
we need a better understanding of the ligament biological components, including cell populations 
and mechanical sensors which control pathological changes in the ligament structure and function. 
Additionally, changes in the viscoelastic behaviour of the ACL occurred in the spontaneous OA 
model. Therefore, changes in the ligament pathology can occur spontaneously, without the need 
for traumatic intervention. Further characterisation of the CD1 spontaneous OA model is needed, 
to determine if ACL mechanical changes precede cartilage degeneration or vice-versa. There is 
also a need to determine similarities and differences in the pathology between post-traumatic and 
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The knee joint is composed of highly-interconnected specialised connective tissues of which the 
exact cellular makeup is only recently starting to be discovered [235-237]. In OA, disease 
pathogenesis affects all knee joint tissues including cartilage, ligaments and synovium and has 
thus been termed a ‘disease of the joint as an organ’ [6]. In Chapter 2, we observed changes in 
murine OA ligament, including ligament cell morphology and marker expression. However, 
ligament cell populations and markers in the healthy ligament and knee joint are not well 
characterised. Fibroblasts have emerged as particularly important, namely unravelling fibroblast 
heterogeneity to discover complex biological functions [238, 239]. To further elucidate the role 
of ligament cells during OA progression, it is necessary to identify the fibroblasts present in 
healthy ligaments. 
Ligament fibroblasts and potentially other cell types play an important role in ligament 
development and homeostasis [2, 240]. Ligaments are composed of a dense ECM with complex 
hierarchical fibre organisation where dispersed ligament fibroblasts, named ligamentocytes, are 
the predominant ligament cell-type [2]. Ligamentocytes play an active role in ligament 
physiology, responsible for matrix synthesis during development and regeneration [240] and cell-
cell communication [241]. Besides ligamentocytes, other ligament cell types are present in the 
more vascular overlying epiligament layer, which contains mast cells, adipocytes and 
neurovascular cells [33]. Additionally, there is evidence of a ligament stem cell population, 
including vascular stem cells [242] and other ligament specific stem cell populations [46]. 
Ligaments host a complex cellular makeup and yet current knowledge of ligament cell markers is 
limited. Tendon-ligament markers, generally grouped together due to similarities in the tissues, 
include development and adult tissue markers such as SCX, TNMD and MKX [53, 243]. 
Ligament-fibroblasts remains poorly defined, particularly in their subpopulation heterogeneity, 
transcriptional markers and pathways. 
The synovial membrane is another specialised connective tissue that lines the inside of the knee 
joint capsule which surrounds the cruciate ligaments and neighbours the collateral ligaments [5]. 
The synovium is comprised primarily of synovial fibroblasts, also known as fibroblast-like 
synoviocytes, which are interspersed with synovial macrophages [244]. The synovial fibroblasts 
are responsible for the production of synovial fluid, an important lubricant for knee joint 
movement [244] and provide structural support and supply of nutrients to the joint [5]. The second 
most prominent cell type found in the synovial lining are the synovial macrophages, which have 
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an important role for innate immune responses [244] and have a unique relationship with synovial 
fibroblasts. Synovial fibroblasts have been shown to carry innate immune receptors and are well 
equipped to sense pathogens and tissue damage [245] and are also involved in disease regulation 
[109]. Other cell populations in the synovium can be found in an outer sub-lining interstitial layer 
rich in nerve cells [244] as well as immune cells that include lymphocytes and dendritic cells 
[244]. Several synovial-specific fibroblast markers have been identified, mostly through bulk 
genetic analysis, such as podoplanin, Thy1 (Cd90), cadherin-11 (Cdh11) and Cd34 [246]. Similar 
to the ligaments, healthy synovial fibroblasts remain largely unresolved. Synovium and ligaments 
are both are rich in fibroblasts but likely to be playing different roles in knee joint homeostasis [2, 
245]. Identification of heterogeneous fibroblast subpopulations and markers in ligaments and 
synovium is needed to elucidate underlying joint organ pathology and potential biomarkers and 
future therapeutic targets. 
Recent technological advances have allowed mapping of transcriptomic markers with high-
resolution using single-cell RNA-sequencing (scRNA-seq). scRNA-seq is a relatively novel 
methodology in the transcriptomics field which can uncover a comprehensive high-resolution 
transcriptional snapshot of a tissue sample [247]. The high-resolution individual cell approach 
allows for the discovery of complex and rare cell populations, when compared to traditional bulk 
RNA sequencing [248] and allows for a true mapping of cell types and subpopulations. This 
technique has recently revealed fibroblast heterogeneity in mouse tendons [236] and human 
synovium [237, 249-251]. 
Transcriptomic single-cell analysis of mouse tendons and human synovial samples has identified 
important subpopulations and markers. In pooled human tendons, four cell types were identified 
including tendon fibroblasts that had a further five subpopulations [235]. In murine Achilles 
tendons, 11 unique cell types were identified with two tendon fibroblast subpopulations [236]. 
Additionally, in diseased and healthy human knee joint synovial tissues, 18 unique cell 
populations were found including four fibroblast subpopulations [237]. This population varied 
slightly from another study on human synovial-derived cells which found 13 unique cell 
populations and three synovial fibroblast subpopulations [249]. Both of these studies reveal the 
heterogeneity of tendon and synovial fibroblasts. Heterogeneity is an important aspect for 
biological function and for the development of new therapies for disease [238, 239]. For this 
reason, creating a single-cell transcriptional atlas is a necessary step forward for the understanding 
of functionally important connective tissue such as ligament and synovium. scRNA-seq has not, 
until now, been used to profile cell populations of murine ligament and synovial tissue. 
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4.1.1 Aims of the study 
The overarching aim of this chapter was to generate a ligament and synovium-derived cellular 
atlas using healthy C57BL/6J adult male mice, with a focus on fibroblast heterogeneity. To 
achieve this aim, scRNA-seq was used due to its power in resolution and ability to detect rare cell 
populations [247, 252].  
Several more specific goals were set for successful scRNA-seq. Firstly the ideal method of cell 
isolation from the fibrous ligament and synovial membrane and joint capsule tissue, was 
determined. This is an important step to ensure extraction encompasses all cells with high quality 
RNA reads [247]. Secondly, a downstream analysis workflow was created to classify major cell 
populations in both ligament and synovial fibroblast subpopulations, which was done following 
already established Seurat workflows [253]. Thirdly, each fibroblast subpopulation was further 
classified based on highly expressed transcriptional markers and predicted canonical pathways 
and upstream regulators [254]. Finally, we aimed to validate our findings by confirming a rare but 




4.2 Materials and Methods 
4.2.1 Animal and ligament and synovial tissue collection for scRNA-seq 
All procedures complied with Animals (Scientific Procedures) Act 1986 and local ethics 
committee. Male 3-month-old C57BL/6J mice were obtained from Charles River (UK) and were 
housed in the specific pathogen free biological services unit at the University of Liverpool, kept 
in polypropylene cages, subjected to 12 hour light/dark cycles, at 21±2˚C and fed standard diet ad 
libitum. Mice were euthanized one day after arrival by exposure to carbon dioxide. 
Mice cadavers were immediately prepared for tissue collection by removing the skin and exposing 
the hindlimbs. Using a dissecting microscope, excess muscle from the pelvic limbs was dissected 
until the fibrous layer of the joint capsule and collateral ligaments were visible (Figure 4.A). 
Firstly, the murine synovial sample was collected which consisted of the whole outer joint capsule 
(made up of the fibrous and synovial layers). The joint capsule was carefully dissected using 
surgical micro-scissors (Agar Scientific) from where the synovial membrane meets the collateral 
ligament to as close as possible to the patella which was repeated for both the medial and lateral 
side of the joint capsule (Figure 4.B). The sample was stored temporarily in an eppendorf with 
Dulbecco's Modified Eagle Medium (DMEM, Thermo) media. Murine synovial samples from 
both legs and multiple mice (n=3) were pooled together into one sample (total n=6 knees). 
Murine ligament samples were then collected. First the lateral and medial collateral ligaments 
were dissected using surgical micro-scissors (Figure 4.C) and placed in a separate eppendorf with 
DMEM media. The knee was further dissected, menisci and all excess tissue were removed 
cleaned until only the cruciate ligaments remained (Figure 4.D). Cruciate ligaments were cut using 
micro-scissors, first from the tibial enthesis and then the femoral enthesis and collected. Murine 
cruciate ligament samples were transferred to the eppendorf with the collateral ligaments and 
DMEM media. Murine collateral and cruciate ligaments from both pelvic limbs and multiple mice 





Figure 4.1 Micro-dissection of murine knee joint synovial membrane and ligaments. (A) Murine pelvic limbs were 
isolated. (B) Excess muscle was removed until fibrous joint capsule (red region) was visible. Joint capsule including 
the fibrous synovial layer were dissected. (C) The medial and lateral collateral ligaments (blue arrow) were dissected 
and collected. (D) Then the anterior and posterior cruciate ligaments (yellow arrow) were dissected and collected. All 
collateral and cruciate ligaments were pooled together (n=6 knees total). 
 
4.2.2 High-quality cell isolation from ligament and synovial tissue 
Cell isolation protocol was based on recently published work on tendon scRNA-seq [251]. This 
protocol was optimised for protease concentration, digestion incubation time, filter size, and spin 
speed; the optimal protocol was chosen based on cell viability, cell yield, amount of debris and 
single-cell clustering (see Section 4.3.1 for an evaluation of cell isolation protocols). Both 
ligament and synovial tissue samples were digested to obtain a viable single cell suspension. Two 
cell isolation protocols are shown in this chapter, first the preliminary cell isolation protocol that 
yielded low cell numbers and high debris. The preliminary cell isolation protocol consisted of 
mincing the ligament and synovium samples and transferring to a 1mL cell digestion buffer with 
3 mg/mL collagenase type I, 8 mg/mL collagenase type II, 2 mg/mL dispase II, and 2 mg/mL 
trypsin. Tissue digestion lasted for 1 hour at 37ºC in a vigorous shaking water bath. 0.5mL of 
DMEM media with 10% fetal bovine serum (FBS) was added to the sample and then passed 
through a 70 µm cell strainer (Sigma) was used. Cells were spun down at 700 G for 5 minutes. 
Supernatant was removed and cells resuspended with 50 µL of DMEM media with 10% FBS. 
For the final optimised protocol, pooled samples were finely minced using a scalpel and 
transferred to an eppendorf with 1mL protease solution of collagenase type I (6 mg/mL), 
collagenase type II (16 mg/mL), and dispase II (4 mg/mL) in DMEM. Both samples were digested 
for 30 minutes at 37ºC using a vigorous shaking water bath. Trypsin was then added (0.2 mg/mL 
final concentration, Sigma) for a further 10 minutes incubation. After digestion, 0.5 mL of DMEM 
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media with 10% FBS was added, samples were passed through a 40 µm cell strainer (Sigma). 
Cells from each sample were then transferred to separate eppendorf tubes and spun at 500 G for 
5 minutes. The supernatant was removed and cells were re-suspended with 50 µL of DMEM 
media with 10% FBS (volume was adjusted based on expected cell retention for each tissue 
sample). 
The amount of debris, cell viability, clustering and concentration was assessed using the Luna-FL 
Dual Fluorescence Cell Counter (Logos). 18 µL of the resuspended sample was taken and mixed 
with 2 µL of acridine orange/ propidium iodide stain (Logos). 10 µL of this mixture was then 
added to a Luna Cell Counting Slide (Logos) and loaded for automated counting. Cell counting 
and viability was critical for successful sequencing and to measure the final cell concentration. 
Samples were then ready for single cell library preparation. 
 
4.2.4 Single-cell library creation and RNA sequencing of ligament and synovial 
samples 
scRNA-seq combines single-cell encapsulation with current RNA-sequencing and gene 
expression profiling [247]. Though there are several approaches, the 10x Genomics method used 
here partitions cells with unique 10x barcoded gel beads using a microfluidic platform. Each 
barcoded cell is consequently encapsulated with oil emulsion mixing primers containing an 
Illumina R1 sequence, a unique molecular identifier, and a dT primer sequence with cell lysate 
and Master Mix. This incubation produces full-length barcoded cDNA which are then sequenced 
to generate libraries. Due to the 10x barcoding, individual reads can then be associated to each 
individual partition. When applied successfully, this method can analyse RNAs from large 
populations of cells and expose critical transcriptional differences of individual cells within these 
populations. 
Libraries were prepared through a collaboration with the University of Liverpool Centre for 
Genomics Research by Dr. Margaret Hughes. Chromium Single Cell 3' Reagent Kit Protocol 
(version 2, 10x Genomics) was used following the steps of the manufacturer. 10,000 cells were 
targeted for recovery in the protocol, mixed with reagents and processed using a Chromium 
Controller (10x Genomics). Following library preparation and quantification, libraries were 
sequenced by an Illumina NovaSeq using an S4 chemistry flow cell (paired-end, 2x150bp 




4.2.5 Single-cell RNA-seq analysis of ligament and synovial cell samples 
Gene expression matrices were generated by Dr. Luca Lenzi from the Center for Genomic 
Research at the University of Liverpool. Matrices were generated using the Cell Ranger pipeline 
(version 3.0.2, 10x Genomics) and were aligned with mm10 transcriptome (C57BL/6J reference 
genome). Cell Ranger and Loupe Cell Browser (version 3.1.0, 10x Genomics) was used for the 
initial pre-processing, to determine quality of reads and total counts of unique molecular 
identifiers (UMI) plotted in t-distributed stochastic neighbour embedding (t-SNE). Downstream 
analysis was done with RStudio version 1.2.5019 (2019) and the Seurat 3.1.1 R package, which 
was designed for quality control and analysis of scRNA-seq data, particularly for identification of 
heterogeneity [253]. An example of the RScript used is provided in the appendix (Sup Fig 3). 
For ligament-derived single-cell analysis, cells with <200 unique feature counts and >40% 
mitochondrial counts were filtered out. This is similar to past studies [250, 251], though it also 
includes a high number of mitochondrial counts. Filtering is necessary to remove artefacts from 
cell isolation method and ensure high quality reads [253]. Data from the remaining 2,165 ligament 
cells was then normalised (‘LogNormalize’ function, 10,000 scale factor) and scaled (linear 
transformation, ‘ScaleData’ function). Dimensionality reduction was then applied using principal 
component analysis (PCA), a statistical methodology that can summarise larger datasets into 
smaller summary indices called principal components. PCA is the most popular dimension 
reduction method used for Seurat [253]. Elbow and Jackstraw plots were used to determine 
‘dimensionality’ of the dataset and find significant principal components. From this, the first 20 
principal components were used for population clustering (‘FindNeighbors’ function, dims 1 to 
20) (‘FindClusters’ function, 0.5 resolution) and then clusters were visualised using non-linear 
dimensional reduction method called uniform manifold approximation and projection (UMAP).  
Synovium-derived single-cell analysis followed the same method as that used for the ligaments 
with modifications to optimise for the synovium quality read. Synovium cells with <200 and 
>3000 unique features, in addition to >10% mitochondrial counts, were filtered out. After 
filtering, reads from the remaining 3,229 cells were normalised, scaled, and dimensionality 
reduction applied (PCA) using the same parameters used on ligament cells. Elbow and Jackstraw 
plots determined significance of the first 20 principal components (dims 1 to 20). Population 
clustering was then completed using the same parameters used on ligament cells (0.5 resolution) 
and visualised with UMAP. 
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Both ligament and synovium samples were examined separately but followed the same workflow 
for cluster analysis. First clusters were classified using known cell type markers. Cell type markers 
were the following: collagen type 1 alpha 2 (Col1a2) a marker for fibroblasts, platelet/endothelial 
cell adhesion molecule-1 (Pecam1) a marker for endothelial cells, haemoglobin alpha adult chain 
1 (Hba-a1) for red blood (RB) cells, protein tyrosine phosphatase receptor type C (Ptprc) for 
immune cells, myelin protein zero, (Mpz) for nerve cells, paired box Pax-7 (Pax7) for satellite 
cells, integrin alpha-IIb (Itga2b) for platelet cells, and myotilin (Myot) for muscle cells. A 
summary of markers and related references can be seen in Table 4.1. 
 
Table 4.1. Cell markers used for cluster cell type identification. The following markers were used: Col1a2 for 
fibroblasts, Pecam1 for endothelial cells, Hba-a1 for red blood cells, Ptprc and CD14 for immune cells, Mpz for nerve 
cells, Pax7 for satellite cells, Itga2b for platelet cells, Myot for muscle cells. 
Marker Cell Type Reference 
Collagen type 1 alpha 2 (Col1a2) Fibroblasts [236, 255] 
Platelet/endothelial cell adhesion molecule-1  
(Pecam1, also known as Cd31) 
Endothelial cells [256] 
Haemoglobin alpha adult chain 1 (Hba-a1) Red blood cells [257] 
Protein tyrosine phosphatase receptor type C (Ptprc 
also known as Cd45) 
Immune cells [258] 
Cluster of differentiation 14 (Cd14) Immune cells (monocytes) [259] 
Myelin protein zero (Mpz) Nerve cells [260] 
Paired box protein Pax-7 (Pax7) Satellite cells [261] 
Integrin alpha-IIb (Itga2b, also known as Cd41) Platelet cells [262] 
Myotilin (Myot) Muscle cells [263] 
 
Differential expression analysis was used to determine marker differences between clusters. Non-
parametric Wilcoxon rank sum test is widely used in differential expression analysis of scRNA-
seq datasets [264] and was used in all differential expression analysis unless otherwise noted. 
Firstly, differential expression analysis (‘FindMarkers’ function) of each cluster compared to all 
other clusters was used to identify major cell types. The second differential expression analysis 
(‘FindMarkers’ function) was between all fibroblast clusters and all other clusters to evaluate 
fibroblast-specific markers within the tissue. The fibroblast clusters were then selected and 
segregated for further analysis. The third differential expression analysis (‘FindMarkers’ function) 
was completed between only the fibroblast clusters, comparing one fibroblast cluster to all other 
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fibroblast clusters to determine fibroblast cluster-specific markers. The top markers from each 
analysis were quantified using feature plots, violin plots, ridge plots, dot plots and heatmaps 
(‘FeaturePlot’, ‘VlnPlot’, ‘RidgePlot’, ‘DotPlot’ and ‘DoHeatmap’ function). 
Lastly, ligament and synovial fibroblast subpopulations were integrated using the SCTransform 
Seurat workflow to allow direct comparison of both fibroblast populations. SCTransform 
workflow uses an improved normalisation workflow (‘SCTransform’, ‘PrepSCTIntegration’, 
‘FindIntegrationAnchors’, and ‘IntegrateData’ function) [253]. This is similar to past studies that 
integrated different tendon samples together [235, 236]. Then the integrated data can be visualised 
using the standard visualisation and clustering workflow (‘RunPCA’, ‘RunUMAP’ function). 
Differential expression analysis was then used to determine marker differences between the 
ligament and synovial fibroblasts (‘FindMarkers’ function). Integration and top markers were 
visualised as before (‘FeaturePlot’, ‘VlnPlot’ function). 
 
4.2.6 Enriched canonical pathway analysis and predicted upstream regulators and 
activation scores 
Pathway analysis of the top predicted canonical pathways and upstream regulators was completed 
with Ingenuity Pathway Analysis (IPA) software (Qiagen). Differential expression data consisting 
of the gene marker identity and the average log fold change was converted from R to a csv file 
(‘write.csv’ function). Differential expression data files were created for each fibroblast 
subpopulation using the top markers with an adjusted p-value ≤ 10-20, this is similar to past 
approaches for IPA analysis [254]. A core analysis was initiated; the data was imported to the IPA 
software. An initial pathway analysis was run using the following parameters: Ingenuity 
Knowledge Base (Genes), species (all), tissues and cell lines (all). Two comparison analysis were 
then completed between the core analysis of ligament fibroblasts (L.F1, L.F2, L.F3, L.F4 and 
L.F5) (Section 4.3.2.9) and synovial fibroblasts (S.F1, S.F2, S.F3 and S.F4) (Section 4.3.3.8). 
Core analysis and comparison analysis showed enriched canonical pathways, predicted upstream 
regulators, associated diseases and functions, networks and other analyses. Enriched canonical 
pathways were ranked based on the predicted activation score among all clusters. Activated 




4.2.7 Transgenic Acan-Cre-tdTomato murine reporter model of ACAN expression for 
validation of an Acan-expressing cell subpopulation 
Acan gene enhancer transgenic murine line (Acan-Cre-tdTomato) was used to spatially explore 
ACAN expression in murine ligament tissue and confirm the presence of an Acan-fibroblast 
subpopulation. This mouse line was provided by Professor George Bou-Gharios and Dr. Ke Liu. 
Animal work was completed in accordance with UK Home Office regulations and the Animals 
(Scientific Procedures) Act 1986. Mice were housed in the specific pathogen free biological 
services unit at the University of Liverpool. An inducible Acan-Cre strain was created using a 
highly conserved -10kb Acan enhancer [265] (10kb upstream of Acan transcriptional start site) 
paired with a tamoxifen inducible Cre (CreERT2). This murine strain has been previously 
characterised [266, 267]. Acan-Cre murine strain was bred with Rosa26–tdTomato strain (R26R–
tdTomato, JAX7914), creating a red fluorescent Acan-Cre-tdTomato reporter. 
Male 8-week-old Acan-Cre-tdTomato mice were used to visualise cellular location of ACAN 
expression in cartilage and in ligaments. At 8 weeks of age, recombination of Acan-CreERT2-
tdTomato was induced using tamoxifen. Tamoxifen was administered intraperitoneally at a dose 
of 1mg/10g body weight three times at intervals of 48 hours. Mice were euthanized 2 weeks after 
tamoxifen injection and knee tissue (left and right hind legs) was collected for histology. 
 
4.2.7.1 Tissue preparation and histology of Acan-Cre-tdTomato murine reporter 
Knee joint tissue samples from Acan-Cre-tdTomato mice was prepared for histology by Professor 
George Bou-Gharios and Dr. Ke Liu. Samples were fixed in 4% paraformaldehyde overnight at 
4°C and decalcified in 15% EDTA for two weeks. Tissue samples were then cryoprotected in 30% 
sucrose/PBS solution overnight at 4°C followed by 30% sucrose/PBS: optimal cutting 
temperature compound (1:1) solution overnight at 4°C. Samples were then embedded in optimal 
cutting temperature compound (TissuTek, Sakura) coronally, solidified with dry ice and stored at 
-80°C. This is a similar protocol for tissue preparation used previously [268]. 
Frozen Acan-Cre-tdTomato knee tissue samples were sectioned and analysed for the purpose of 
this study. Knee samples were cryo-sectioned (Cryostat, Leica) at -20°C cutting 7 µm thick 




4.2.7.2 Fluorescent imaging of Acan-Cre-tdTomato murine reporter 
Slides were mounted with Vectashield antifade mounting medium with DAPI (Vector 
Laboratories) to visualise nuclei. Slides were imaged with a Zeiss M1 fluorescent microscope 
using the following excitation and emission filters: tdTomato (Ex. 543 nm, Em. 581 nm), DAPI 
(Ex. 405 nm, Em. 461). Images of brightfield, tdTomato and DAPI were saved individually and 
overlaid using Zen Imaging Analysis software. Images of cruciate ligaments and collateral 





4.3.1 Evaluation of ligament and synovium cell isolation quality  
As previously mentioned, cell isolation from healthy murine ligament and synovial tissue samples 
was optimised for high cellular yield and quality (see Section 4.2.2). Isolation of live cells of 
sufficient quality for scRNA-seq has previously been done on murine tendons [236, 251] and is a 
critical step for high quality RNA reads. The preliminary protocol of cell isolation consisted of 
lower protease concentration (except higher trypsin concentration), longer incubation time, larger 
filter size and faster spin speed. This yielded low cell counts (~10,000 cells for ligament, ~12,000 
cells for synovium), low cell viability (65.5% for ligament, 63.7% for synovium) and cell 
clustering (≤80% single-cell clusters for both samples) (Figure 4.2). The synovium sample also 
showed bulky masses of debris (Figure 4.2B) and cell clustering including 1.2% of >5-cell clusters 
(Figure 4.2D). Cell quantity and quality was low in the preliminary cell isolation protocol. 
 
Figure 4.2 Analysis of cell viability and clustering for cell isolation protocol optimisation. (A) Live/Dead fluorescence 
images where green are viable and red are dead cells of ligament samples protocol showed low cell numbers (10,000 
cell yield) and low viability (65.5%). (B) The synovium sample also had low cell yield (12,000 cells), high debris, cell 
clumping, and high dead (red) fluorescence tag (63.7% viability). (C-D) Cell clustering analysis showed ≤80% single-
cell clusters for the ligament and synovium sample. Preliminary cell isolation protocol needed further optimisation. 
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The final cell isolation protocol (see Section 4.2.2) yielded reproducible cell isolation with 
sufficient cell numbers, high cell viability and low debris. Images from the automated cell 
counting (Figure 4.3A-B) confirmed high quality of cells for both samples. Pooling knee joint 
tissue samples from three healthy male mice yielded enough cells (40,000) from both ligament 
and synovium samples with a final concentration of 560 cells/µL and 720 cells/ µL respectively. 
Fluorescence cell counting also confirmed high viability of 89.2% for ligament-derived cells and 
88.4% for synovial-derived cells (Figure 4.3A-B) and low cell clustering including >90% 1-cell 
clusters (Figure 4.3C-D). Therefore high quality cell clusters were confirmed, necessary to ensure 
high-quality RNA reads. 
 
 
Figure 4.3 Analysis of cell viability and clustering for the final cell isolation protocol. (A-B) Live/Dead fluorescent 
images (where green are live cells, and red are dead cells) of cells isolated from (A) ligament sample and (B) synovium 
sample showed highly viable (green) cells, calculated as 89.2% viability for ligament cells and 88.4% viability for 
synovial cells. (C-D) Cell clustering analysis confirmed high single-cell clusters including (C) 91.7% 1-cell clusters for 




4.3.2 Analysis of ligament-derived cell populations and markers 
Ligament-derived cell populations were initially analysed for quality control initially using Loupe 
Cell Browser to determine the quality of reads and total counts of UMIs. Cells were then further 
characterised based on downstream analysis following the standard Seurat workflow for cell 
identification and gene expression analysis [253], similar to recent papers on tendon cell 
populations [236, 251]. Pre-processing analysis and downstream analysis revealed numerous cell 
populations and distinct fibroblast subpopulations. 
 
4.3.2.1 Quality control of ligament-derived library reads 
Initial quality control post-sequencing with Loupe Cell Browser confirmed 5,574 ligament-
derived cells were analysed with a mean of 109,289 reads per cell and a median of 287 genes per 
cell. This was a relatively low cell retention from the expected 10,000 cells and could be due to 
sample debris or the cell isolation protocol. Each individual cell was visualised using unguided t-
SNE and labelled with their UMI counts which represented the absolute number of observed 
transcripts from each cell. UMI counts ranged from 2000 to 8000 counts (Figure 4.4A), where 
cells with higher UMI counts likely have higher RNA content. The t-SNE plot aggregated cells 
with similar gene expression profiles (Figure 4.4A). 
Sequencing saturation and median genes per cell increased and an eventually plateaued at higher 
mean reads per cell (Figure 4.4B-C) and confirmed high sequencing saturation and therefore high 
fraction library complexity from our mean reads per cell, an important factor to ensure recovery 
of lowly expressed transcripts, particularly from rare cell populations. These initial results verified 
successful library creation and sequencing of ligament-derived cells, ready for downstream 
analysis. 
 
4.3.2.2 Identification of ligament cell types and subpopulations 
Seurat downstream analysis of ligament-derived cells filtered out low quality reads including low 
unique features and high mitochondrial genes. This filtering resulted in a remaining 2,165 
ligament cells which were categorised into 20 distinct clusters using modularity optimisation 





Figure 4.4 Quality control post-sequencing of the ligament-derived cells. (A) Unguided t-distributed stochastic 
neighbour embedding (t-SNE) projection of unique molecular identifiers (UMI) counts for each individual ligament-
derived cell showed a range from 2000-8000 counts. This confirms a high number of absolute transcripts read for all 
the ligament-derived cells. (B) High sequencing saturation was confirmed and increased with the number of mean reads 
per cell. (C) Median genes per cell also increased as mean reads per cell increased. This confirmed successful library 
creation and high mean reads per cell an indicator of library complexity. 
 
Each cluster was identified based on the presence of known cell-type markers (see Section 4.2.5 
and Table 4.1 for details on known cell markers). Cell-type markers revealed nine distinct 
ligament cell-types (Figure 4.5): five fibroblast clusters (based on Col1a2 gene expression), five 
immune cell clusters (based on Ptprc gene expression), three endothelial cell clusters (based on 
Pecam1 gene expression) and two RB cell clusters (based on Hba-a1 gene expression) (Figure 
4.5B-E). The remaining clusters comprised of one nerve cell cluster (based on Mpz gene 
expression), one satellite cell cluster (based on Pax7 gene expression), one platelet cell cluster 
(based on Itga2b gene expression), one muscle cell cluster (based on Myot gene expression) and 
one unidentified cell cluster (Figure 4.5F). Average expression and percent cell expression of each 





Figure 4.5 Identified ligament-derived cell populations. (A) Uniform manifold approximation and projection (UMAP) 
of all ligament clusters colored, numbered and labelled by cell type. Cell types included fibroblasts, endothelial cells, 
immune cells, nerve cells, red blood (RB) cells, satellite cells, platelet cells, muscle cells and an unidentified cluster. 
(B-E) The cell identification markers included Pecam1 for endothelial cells (B), Col1a2 for fibroblasts (C), Ptprc for 
immune cells (D) and Hba-a1 for RB cells (E). (F) Dot plot of all cell type markers also included the remaining 
identification markers: Mpz for nerve cells, Pax7 for satellite cells, Itga2b for platelet cells and Myot for muscle cells. 
 
The top differentially expressed markers of each ligament cell-type cluster highlighted gene 
expression differences within similar cell types including the fibroblasts. The top three markers 
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of each fibroblast cluster show some overlap between all cell clusters (Figure 4.6A). Fibroblast 
cluster 1 markers included STEAP family member 4 (Steap4), complement component 1 s-
subcomponent (C1s1) and cytoglobin (Cygb) (Figure 4.6A). Fibroblast cluster 2 markers included 
endosialin (Cd248), endothelial protein C receptor (Procr) and peptidase inhibitor 16 (Pi16) 
(Figure 4.6A). Fibroblast cluster 3 markers included thrombospondin 4 (Thbs4), cartilage 
intermediate layer protein 2 (Cilp2) and coiled-coil domain-containing protein 3 (Ccdc3) (Figure 
4.6A). Fibroblast cluster 4 markers included immunoglobulin superfamily containing leucine-rich 
repeat protein 2 (Islr2) and immunoglobulin-like domain containing receptor 2 (Ildr2) and also 
olfactomedin-like 2A (Olfml2a) (Figure 4.6A). Fibroblast cluster 5 markers included leucine-rich 
repeat-containing G-protein coupled receptor 6 (Lgr6), tumor necrosis factor receptor superfamily 
member 11B (Tnfrsf11b, also known as osteoprotegerin) and hyaluronan and proteoglycan link 
protein 1 (Hapln1) (Figure 4.6A). Fibroblasts will be analysed in more detail in Section 4.3.2.3. 
Ligament-derived immune cell clusters also had different transcriptional profiles with unique 
markers. The top differentially expressed markers of the immune clusters showed some overlap 
between the immune cell cluster 3 and 4 (Figure 4.6B). Immune cluster 1 had neutrophil-
associated markers such as matrix metallopeptidase 9 (Mmp9) [269] and matrix metallopeptidase 
8 (Mmp8) [270] and other lesser known markers such as solute carrier family 7 member 11 
(Slc7a11) (Figure 4.6B). Immune cluster 2 and 3 showed macrophage-associated markers. 
Immune cluster 2 markers included macrophage associated markers such as folate receptor beta 
(Folr2) [271], mannose receptor C-type 1 (Mrc1) [272] and carbonyl reductase 2 (Cbr2) [273] 
(Figure 4.6B). Immune cluster 3 markers included macrophage and monocyte-associated markers 
such as C-C chemokine receptor type 2 (Ccr2) [274], macrophage-expressed gene 1 (Mpeg1) 
[275] and phospholipase D family member 4 (Pld4) [276] (Figure 4.6B). Although there was 
overlap in markers between immune cluster 3 and 4, immune cluster 4 markers included 
membrane-spanning 4-domains subfamily A3 (Ms4a3) an early myeloid marker [277] and lesser 
known markers such as 1700020L24Rik, and cystatin-F (Cst7) (Figure 4.6B). Immune cluster 5, 
the least numerous, comprised of a B lymphocyte associated markers, such as immunoglobulin 
lambda constant 3 (Iglc3) [278], B-cell antigen receptor complex-associated protein (Cd79a) 




Figure 4.6 Dot plot of the top three differentially expressed markers of all ligament cell clusters for cluster 
identification. (A) The top three markers of the fibroblast clusters showed some overlap in marker expression between 
fibroblast clusters. (B) The top markers of the immune cell clusters showed high specificity except between immune 
cluster 3 and 4. (C) The top markers of the remaining endothelial, red blood (RB), unidentified, nerve, satellite, platelet, 
and muscle cell clusters showed high specificity except for the endothelial and RB clusters. High specificity could 
indicate distinct cell subpopulations. 
 
The three endothelial cell clusters were identified based on high expression of Pecam1 (Figure 
4.5). Endothelial cell cluster 1 included vascular-endothelial markers such as vascular-endothelial 
cadherin (Cdh5, encoding VE-Cadherin also known as CD144) [279], vascular endothelial growth 
factor receptor 1 (Flt1, encoding VEGFR-1) [280] and vascular endothelial protein tyrosine 
phosphatase (Ptprb, encoding VE-PTP) [279] (Figure 4.6C). Endothelial cell cluster 2 included a 
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range of lesser-known markers such as coiled-coil domain containing 85A (Ccdc85a), aquaporin 
7 (Aqp7) and carbonic anhydrase 4 (Car4) (Figure 4.6C). Endothelial cell cluster 3 included 
neuronal-associated makers such as amyloid beta A4 precursor protein-binding family A2 
(Apba2) [281] and neurotensin (Nts) a marker associated with smooth muscle contraction [282] 
(Figure 4.6C). The dot plot showed overlap in markers between endothelial cluster 1 and 2 (Figure 
4.6C) suggesting similar expression profiles. 
The remaining clusters included a range of cell types and generally distinct top marker expression. 
This included two RB cell clusters (RB 1: Rhd, Ermap, Cldn13; RB 2: Snca, Alas2, Bpgm), a 
nerve cell cluster (Dusp15, Slc36a2, Hcn1), a satellite cell cluster (Chodl, Pax7, Myf5), platelet 
cell cluster (Mpig6b, Gp1ba, Gp6) and a muscle cell cluster (Hfe2, Tmod4, Myot). Lastly, an 
unidentified cell cluster (Myh11, Slc35f1, Pln) had distinct markers from a range of associated 
cell-types, from smooth muscle markers such as Myh11 [283] to stem cells marker such as Foxd3 
(not shown here) [284] and neural crest markers such as Sox10 (not shown here) [285]. Except 
for the RB cell clusters, all other clusters had distinct and cluster-specific marker expression 
(Figure 4.6C). Cluster-specificity of the top markers supports the idea that each cluster is a 
transcriptionally diverse subpopulation. 
 
4.3.2.3 Analysis of ligament fibroblast markers 
Ligament fibroblasts subgroups were separated (based on Col1a2 expression) (Figure 4.7A). 
Downstream analysis with Seurat (see Section 4.2.5) found five distinct ligament fibroblast 
clusters, labelled L.F1 (258 cells), L.F2 (240 cells), L.F3 (219 cells), L.F4 (135 cells), and L.F5 
(78 cells) respective of cluster size (Figure 4.7B).  
Ligament fibroblast markers were determined via differential expression analysis of all fibroblast 
clusters compared to all other ligament cell-type clusters (see Section 4.2.5). A heatmap of the top 
20 markers confirmed marker specificity to the fibroblast clusters (Figure 4.7C). Fibroblast-
marker specificity was slightly lower in the L.F5 cluster which had low or negative expression of 
Col1a1, Serpinf1, Serping1, Clec3b and Fstl1 (Figure 4.7C). Despite this, prominent fibroblast 
ECM markers were present in L.F5 cluster including decorin (Dcn), Col1a2 and Col3a1 as well 
as high expression of other significant fibroblast collagens (Col6a1, Col6a2, Col5a2) (Figure 
4.7C). Differences in the L.F5 transcriptional makeup cluster could suggest it is a distinct 
fibroblast subpopulation. Additional analysis of each individual fibroblast cluster is necessary to 




Figure 4.7 Ligament fibroblasts subgroups and the top differentially expressed fibroblast markers. (A) ‘Ligament 
Fibroblasts’ clusters expressing Col1a2 were further analysed. (B) Ligament fibroblast subgroups were five in total 
according to Seurat downstream analysis and labelled LF1 to LF5. (C) Heatmap of the top 20 ligament fibroblast 
markers calculated via differential expression analysis included: Dcn, Col1a2, Col3a1, Igfbp6, Tnxb, Pcolce, Col6a1, 
Gsn, Col1a1, Lrp1, Serpinf1, Serping1, Col6a2, Timp2, Col5a2, Clec3b, Gas1, Abi3bp, Prrx1 and Fstl1. The heatmap 
demonstrated high expression and specificity for the fibroblast clusters. 
 
4.3.2.4 Ligament fibroblast 1 (L.F1) subpopulation 
L.F1 cluster was the largest ligament fibroblast cluster made up of 258 cells (Figure 4.8A). 
Differential expression analysis between L.F1 and the remaining fibroblast clusters found unique 
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high-expressing markers such as six transmembrane epithelial antigen of prostate 4 (Steap4), 
hemicentin 2 (Hmcn2), gamma-glutamyltransferase 5 (Ggt5), chemokine CXC motif ligand 14 
(Cxcl14), secreted frizzled-related protein 1 (Sfrp1), and glypican 3 (Gpc3) (Figure 4.8B). A 
heatmap of the top 20 differentially expression L.F1 markers confirmed specificity to the L.F1 




Figure 4.8 The top differentially expressed markers of the ligament fibroblast 1 (L.F1) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of L.F1 and the other fibroblast cells. (B) Feature and violin plot comparing 
the top differentially expressed L.F1 markers: Steap4, Cxcl14, Ggt5, Hmcn2, Sfrp1, and Gpc3. (C) A heatmap of the 
top 20 differentially expressed L.F1 markers included Steap4, Cxcl14, Cygb, Ggt5, Hmcn2, Cxcl12, Sfrp1, Penk, Gpc3, 
Bmper, Gdf10, Scn7a, Srpx, Inmt, Mme, Fam198b, Emb, Tmem176b, Sparcl1 and Adm. Heatmap confirmed marker 
specificity for the L.F1 cluster with minor overlap with the L.F2 cluster, indicating potential transcriptional similarities 




4.3.2.5 Ligament fibroblast 2 (L.F2) subpopulation 
Differential expression analysis of L.F2 cluster (240 cells) identified L.F2-specific markers. These 
gene expression markers included peptidase inhibitor 16 (Pi16, encoding CD364) and IL-1 
receptor type II (Il1r2), sphingomyelin phosphodiesterase 3 (Smpd3), transmembrane protein 26 
(Tmem26), endo-beta-N-acetyl-glucosaminidase (Engase) and allograft inflammatory factor 1-
like (Aif1l). L.F2 cluster heatmap showed overlap with the L.F4 cluster (Figure 4.9C) indicating 
potential transcriptional similarities between the two clusters. 
 
 
Figure 4.9 The top differentially expressed markers of the ligament fibroblast 2 (L.F2) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of L.F2 and other fibroblast cells. (B) Feature and violin plot of the top 
differentially expressed L.F2 markers: Pi16, Smpd3, Tmem26, Engase, Aif1l, Il1r2. (C) A heatmap of the top 
differentially expressed L.F2 markers showed some overlap with L.F4, indicating transcriptional similarities between 
the two clusters. The top 20 differentially expressed markers included Pi16, Procr, C3, Cd34, Ace, Efhd1, Ly6c1, 




4.3.2.6 Ligament fibroblast 3 (L.F3) subpopulation 
Differential expression analysis of the L.F3 cluster (219 cells) (Figure 4.10A) found cluster-
specific markers such as scleraxis (Scx), tenomodulin (Tnmd), mohawk (Mkx), fibromodulin 
(Fmod), glycoprotein thrombospondin-4 (Thbs4), myosin light chain kinase (Mylk) (encoding 
kinase-related protein, telokin), keratocan (Kera), and leptin receptor (Lepr) (Figure 4.10B-C). A 




Figure 4.10 The top differentially expressed markers of the ligament fibroblast 3 (L.F3) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of L.F3 and other fibroblast cells. (B) Feature and violin plot of the top 
differentially expressed L.F3 markers included Thbs4, Mylk, Kera, Lepr, Scx, and Tnmd. (C) A heatmap of the top 20 
differentially expressed L.F3 markers showed cluster-specific markers. The top 20 differentially expressed markers 
included Thbs4, Fmod, Ccdc3, Angptl7, Mylk, Col12a1, Kera, Lepr, Itgbl1, Uts2r, Kcnma1, Scx, Tnmd, Mkx, Fgf9, 




4.3.2.7 Ligament fibroblast 4 (L.F4) subpopulation 
The top differentially expressed L.F4 subpopulation (135 cells) markers included 
immunoglobulin superfamily containing leucine-rich repeat 2 (Islr2), immunoglobulin-like 
domain receptor 2 (Ildr2), hemicentin-1 (Hmcn1, encoding Fibulin-6), integrin beta 3 (Itgb3, 
encoding CD61), olfactomedin-like 2A (Olfml2a), and ovarian carcinoma immunoreactive 
antigen domain 2 (Ociad2) (Figure 4.11B). A heatmap of the top 20 differentially expressed 
markers confirmed high expression and cluster-specificity (Figure 4.11C). 
 
 
Figure 4.11 The top differentially expressed markers of the ligament fibroblast 4 (L.F4) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of L.F4 and other fibroblast cells. (B) Feature and violin plot of the top 
differentially expressed L.F4 markers: Itgb3, Olfml2a, Islr2, Ildr2, Hmcn1, and Ociad2. (C) A heatmap of the top 20 
differentially expressed L.F4 markers shows L.F4 cluster specificity. Top 20 differentially expressed markers included 
Itgb3, Olfml2a, Prss23, Islr2, Ildr2, Dlx3, Ptgs1, Chst15, Hmcn1, Cdk6, Cd80, Lrrc8c, Ociad2, Tmtc2, Tspan15, 




4.3.2.8 Ligament fibroblast 5 (L.F5) subpopulation 
L.F5 was the smallest subpopulation of fibroblasts (Figure 4.12A) made up of 78 cells. The top 
differentially expressed markers included cartilage associated markers such as Acan and 
hyaluronan and proteoglycan link protein 1 (Hapln1, encoding CRTL1). Other L.F5 markers 
included leucine-rich repeat-containing G-protein coupled receptor 6 (Lgr6), Egl nine homolog 3 
(Egln3), melanotransferrin (Meltf, encoding CD228) and tumor necrosis factor receptor 
superfamily member 11b (Tnfrsf11b) (Figure 4.12B). A heatmap showed high specificity and 
expression for the top 20 differentially expressed L.F5 markers (Figure 4.12C). Other cartilage 
markers specific to L.F5 included transcription factor Sox-9 (Sox9) and COL2 alpha 1 (Col2a1) 
both of which were highly expressed and specific (Figure 4.12D-E). These cartilage-associated 
markers indicate a cluster-specific transcriptional shift in this fibroblast subpopulation. 
 
4.3.2.9 Enriched canonical pathways and predicted upstream regulators 
The top 20 enriched canonical pathways of the healthy murine ligament fibroblast clusters 
predicted by the IPA software revealed similar signalling pathways. GP6 signalling pathway 
received the highest activation scores in all ligament fibroblast clusters (Table 4.2). The same was 
also true for the cardiac hypertrophy signalling, dendritic cell maturation, and OA pathways 
(Table 4.2). The only signalling pathways that had predicted inactivation was WNT/β-catenin 
(L.F1, L.F3, L.F5) and RhoGDI signalling pathways (L.F4) (Table 4.2). Furthermore, there were 
six canonical pathways that were activated in both L.F2 and L.F4 (Table 4.2), confirming the 
close relationship between the two clusters seen previously (Figure 4.9C). From the top 20 
enriched canonical pathways, the only pathways that were unique to one cluster were the integrin 
signalling pathway (L.F4), the fibroblast growth factor (FGF) signalling pathway (L.F5) and the 
RhoGDI signalling pathway (L.F4). Canonical pathway analysis did not reveal major differences 





Figure 4.12 The top differentially expressed markers of the ligament fibroblast 5 (L.F5) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of the L.F5 cluster relative to other ligament fibroblast clusters. (B) Feature 
and violin plot of the top differentially expressed L.F5 markers: Lgr6, Egln3, Acan, Meltf, Hapln1 and Tnfrsf11b. (C) 
A heatmap of the top differentially expressed markers: Lgr6, Egln3, Acan, Meltf, Hapln1, Tnfrsf11b, Eps8l2, Susd5, 
Slc38a1, Cdo1, Trpv4, Kcna6, Sdk2, Tesc, Tnfrsf21, Gldc, Htra4, Spp1, Foxd1 and Slc16a3. (D) A heatmap of cartilage-
associated markers Sox9 and Col2a1 show L.F5 specificity. (E) Feature and violin plot of Sox9 and Col2a1 confirm 





Table 4.2 Predicted enriched canonical pathways for each ligament fibroblast cluster. Canonical pathway activation 
revealed similarities between the ligament fibroblast clusters. The respective activation z-score of each canonical 
pathway was colour graded: red is positive and blue is negative. Enriched canonical pathway analysis was predicted 
with Ingenuity Pathway Analysis (IPA) software. 
Top 20 Enriched Canonical Pathways 
Activation z-score 
L.F1 L.F2 L.F3 L.F4 L.F5 
GP6 Signalling Pathway 3.464 2.828 3.606 3.317 3.317 
Cardiac Hypertrophy Signalling (Enhanced) 2.449 3 2.646 2 3.873 
Dendritic Cell Maturation 2.236 2 2.449 2.449 2 
Synaptogenesis Signalling Pathway 2 2.449 2.449 2.53 N/A 
NF-κB Signalling 2 2.646 N/A N/A 2 
Osteoarthritis (OA) Pathway 1 2.111 1.342 1.265 0.688 
Glioblastoma Multiforme Signalling N/A 2.236 N/A 2.236 1.342 
Colorectal Cancer Metastasis Signalling N/A 3 N/A 2.449 N/A 
IL-8 Signalling N/A 2.449 N/A 2.828 N/A 
ILK Signalling N/A 2.646 N/A 2.53 N/A 
STAT3 Pathway 2 2.646 N/A N/A N/A 
Cholecystokinin/Gastrin-mediated Signalling N/A 2 N/A 2 N/A 
Apelin Liver Signalling Pathway 2 N/A 2 N/A N/A 
Sphingosine-1-phosphate Signalling N/A 2 N/A 2 N/A 
WNT/β-catenin Signalling -1 0 -0.447 0.447 -1.667 
Leukocyte Extravasation Signalling N/A 1 1 1.414 N/A 
Integrin Signalling N/A N/A N/A 2.828 N/A 
Glioma Invasiveness Signalling N/A 1 N/A 1.667 N/A 
FGF Signalling N/A N/A N/A N/A 2.449 
RhoGDI Signalling N/A N/A N/A -2.449 N/A 
 
Predicted upstream regulators for each ligament fibroblast cluster were also assessed using IPA 
software. The top six predicted activated upstream regulators were very similar among all the 
clusters and included transforming growth factor beta 1 (Tgfb1) which was activated in all 
ligament fibroblast subpopulations (Table 4.3). The total number of activated upstream regulators 
for each ligament fibroblast cluster was highly variable and the percentage of those regulators 
which were also activated in other ligament fibroblast cluster confirmed a high overlap of 
upstream regulators (from 38.8-80.0%) (Table 4.3). The top cluster-specific upstream regulators 
were determined based on their predicted activation score. These ligament fibroblast 
subpopulation-specific upstream regulators could provide insight into cluster-specific roles (Table 








Table 4.3 Predicted activated upstream regulators in the ligament fibroblast subpopulations. The total number of 
predicted activated upstream regulators varied between clusters. The top six predicted activated upstream regulators 
were similar between in all ligament fibroblast clusters. The top five cluster specific activated upstream regulators for 
each ligament fibroblast cluster could provide insight into cluster-specific roles. Activated upstream regulators were 
predicted with Ingenuity Pathway Analysis (IPA) software. 
   Predicted Activated Upstream Regulators 
Cluster Total # Top 6 Top 5 Cluster Specific 
L.F1 201 Ccr2, Ikbkb, Tgfb1, Ikbkg, Prl, Twist1 Mafb, Tcr, Eif4e, Cpxm1, Stat 
L.F2 278 Pdgf Bb, Prl, Sp1, Il1B, Egf, Tp53 Fgf7, Lhx1, F3, F7, Tlr3 
L.F3 135 Tgfb1, Ccr2, Htt, Hif1A, Twist1, Tgf Beta Id2, Otx2, Hoxd3, Atf6, Neurog1 
L.F4 205 Tgfb1, Tp53, Il1B, F2, Il5, Sp1 Kmt2d, Ret, Il15, Sox11, Ptpn3 
L.F5 228 Tgfb1, Ctnnb1, Tgf Beta, Bmp2, Hif1A, Pgr Nfat5, Bmpr1b, Bmpr1a, Gper1, Cav1 
 
 
4.3.3 Analysis of synovium-derived cell populations and markers 
Similar to the ligament cell populations, synovium-derived cell populations were analysed via 
scRNA-seq using the same cell isolation protocol (Section 4.2.2), library creation and sequencing 
method (Section 4.2.4), and analysis method (Section 4.2.5). 
 
4.3.3.1 Quality control of synovial-derived library reads 
Synovium-derived cells post-sequencing had a final output of 6,228 cells with 99,451 reads per 
cell and a median of 1,624 genes per cell which was a lower cell retention than the 10,000 cells 
expected but enough for further analysis. Overall, t-SNE projection showed several aggregations 
of synovial cells and the absolute number of UMI counts ranged from 2,000 to 10,000 counts per 
cell (Figure 4.13A), slightly higher than the UMI counts for the ligament-derived cells (Figure 
4.4). Sequencing saturation and median genes per cell both show an increase and plateau as the 
mean reads per cell increases (Figure 4.13B) which suggested high fraction library complexity 





Figure 4.13 Quality control post-sequencing of the synovial-derived cells. (A) Unguided t-distributed stochastic 
neighbour embedding (t-SNE) projection of unique molecular identifiers (UMI) counts for each synovial-derived cell 
showed a range from 2000 to 10,000 counts. (B) High sequencing saturation was confirmed and increased with the 
number of mean reads per cell. (C) Median genes per cell also increased as mean reads per cell increased. This 
confirmed successful library creation and high library complexity. 
 
4.3.3.2 Identification of synovial cell types and subpopulations 
Seurat downstream analysis of synovial-derived cells filtered out low quality reads including low 
unique features and high mitochondrial genes (see Section 4.2.5). This filtering resulted in a 
remaining 3,229 synovial cells which were categorised into 11 unique cell clusters using 
modularity optimisation techniques and visualised using UMAP (Figure 4.14A). 
The 11 clusters were classified based on the presence of certain cell markers (see Section 4.2.5). 
Cell identification markers showed 4 distinct cell types (Figure 4.14A). These consisted of four 
fibroblast clusters (based on Col1a2 and Col3a1 expression), five immune cell clusters (based on 
Ptprc and Cd14 expression, one endothelial cell cluster (based on Pecam1 expression) and one 
RB cell cluster (based on Hba-a1 expression) (Figure 4.14B). Average marker expression and cell 





Figure 4.14 Overview of synovium-derived cell types. (A) Uniform manifold approximation and projection (UMAP) of 
all synovial cell clusters colored, numbered and labelled by cell type. (B) Major known cell type markers were 
visualised with feature plots to classify clusters and included Col1a2 and Col3a1 for fibroblasts, Hba-a1 for red blood 
cells, Pecam1 for endothelial cells, and Ptprc (Cd45) and Cd14 for immune cells. (C) Dotplot of the major cell identity 
markers quantified expression of these identification markers in each synovial cell cluster. 
 
The top three markers of each cluster based on differential expression analysis are summarised in 
Figure 4.15. Top markers for synovial fibroblast cluster 1 (S.F1) included fibroblast markers 
Steap4, Col3a1 and Gsn (Figure 4.15A). These markers were similarly expressed in ligament 
fibroblasts including Steap4 in L.F1 (Figure 4.8). Synovial fibroblast cluster 2 (S.F2) markers 
consisted of phospholipase A1 (Pla1a), epidermal growth factor-containing fibulin-like ECM 
protein 1 (Efemp1) and annexin A3 (Anxa3) (Figure 4.15A). Markers for synovial fibroblast 
cluster 3 (S.F3) were ECM protein 1 (Ecm1), annexin A8 (Anxa8) and synovial fibroblast marker 
Cd34 (Figure 4.15A). Synovial fibroblast cluster 4 (S.F4) markers included angiopoietin-related 
protein 7 (Angptl7), keratocan (Kera) and coiled-coil domain-containing protein 3 (Ccdc3) 
(Figure 4.15A). All the S.F4 markers were cluster-specific and were also present in the ligament 
(L.F3 cluster, Figure 4.10). Overall, many of the synovial-derived fibroblast markers were also 
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expressed in the ligament-derived fibroblasts, indicating similar transcriptional similarities in the 
fibroblasts of the two tissues. Fibroblast clusters will be explored in more detail in Section 4.3.3.3. 
The five synovial immune clusters had markers associated to macrophages. Synovial immune 
cluster 1 top differentially expressed markers included macrophage associated markers such as 
platelet factor 4 (Pf4, encoding CXCL4), coagulation factor XIII A (F13a1) and complement C1q 
subcomponent subunit A (C1qa) [238] (Figure 4.15C). All the top differentially expressed 
immune cluster 1 markers overlapped with immune cluster 4 (Figure 4.15C), suggesting similar 
transcriptional profiles. Immune cluster 2 markers included napsin-A (Napsa) a dendritic cell 
marker [238], and lesser known markers such as phospholipase B domain containing 1 (Plbd1) 
and class II histocompatibility antigen M beta 1 chain (H2-DMb1) (Figure 4.15C). The top 
differentially expressed markers of immune cluster 2 were also expressed in immune cluster 3, 
indicating similar transcriptional profiles (Figure 4.15C). Immune cluster 3 top differentially 
expressed markers included inflammatory and macrophage associated markers such as regulator 
of G-protein signalling 1 (Rgs1) [286] and chitinase-like protein 3 (Chil3) [287] and lesser known 
markers such as signal-regulatory protein beta 1C (Sirpb1c) (Figure 4.15C). Immune cluster 4 
differentially expressed markers also included inflammatory and macrophage associated markers 
such as v-set and immunoglobulin domain containing 4 (Vsig4) [288] and oxidised low-density 
lipoprotein receptor 1 (Olr1, encoding LOX-1) [289] as well as leukocyte-associated 
immunoglobulin-like receptor 1 (Lair1, encoding CD305) [290] (Figure 4.15C). Immune cluster 
5 top differentially expressed markers also consisted of inflammatory and macrophage associated 
markers such as aconitate decarboxylase 1 (Acod1) [291] and resistin-like gamma (Retnlg) [292] 
and also a lesser known marker AC110211.1 (Figure 4.15C). Overall, overlap between the top 
differentially expressed markers from immune cluster 1 and 4 and immune cluster 2 and 3 indicate 
transcriptional similarities between those clusters. 
The two remaining synovial cell clusters were the RB cell cluster and the endothelial cell cluster. 
The top three differentially expressed markers for the RB cluster consisted of delta-
aminolevulinate synthase 2 (Alas2), alpha-synuclein (Snca) and solute carrier family 4 member 1 
(Slc4a1) (Figure 4.15B). The top three differentially expressed markers for the endothelial clusters 
were vascular endothelial cadherin (Cdh5, encoding CD144), kinase insert domain receptor (Kdr, 
encoding VEGFR2) and Pecam1, the previously mentioned endothelial marker (Figure 4.15B). 
Synovial RB and endothelial markers showed high cluster-specificity (Figure 4.15B) suggesting 





Figure 4.15 Dot plot of the top three differentially expressed markers in each synovial cell cluster. (A) Dot plot of the 
top three differentially expressed markers in the synovial fibroblast clusters showed overlap in expression between the 
clusters. (B) Dot plot of the top three differentially expressed markers from the synovial red blood and endothelial cell 
clusters were cluster specific. (C) Dot plot of the top three differentially expressed markers in the synovial immune cell 
clusters showed overlap in expression between immune cluster 1 and 4 and immune cluster 2 and 3. Overlap in 
expression indicates similar transcriptional profiles between the clusters. 
 
4.3.3.3 Analysis of synovial fibroblast markers 
Synovial fibroblast subgroups were selected (Figure 4.16A) based on the high expression of 
Col1a2 and Col3a1 (Figure 4.14). The four identified synovial fibroblast clusters were labelled 
S.F1 (730 cells), S.F2 (587 cells), S.F3 (478 cells) and S.F4 (354 cells) respective of cluster size 
202 
 
(Figure 4.16B). Differential expression analysis between the synovial fibroblast clusters and other 
cell-type clusters revealed synovial fibroblast specific markers. A heatmap of the top 20 
differentially expressed fibroblast markers from murine synovium samples confirmed specificity 
to the fibroblast clusters and high expression (Figure 4.16C). Notable differences were only 
present in S.F4 which had low or negative expression of Gsn, Fstl1, C3, Dpt and C1s1 which 
could suggest a divergence of this cluster (Figure 4.16C).  
 
 
Figure 4.16 Synovial fibroblasts subgroups and the top differentially expressed fibroblast markers. (A) Synovial 
fibroblast cells were identified based on Col1a2 and Col3a1 expression. (B) Seurat downstream analysis found four 
distinct synovial fibroblast clusters labelled S.F1 to S.F4. (C) Differential expression analysis between the synovial 
fibroblast clusters and all other synovial cell types determined the following top 20 synovial fibroblast markers: Dcn, 
Col3a1, Col1a2, Gsn, Col1a1, Ogn, Plpp3, Fstl1, Igfbp6, Serping1, Serpinh1, Clec3b, C3, Sparc, Serpinf1, Dpt, 
Col6a1, C1s1, Tnxb, Pcolce. The heatmap confirmed specificity of these markers to the fibroblast clusters. 
203 
 
4.3.3.4 Synovial fibroblast 1 (S.F1) subpopulation 
Differential expression analysis of the S.F1 cluster (730 cells) found markers such as growth 
differentiation factor 10 (Gdf10), BMP endothelial regulator (Bmper), Sparc-like protein 1 
(Sparcl1), matrix metalloproteinase 3 (Mmp3), embigin precursor (Emb) and metalloreductase 
STEAP family member 4 (Steap4) (Figure 4.17B). Steap4 was previously noted as a L.F1 marker 
(Figure 4.8). A heatmap of the top 20 differentially expressed S.F1 markers demonstrated 
specificity to the S.F1 cluster, though a few markers (Cxcl14 and Lum) were also expressed in 
S.F4 (Figure 4.17C). 
 
 
Figure 4.17 The top differentially expressed markers of the synovial fibroblast 1 (S.F1) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of S.F1 relative to the other fibroblast clusters. (B) Feature and violin plot 
showing expression of the top differentially expressed S.F1 markers which included Steap4, Gdf10, Bmper, Sparcl1, 
Mmp3, and Emb. (C) A heatmap of the top 20 differentially expressed S.F1 markers showed high expression and 
specificity for S.F1 and included Steap4, Col4a1, Gdf10, Cxcl14, Col4a2, Col5a3, Bmper, Cxcl12, Smoc2, Sparcl1, 
Lum, Penk, Mmp3, Cygb, Emb, Srpx, Itm2a, Col18a1, Podn and F3. 
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4.3.3.5 Synovial fibroblast 2 (S.F2) subpopulation 
S.F2 cluster (587 cells) differentially expressed markers (Figure 4.18A) included suprabasin 
(Sbsn), placenta-specific protein 8 (Plac8), brain acid soluble protein 1 (Basp1), electrogenic 
sodium bicarbonate cotransporter 1 (Slc4a4, encoding NBCe1), carbohydrate sulfotransferase 1 
(Chst1), and aldehyde dehydrogenase 1 family member A3 (Aldh1a3) (Figure 4.18B). A heatmap 
of the top 20 differentially expressed S.F2 markers demonstrated specificity of markers to the 
S.F2 cluster, though some markers such as Efemp1, Dpp4, Smpd3 and Emilin2 were also 
expressed in S.F3 (Figure 4.18C). 
 
 
Figure 4.18 The top differentially expressed markers of the synovial fibroblast 2 (S.F2) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of S.F2 cells relative to the other fibroblast clusters. (B) Feature and violin 
plots of the top differentially expressed S.F2 markers which included Sbsn, Plac8, Basp1, Slc4a4, Chst1, and Aldh1a3. 
(C) A heatmap of the top 20 differentially expressed markers included Pla1a, Efemp1, Sbsn, Dpp4, Smpd3, Plat, Plac8, 
Basp1, Slc43a3, Ptgs2, Slc4a4, Chst1, Aldh1a3, Emilin2, Qpct, Dact1, Gm12840, Smurf2, Dmkn and Ccl11. Markers 




4.3.3.6 Synovial fibroblast 3 (S.F3) subpopulation 
The top differentially expressed markers for the S.F3 cluster (478 cells) included annexin A8 
(Anxa8), calcitonin receptor-like receptor (Calcrl), stathmin 4 (Stmn4), hyaluronan synthase 2 
(Has2), t-box transcription factor 5 (Tbx5) and ankyrin repeat domain-containing protein 29 
(Ankrd29) (Figure 4.19B). Moreover, heatmap of the top 20 differentially expressed S.F3 markers 
showed little specificity to S.F3 and repeated overlap with the S.F2 cluster (Figure 4.19C), 
suggesting a similar transcriptional profile between the two clusters. 
 
 
Figure 4.19 The top differentially expressed markers of the synovial fibroblast 3 (S.F3) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of the S.F3 cluster relative to other synovial fibroblast clusters. (B) Feature 
and violin plots of the top differentially expressed S.F3 markers included Anxa8, Stmn4, Calcrl, Has2, Ankrd29, and 
Tbx5. (C) A heatmap of the top 20 differentially expressed markers included: Anxa8, Stmn4, Calcrl, Tmem26, Cyb561, 
Has2, Fhl1, Ackr1, Fez1, 1700019D03Rik, Adgrg2, Tnfsf9, Ankrd29, Wnt10b, Spsb1, Rabgap1l, Myh10, Il13ra1, Tbx5 
and Rorb. Heatmap showed that the top differentially expressed S.F3 markers were also expressed in the S.F2 cluster, 




4.3.3.7 Synovial fibroblast 4 (S.F4) subpopulation 
The top differentially expressed markers for the S.F4 cluster (354 cells) included cartilage 
intermedia layer protein 2 (Cilp2), collagen type X1 alpha 1 (Col11a1), calcium-activated 
potassium channel subunit (Kcnma1), coiled-coil domain-containing 3 (Ccdc3), fin bud initiation 
factor homolog (Fibin), and Kera (Figure 4.20B). Kera marker expression was also present in the 
L.F3 cluster (Figure 4.10B). Other tendon-associated markers were also present in the S.F4 
heatmap including Scx, Fmod and Tnmd (Figure 4.20C). A heatmap further showed high 




Figure 4.20 The top differentially expressed markers of the synovial fibroblast 4 (S.F4) cluster. (A) Uniform manifold 
approximation and projection (UMAP) of the S.F4 cluster relative to the other synovial fibroblast clusters (B) Feature 
and violin plots of the top differentially expressed S.F4 markers included Cilp2, Col11a1, Kcnma1, Ccdc3, Fibin, and 
Kera. (C) A heatmap of the top 20 differentially expressed S.F4 markers included Cilp2, Col11a1, Kcnma1, Ccdc3, 
Fibin, Kera, Scx, Angptl7, Mylk, Thbs4, Lepr, Col12a1, Fmod, Crispld2, Uts2r, 1500015O10Rik, Itgbl1, Mt3, Tnmd, 
and Chad. Heatmap showed that marker expression was specific to S.F4. 
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4.3.3.8 Enriched canonical pathways and predicted upstream regulators 
The top 20 predicted enriched canonical pathways according to IPA software analysis revealed 
similar signalling pathways between the synovial fibroblast clusters as can be seen in Table 4.4. 
Cardiac hypertrophy, colorectal cancer metastasis, GP6 and IL-8 signalling pathways received the 
highest predicted activation scores in all clusters (Table 4.4). Signalling pathways with predicted 
inactivation included PTEN signalling, endocannabinoid cancer inhibition and PPARα/RXRα 
activation pathways (Table 4.4). Canonical pathway analysis showed similar enriched pathways 
in the synovial fibroblast clusters. 
 
Table 4.4 Predicted enriched canonical pathways for each synovial fibroblast cluster.The respective activation z-score 
for each canonical pathway was graded color scale where red is positive and blue is negative. Canonical pathway 
analysis was completed with Ingenuity Pathway Analysis (IPA) software. 
Top 20 Enriched Canonical Pathways 
Activation z-score 
S.F1 S.F2 S.F3 S.F4 
Cardiac Hypertrophy Signalling (Enhanced) 3.051 5 3.051 1.807 
Colorectal Cancer Metastasis Signalling 3.464 4.359 2.449 1.414 
GP6 Signalling Pathway 3.9 2.111 2.333 3 
IL-8 Signalling 2.333 4 3 0.707 
Glioblastoma Multiforme Signalling 2.646 3.051 1.342 1.414 
STAT3 Pathway 2.333 2.333 2.646 1 
CXCR4 Signalling 2.236 3 2 1 
Cardiac Hypertrophy Signalling 1.633 3.207 2.236 1.134 
ILK Signalling 1.633 3.411 2.333 0.333 
PTEN Signalling -2.236 -2.449 -1.633 -1.342 
Cholecystokinin/Gastrin-mediated Signalling 2 3.317 2.236 N/A 
Endocannabinoid Cancer Inhibition Pathway -2 -2.121 -0.447 -2.646 
NF-κB Signalling 2.121 1.732 2.333 1 
Role of NFAT in Cardiac Hypertrophy 1.342 1.897 2 1.89 
Acute Phase Response Signalling 2.333 3 N/A -1.414 
Thrombin Signalling N/A 3.464 2.236 1 
Adrenomedullin signalling pathway 1.342 1.508 2.236 1.414 
IL-6 Signalling 2.828 3.162 N/A -0.378 
Osteoarthritis Pathway 1.265 2.683 1.265 1.155 
PPARα/RXRα Activation -1.897 -2.333 -1.414 -0.707 
 
Upstream regulators predicted by IPA software analysis also sound similar upstream regulators in 
the synovial fibroblast clusters (Table 4.5). The top five upstream regulators all overlapped with 
other clusters except for Mycn which was a top activated and cluster specific upstream regulator 
of S.F2 (Table 4.5). Similar to the ligament fibroblasts, synovial fibroblast clusters had similar 
upstream regulators that overlapped between clusters. Furthermore, cluster specific upstream 
regulators were predicted by IPA software and were ranked based on the highest activation score. 
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Table 4.5. Predicted activated upstream regulators in the synovial fibroblast subpopulations. The total number of 
predicted activated upstream regulators varied between clusters. The top five predicted activated upstream regulators 
based on activation score showed similar activated regulators in all synovial fibroblast clusters. The top five cluster 
specific activated upstream regulators for each synovial fibroblast cluster was determined based on activation score. 
   Predicted Activated Upstream Regulators 
Cluster Total # Top 5 Top 5 Cluster Specific 
S.F1 597 Tgfb1, Ctnnb1, Tp53, Xbp1, Edn1 Cpxm1, Nr5a2, H2afb3, Il11, Skil 
S.F2 609 Mycn, Il1b, Vegf, Pdgf bb, Nfkb Mycn, Rps15, Tbk1, Crem, Tlr7  
S.F3 294 Sp1, Vegf, Egf, Tp53, Ctnnb1 Lhx1, Ascl1, Srebf2, Nkx2-1, Dcn 
S.F4 308 Tgfb1, Wnt3a, Sp1, Htt, Tgf Beta Hoxd3, Otx2, Wls, Tmpo, Mdm2 
 
4.3.4 Confirmation of Aggrecan (ACAN)-expressing ligament cell subpopulation 
ACAN expression was analysed using an Acan-Cre-tdTomato transgenic murine model, which 
allows for indirect monitoring of Acan transcriptional activity using fluorescently labelled induced 
ACAN expression with a tdTomato reporter [266]. Fluorescent images of the Acan-Cre-tdTomato 
medial tibial cartilage, a positive control, demonstrated the expected ACAN tdTomato expression 
in the cartilage chondrocytes and surrounding niches (Figure 4.21). These findings confirm Acan-
Cre-tdTomato as a working ACAN expression reporter model. 
 
 
Figure 4.21 Fluorescent images of the murine Aggrecan (Acan)-Cre-tdTomato medial tibial cartilage. Fluorescence 
showed ACAN expression in the articular cartilage chondrocytes and the surrounding pericellular matrix. Fluorescent 
images show chondrocyte nuclei (DAPI) (blue), ACAN expression from an induced Acan-Cre enhancer with a tdTomato 
reporter (tdTomato) (red), brightfield and merged images. Scale bar is 50 µm. 
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ACAN expression was then analysed in murine knee ligaments (n=4) using the established Acan-
Cre-tdTomato reporter model. ACAN expression was found in the PCL in specific ligament cells 
in the midsection of the ligament (Figure 4.22). These findings would suggest a unique ligament 
cell subpopulation identified with an ACAN marker, confirming the results from the scRNA-seq 
analysis of a cartilage-like Acan-L.F5 subpopulation (Figure 4.12). 
 
 
Figure 4.22 Fluorescent images of Aggrecan (Acan)-Cre-tdTomato posterior cruciate ligament. Fluorescence reveals 
ACAN expression in certain subpopulations of ligament cells in the mid-ligament region. Fluorescence shows all 
ligament nuclei staining (DAPI) (blue), ACAN expression from an induced Acan-Cre enhancer with a tdTomato 
reporter (tdTomato) (red), and brightfield and merged images. Scale bar is 100 µm for the channel and merged images, 
and 50 µm for x40 images. 
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4.3.5 Comparison of ligament and synovial fibroblasts 
Ligament and synovial fibroblast datasets were integrated and compared using the SCTransform 
Seurat integration workflow [253]. Integration of the two datasets was confirmed in Figure 4.23A. 
Side by side comparison of the datasets revealed similar UMAP approximation between the L.F1 
and S.F1 cluster, as well as between the L.F2, L.F4, S.F2 and S.F3 clusters, and between the L.F3, 
L.F5 and S.F4 clusters (Figure 4.23B). UMAP approximation indicate similar transcriptional 
profiles between these clusters. This confirms our past findings of similar markers between 
ligament and synovial fibroblast subpopulations (Figure 4.7 and Figure 4.16). 
Differential expression analysis between ligament fibroblasts and synovial fibroblasts revealed 
potential tissue specific fibroblast markers. The top five differentially expressed markers 
upregulated in the ligament fibroblasts included Cilp2, Ccdc3 and Thbs4, however these markers 
were also upregulated in the synovial S.F4 cluster (Figure 4.23C) indicating that these markers 
are not tissue specific. Ligament fibroblast markers cytokine-like 1 (Cytl1) and osteopontin (Spp1) 
were upregulated and downregulated in the L.F5 cluster only and were not expressed in any of 







Figure 4.23 Integrated ligament and synovial fibroblasts and differential expression analysis. (A) Uniform manifold 
approximation and projection (UMAP) of the integrated ligament (red) and synovial (green) fibroblast dataset. (B) 
UMAP of the integrated ligament and synovial datasets split by tissue type and color coded by cluster identity (L.F1-5 
and S.F1-4). (C) Differential expression analysis of the top five markers upregulated in the ligament fibroblast dataset 
included Cytl1, Cilp2, Ccdc3, Spp1 and Thbs4. Violin plot of these markers showed that Cytl1 and Spp1 were mainly 






4.3.6 Summary of results 
Summary of ligament and synovial cell populations and fibroblast subpopulations can be seen in 
Table 4.6. Ligament-derived cells had nine distinct cell populations from which there were five 
fibroblast subpopulations (L.F1-5). Synovial-derived cells had four distinct cell populations and 
had four fibroblast subpopulations (S.F1-4). Fibroblast specific markers and upstream regulators 
are summarised in Table 4.6, as well as the potential role of each fibroblast subpopulation which 
are further discussed in Section 4.4.1-2. 
 
Table 4.6 Summary of murine ligament and synovial cell populations and fibroblast subpopulations. Ligament-derived 
cells consisted of nine cell types with five fibroblast subpopulations (L.F1-5). Synovium-derived cells had four distinct 
cell types and four fibroblast subpopulations (S.F1-4). The top differentially expressed specific markers, upstream 
regulators and potential roles of each fibroblast subgroup are summarised.  
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This study identified cell populations from murine ligament and synovial tissue and analysed 
fibroblast subpopulations and their transcriptional markers and associated pathways. Ligament-
derived cell populations had nine distinct cell types which included fibroblasts with five 
subpopulations (L.F1-5) (Figure 4.5). The L.F5 subpopulation markers contained Acan expression 
(L.F5) (Figure 4.12) which was confirmed by an Acan-Cre-tdTomato transgenic reporter mouse 
line (Figure 4.22). In the synovial-derived cells, four different cell types were discovered, from 
which fibroblasts had four subpopulations (S.F1-4) (Figure 4.14). Synovial fibroblast markers had 
numerous overlaps with the ligament fibroblasts, and comparison of the ligament and synovial 
fibroblasts confirmed overlap in fibroblast heterogeneity and identified ligament subpopulation 
specific markers. 
 
4.4.1 Ligament fibroblast subpopulations and potential roles 
Ligament fibroblast subpopulations had distinct markers and associated roles. This included a 
mineralisation-related (L.F1), inflammatory-related (L.F2), tendon-related (L.F3), sensory-
related (L.F4) and cartilage-related (L.F5) subpopulations. The associated roles of these 
subpopulations are based on current literature, but many markers remain unknown particularly 
within ligament tissue. 
The L.F1 cluster was made up of 258 cells which accounted for 28% of all ligament fibroblasts. 
The top L.F1 differentially expressed markers (Figure 4.8) included markers associated with 
mineralisation such as Steap4 [293], Sfrp1 [294] and Gpc3 [295]. Some of these markers are also 
expressed in developing mouse tendons including Steap4 [296], Gpc3 [297] and Cxcl14 [298]. 
The predicted L.F1-specific upstream regulators comprised of Mafb, Tcr, Eif4e, Cpxm1 and Stat. 
Of these, Mafb encodes a transcriptional factor involved in regulating osteoblast differentiation 
[299]. L.F1 markers and upstream regulators indicate an important mineralisation and 
developmental role of this subpopulation. 
The L.F2 cluster, which represented 26% of all ligament fibroblasts, had differentially expressed 
markers (Figure 4.9) suggesting an inflammatory role. Markers associated with inflammatory 
regulation are Pi16 (CD364) [300], Aif1l [301] and Il1r2 [302] which is also expressed in 
developmental tenocytes [303]. From the predicted L.F2-specific upstream regulators, several are 
involved in immune response and inflammatory pathways, such as F3 and F7 [304] as well as 
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Tlr3 [305]. The presence of these markers and upstream regulators suggest an inflammatory-
related role for this fibroblast subpopulation. 
Tendon-ligament associated markers were differentially expressed in the L.F3 subpopulation 
which correspond to 24% of all ligament fibroblasts (Figure 4.10). This included the presence of 
Mkx, Scx and Tnmd which are established tendon-ligament markers [52, 243]. Scx, Tnmd and Mkx 
expression was found in two distinct murine Achilles tendon fibroblast subpopulations [236], 
whereas our results revealed that these markers were concentrated in one ligament fibroblast 
subpopulation (L.F3). Other tendon associated markers in the L.F3 subpopulation included Thbs4 
[306], Fmod [307]; and Kera [308]. Predicted L.F3-specific upstream regulators included Id2, 
Otx2, Hoxd3, Atf6, Neurog1. Id2 is a SCX regulator during early development [309]. Neurog1 
and Otx2 are known neuronal differentiation regulators [310, 311]. L.F3 specific upstream 
regulators showed tendon and neuronal development regulators, but failed to show further 
pathways, likely because many of these pathways are still undiscovered. The presence of multiple 
tendon-associated markers and upstream regulators suggests a more tendon-like role for the L.F3 
subpopulation. 
The L.F4 cluster comprised of 14% of all ligament fibroblasts. The top six differentially expressed 
L.F4 markers (Figure 4.11) included Islr2, Ildr2, Hmcn1, Itgb3, Olfml2a, and Ociad2. From these 
markers, Islr2 is expressed in murine neural tissue [312] and Ildr2 in murine immune cells [313]. 
Hmcn1 is found in many tissues but also anchors mechanosensory neurons [314]. Furthermore, 
predicted L.F4 upstream regulators included Il15, an immune regulator [315], and Ret and Sox11, 
known neuronal mechanosensor regulators [316, 317]. The presence of immune and neuronal 
markers (including mechanosensory) could indicate an important sensory role for this L.F4 
subpopulation. 
The L.F5 subpopulation was the least numerous cluster and consisted of 8% of all ligament 
fibroblasts. The presence of established cartilage-specific cell markers such as Acan, Sox9 and 
Col2a1 in the L.F5 subpopulation (Figure 4.12) indicate a unique cartilage-like role for this 
cluster. Many of these markers have been previously shown in the transitional fibrocartilaginous 
region of the ligament-bone insertion site [318]. However, spatial confirmation of an ACAN-
expressing subpopulation of cells was found in the mid-ligament region of the PCL in the murine 
ACAN-Cre-tdTomato reporter line (Figure 4.22). Even though this was the smallest 
subpopulation, equivalent of 8% of ligament fibroblasts and 4% of all ligament-derived cells 
across 4 different knee ligaments from 6 pooled knee joints, histological sections revealed 8 
adjacent ACAN expressing cells in the PCL (Figure 4.22). These results confirm the powerful 
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resolution of single-cell sequencing. However, it is possible that specific fibroblasts 
subpopulations are more common in certain knee ligaments or micro-anatomical sites and 
warrants further investigation via spatial analysis or single-cell analysis of each individual 
ligament. Spatial analysis is also important, as our findings confirmed that an Acan-subpopulation 
of fibroblast cells were not only found in the ligament fibrocartilaginous region as previously 
thought but also in the mid-ligament region of healthy ligaments. ACAN-expressing cells were 
also previously found in healthy canine ACLs [20] and could be indicative of compressive load 
occurring in the mid-ligament region. 
Though this was the smallest ligament fibroblast cluster, Acan-fibroblasts could play an important 
role in murine ligament homeostasis and disease progression. Acan, Sox9 and Col2a1 gene 
expression was elevated in the overuse tendinopathy model in rats [319]. Similarly ACAN, SOX9, 
and COL2 protein expression has been described in the ACL mid-ligament region in OA patients 
[207]. SOX9 and COL2 protein markers were also found in the murine spontaneous and post-
traumatic OA ligaments (Chapter 2). This could suggest an important role in OA for this L.F5 
subpopulation. Furthermore, L.F5-specific canonical pathway included the FGF pathway and 
L.F5-specific upstream regulators included two BMP receptors (Bmpr1b, Bmpr1a). Both FGF and 
BMP signalling are involved in chondrogenesis [320]. These findings confirm an important 
cartilage-like role for the L.F5 subpopulation and indicate potential pathways in ligament OA 
progression. 
 
4.4.2 Synovial fibroblast subpopulations and potential roles 
Synovial fibroblast clusters included a regulatory-related (S.F1), neuronal-related (S.F2) and a 
tendon-related (S.F4) subpopulation as well as an intermediary subpopulation (S.F3). 
In the S.F1 subpopulation, made up of 34% of all synovial fibroblasts, the top differentially 
expressed markers included Gdf10, Bmper, Sparcl1, Mmp3, Emb and Steap4 (Figure 4.17). From 
these markers, four are associated with disease progression: Mmp3 and Sparcl1 are upregulated 
in OA synovial fluid [321, 322], Steap4 is present in rheumatoid arthritis synovium [323] and 
Gdf10 is found in OA and rheumatoid arthritis synovial fibroblasts [324]. Furthermore, of the 
predicted S.F1-specific upstream regulators, Il11 is an inflammatory cytokine [325]. The 
relationship of S.F1 markers with disease progression suggests an important regulatory role for 
this large subpopulation. 
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S.F2 consisted of 27% of all synovial fibroblasts and its top differentially expressed markers 
(Figure 4.18) Basp1 and Slc4a4 have been linked to neuronal activity [326, 327]. Basp1 is also 
associated with rheumatoid arthritis in murine synovial fluid [328]. Furthermore, Chst1 marker is 
involved in the immune response [329]. From the S.F2 predicted upstream regulators, Mycn 
regulates neurogenesis [330] and is involved in disease progression including rheumatoid arthritis 
and OA [331]. Other upstream regulators, Tbk1 and Tlr7 regulate the innate immune response and 
are expressed in the synovium of rheumatoid arthritis patients [332, 333]. S.F2 markers and 
upstream regulators suggest a potential neuronal and immune activity for the S.F2 subpopulation.  
The S.F3 subpopulation consisting of 22% of all synovial fibroblasts, had top differentially 
expressed markers which largely lacked specificity and were also expressed in the S.F2 cluster 
(Figure 4.19). From the top differentially expressed S.F3 markers, two are associated with 
neuronal pathways including Stmn4 [334] and Calcrl [335]. Another marker, Has2 is expressed 
in healthy synovium and downregulated in OA and rheumatoid arthritis synovium [336]. Tbx5, 
another S.F3 marker, is upregulated in rheumatoid arthritis synovium [337]. From the predicted 
S.F3 upstream regulators, several regulate neuronal differentiation including Lhx1 [338] and Ascl1 
[339]. Other S.F3 specific upstream regulators included Dcn a known ligament SLRP marker [2]. 
S.F3 markers indicate that S.F3 has a role in neuronal activity and disease pathways similar to the 
S.F1 and S.F2 subpopulations suggesting that S.F3 is an intermediary subpopulation. 
The S.F4 subpopulation was the smallest synovial fibroblast cluster comprising 16% of all 
synovial fibroblast. Its top differentially expressed markers (Figure 4.20) included markers 
associated with other knee joint tissues, such as Kera, Scx, Fmod and Tnmd which are tendon-
associated markers [308] and Col11a1 which is found in multiple skeletal tissues including tendon 
[340]. Cilp2 is another S.F4 marker usually expressed in the cartilage intermediate layer and in 
the OA synovial membrane [341].Though these markers are associated with neighbouring tissue, 
Fmod and Tnmd are also expressed in healthy synovial fibroblasts [342, 343]. Furthermore, 
predicted upstream regulators of S.F4 included Otx2, a neuronal regulator [311], which was also 
found in the L.F3 subpopulation. S.F4 markers and upstream regulators indicate a tendon-like role 
of the S.F4 subpopulation. The presence of cartilage and tendon-associated markers in S.F4 could 
be due to contamination, however the fact that some of these markers have been found in synovial 




4.4.3 Ligament versus synovial fibroblast markers and subpopulations 
Fibroblast markers were first analysed separately in both ligament and synovial-derived cells. 
Ligament fibroblast markers showed many of the known tendon-ligament markers such as Dcn, 
Col1a2, Col3a1, Col1a1, Col6a1, Col6a2 and Col5a2 (Figure 4.7) which make up the dense ECM 
structure of the ligament [2]. The top 20 synovial fibroblast markers (Figure 4.16) had numerous 
overlaps with the top 20 ligament fibroblast markers (65%). Similar markers included Dcn, 
Col3a1, Col1a2, Gsn, Col1a1, Fstl1, Igfbp6, Serping1, Clec3b, Serpinf1, Col6a1, Tnxb and 
Pcolce. These results reinforce that ligament and synovial fibroblast markers are similar in their 
transcriptional profiles. 
Overlap between ligament and synovial fibroblast extended to their subpopulations. From the top 
20 differentially expressed S.F1 markers (Figure 4.17), 50% of them were also in the top 20 
differentially expressed L.F1 markers (Figure 4.8). From the S.F4 top 20 differentially expressed 
markers (Figure 4.20), 65% were also highly differentially expressed in the L.F3 cluster (Figure 
4.10). Overlap between ligament and synovial fibroblast subpopulations was also apparent in the 
combined synovial and ligament fibroblast UMAP. UMAP, an indication of transcriptional profile 
similarity, showed an overlap of regions between L.F1 and S.F1 cluster, between the L.F2, L.F4, 
S.F2 and S.F3 clusters, and between the L.F3, L.F5 and S.F4 clusters (Figure 4.23B). 
Besides similarities between the fibroblasts, comparison analysis of the two tissues revealed 
differentially expressed ligament subpopulation-specific markers. This included Cytl1 and Spp1 
which were not expressed in any synovial fibroblast cluster (Figure 4.23C). Cytl1 is a 
chondrogenesis marker [344] and Spp1 is a mineralisation and osteogenic regulator [345], and 
both were upregulated and downregulated in the L.F5 cartilage-like subpopulation (Figure 4.23C). 
Hence, these ‘ligament specific markers’ are only specific to a unique subpopulation of ligament 
fibroblasts and are not whole tissue specific. Whole tissue specific markers could not be identified. 
This is yet another example of the importance of fibroblast heterogeneity over tissue specificity 
and highlights the overlap between ligament and synovial fibroblasts. This is also further evidence 
that L.F5 subpopulation plays a unique role in the ligament, a role not found in the neighbouring 
synovial fibroblasts. 
 
4.4.4 Current literature 
A cellular atlas of knee joint ligaments does not currently exist. However, as previously 
mentioned, two recent publications identified cell populations in mouse Achilles tendon [236] and 
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in pooled human tendons [235]. In the murine Achilles tendon, only two tendon fibroblast 
subpopulations were identified [236], demonstrating less fibroblast heterogeneity when one 
tendon was sequenced. Murine Achilles tendon fibroblast subpopulation 1 (TF1) had high 
expression of Spp1 [236], the previous identified ligament subpopulation specific marker (Figure 
4.23C), which is evidence that Spp1 is not ligament tissue specific. Furthermore, Acan was also 
highly expressed in the Achilles TF1 subpopulation, as well as Scx and Mkx [236]. In our ligament 
samples, these markers were found in two different subpopulations (L.F5 and L.F3). These could 
be differences in transcriptional profiles between tendons and ligaments or, more likely, 
differences in specific tissues (Achilles vs pooled knee ligaments) and their function. This 
research highlights the importance of mapping individual tissues, allowing for a better 
understanding of fibroblast heterogeneity and the roles of subpopulations. Future research should 
focus on mapping individual ligaments and microanatomical sites (enthesis, midbody). 
Pooled human tendons (from the knee, ankle, and foot), also revealed high fibroblast 
heterogeneity similar to our results, including five tendon fibroblast subpopulations [235]. 
However, this study used cellular indexing of transcriptomes and epitopes by sequencing, also 
known as CITE-seq analysis [235] which combines scRNA-seq with a panel of surface epitopes 
which can achieve more detailed cellular identification [346]. In the pooled human tendon 
samples, a small fibroblast subpopulation also had cartilage-associated markers including Comp, 
Pcolce2 and Cilp, however there was no expression of Col2a1 which was attributed to the lack of 
cells from the tendon-bone enthesis [235]. It is possible that Col2a1 and Acan-expressing 
fibroblasts is a difference between murine and human tendons-ligaments. However, both studies 
showed a cartilage-like fibroblast subpopulation which could have important disease applications 
and needs to be properly characterised. 
Recent transcriptomics of the human knee synovial cell populations using scRNA-seq found two 
distinct synovial fibroblast subpopulations with similar markers from those in our murine synovial 
fibroblasts but distinct clustering (labelled Fibro 1, Fibro 2a-b) [249]. In Fibro 1, genes 
differentially expressed included Mmp3, Thbs4 and Cd55 [249]. In our murine synovial fibroblasts 
these markers were expressed in different clusters, mainly Mmp3 in S.F1 (Figure 4.17), Thbs4 in 
S.F4 (Figure 4.20) and Cd55 in S.F2 and S.F3 (not shown here). Additionally, Thy1 (CD90) was 
a prominent differentially expressed marker in the human synovial Fibro 2 subpopulation [249], 
however this marker was present in all the murine synovial fibroblasts (not shown here). 
Differences in these markers between human and murine synovial fibroblasts could highlight 
important species-specific differences. 
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A separate scRNA-seq analysis of diseased human knee joint synovial tissue revealed four distinct 
fibroblast subpopulations (F1-F4), each with specific differentially expressed markers: Cd34 (F1), 
Hla-dra (F2), Dkk3 (F3) and Cd55 (F4) [237]. In our murine synovial fibroblasts, both Cd34 and 
Cd55 were present in the S.F2 and S.F3 clusters (not shown here), Dkk3 was present in the S.F4 
cluster (not shown here), and Hla-dra was not present. These two studies [237, 249] on human 
synovial fibroblasts highlight potential species-specific differences but differences in markers 
could also be due to different methodologies (cell isolation, sample preparation, single-cell library 
creation). These findings confirm that cellular heterogeneity in synovial fibroblasts remains 
poorly understood. 
 
4.4.5 Limitations of the study 
This study is limited by several tissue and analytical factors. The first general limitation is the 
samples and murine tissue used, which only gives a snapshot of one age, strain, and gender of 10-
week-old C57BL/6J male mice. Additionally, there were limitations in tissue size and sample 
preparation. As previously mentioned, the small size of murine tissue could be a cause for 
potential cross-contamination of our sample, especially considering that the synovial membrane 
directly borders the collateral ligaments (Figure 4.B-C). Furthermore, pooling ligament and 
synovial samples together might give rise to more heterogeneity. This finding is particularly true 
for the ligament fibroblasts which had a greater number of subpopulations compared to the 
synovial fibroblasts. Different types of knee joint ligaments (extracapsular/intracapsular), which 
were pooled together, could be host to diverse fibroblast subpopulations. However, sample tissue 
pooling was necessary in large part to ensure recovery of enough cells for scRNA-seq analysis. 
Methodologies for scRNA-seq are still evolving, however sample preparation and downstream 
analysis are the main determinant factors [247]. Sample preparation has been shown to limit the 
quality of RNA reads and the method for normalisation during downstream analysis has been 
shown to dominate pipeline analysis performance [247]. Our sample preparation ensured the 
highest quality cells, however during cell isolation optimization we could only measure cell 
viability and not RNA library quality. Cellular bias based on the cell isolation technique is also 
an important factor to consider with scRNA-seq. This is particularly important with less cellular 
and matrix-rich tissue such as ligaments, where enzymatic digestion could result in bias towards 
smaller or more robust cells which are easier to isolate. To account for this, the cell isolation 
protocol also included mincing of the ligament sample, to allow the release of cells from all areas 
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of the tissue. However, sequencing results for the ligament-derived cells included an initial 5,574 
cells, which were filtered due to low UMI count or mitochondrial genes into the final 2,165 cells 
which were analysed. It is possible that in this filtering step we are only analysed the most ‘robust’ 
cells unaffected by the enzymatic isolation. In addition, enzymatic isolation has also been shown 
to introduce a transcriptional bias due to the cellular stress-response [347]. Despite these 
limitations enzymatic digestion has been extensively used for tendon cell isolation for RNA-seq 
[235, 236, 251, 348, 349]. One possible way to prevent such bias is the use of single-nucleus 
sequencing, another isolation technique that requires snap freezing tissue, dissection of tissue and 
a detergent buffer for the release of nuclei [350]. Studies comparing single-cell vs single-nucleus 
RNA-seq in tumors have found similar cell populations with slight varying proportions of cells 
[350]. This would suggest that enzymatic digestion is still able to capture nearly all cell types and 
the high-resolution capacity of single-cell sequencing ensures that all cell types are represented. 
In terms of transcriptomics, 10X Genomics single-cell 3’ assay also includes some limitations 
since it only capture polyadenylated transcripts, found in most eukaryotic messenger RNA 
(mRNA) [351] and some long noncoding RNAs and precursor pri-miRNAs [352] but does not 
capture the whole transcriptome. While this is a limitation, polyadenylated transcripts are 
sufficient for the purposes of this study to determine fibroblast subpopulations. RNA stability is 
another important potential limitation. In this regard, polyadenylated tails in eukaryotic mRNA 
offer some protection from mRNA decay by acting as stabilisers [353]. However, mRNA decay 
can still occur and time of processing is particularly important for RNA quality of tendon tissue 
[354]. For this reason, our protocol aimed to shorten the time necessary for enzymatic digestion 
and cell isolation. Generally, mRNA most likely to decay first includes mRNA that code for 
transcriptional factors which have shorter half-lives (< 2h) while protein encoding mRNAs have 
longer half-lives [355]. This is an important limitation to consider, which could limit the number 
of transcriptional factors important to properly characterise cluster function and pathway analysis. 
Data analysis for differentially expressed markers and for predicted enriched canonical pathway 
and upstream regulators is also limited based on methodology and software used. Pathway 
analysis is limited by the IPA software which allocates genes to pathways curated from literature 
which will only highlight known and studied pathways and upstream regulators. Further research 
is needed to better understand fibroblast signalling pathways, particularly in the knee joint. 
Despite these limitations, our findings provide a preliminary atlas of ligament and synovial 





Through scRNA-seq analysis, we identified distinct ligament and synovial-derived cell clusters 
and categorised ligament and synovial fibroblast subpopulations based on their transcriptional 
profiles. In the murine ligament, nine distinct cell types were found including five ligament 
fibroblast subpopulations with distinct markers and associated functions (Figure 4.7). Ligament 
fibroblast subpopulations included L.F1 with mineralisation-related markers, L.F2 with 
inflammatory-related markers, LF3 with tendon-related markers, L.F4 with sensory-related 
markers and L.F5 with cartilage-related markers (Section 4.4.1). The L.F5 subpopulation was of 
particular interest due to the presence of cartilage (Acan) and OA associated markers (Figure 
4.12). Presence of an ACAN-expressing fibroblast subpopulation in the mid-ligament region of 
the PCL was confirmed with an Acan-Cre-tdTomato reporter line (Figure 4.22). This data 
indicates five ligament fibroblast subpopulations each with unique markers and likely roles during 
homeostasis and disease progression that remain to be explored. 
Murine synovial fibroblasts had less numerous subpopulations but similar differentially expressed 
markers to the ligament fibroblasts. Synovial fibroblast subpopulations included S.F1 with 
regulatory-related markers similar to those of L.F1, S.F2 with neuronal-related markers, S.F3 an 
intermediary subpopulation, and S.F4 with tendon-related markers similar to those of L.F3 
(Section 4.4.2). Many synovial and ligament fibroblast differentially expressed markers 
overlapped (Section 4.4.3), highlighting fibroblast similarities between neighbouring tissues of 
the joint organ. 
Overall, the identification of these ligament and synovium fibroblast markers provides a strong 
foundation to explore ligament and synovial fibroblast heterogeneity and spatial identity of each 
subpopulation. This also provides a baseline to compare joint organ fibroblast subpopulations in 
healthy and diseased murine tissue to further explore disease pathways and potential biomarkers 





























5.1 General Discussion 
Ligaments are important biological structures in the knee joint, crucial to the function of the 
musculoskeletal system. Damage to the ligament is a common musculoskeletal injury primarily 
due to ageing and or trauma [21], and though healing potential can vary, the ACL is considered 
to have a low healing potential [37] resulting in pain, immobility and the development of 
degenerative joint diseases such as OA [112]. The link between ligament trauma and OA 
development has long been established. However, ligaments might play a larger role than 
originally thought in OA development, and several findings have shown that ligament 
degeneration occurs before cartilage degeneration without initial trauma in human [207] and 
animal knee joints [121]. The biological and mechanical role that ligaments play for normal knee 
joint homeostasis is not well understood, even more so during OA development. 
The aim of this project was to characterise and identify markers and mechanical properties in 
healthy and OA ligaments. Ligament pathology is often ignored when exploring OA, and this 
research would allow for an overview of healthy ligament biology and of ligament changes during 
OA pathology which could potentially uncover clues of the involved cells and OA pathways in 
the knee joint organ [6]. 
In this study, murine post-traumatic and spontaneous OA models were chosen to explore OA 
pathology in the early and late stages of disease progression. Despite differences in gait and weight 
distribution, the murine knee joint ligaments have a similar function and anatomy to the human 
knee joint [13]. Furthermore murine spontaneous OA models offer many similarities to human 
OA disease pathology, including with spontaneous OA models such as the STR/ort mice [118]. 
In addition, the post-traumatic OA non-invasive mechanical loading murine model allowed us to 
explore early stages of ligament injury and post-traumatic OA with all ligaments intact [153]. It 
was hypothesised that in both the post-traumatic and spontaneous OA models we would see 
changes in the ligament matrix, cellular markers and viscoelastic properties that coincided with 
disease progression. 
Our results confirmed changes during OA in the ACL ECM (Section 2.3-2.6) and viscoelastic 
properties (Section 3.3). In the post-traumatic and spontaneous OA murine models, the ACL ECM 
changes in the early stages of OA included proteoglycan and COL2 deposition in the mid-ligament 
region and at the tibial enthesis, as well as evidence of thicker collagen birefringence in the tibial 
enthesis (Section 2.5 and 2.6). These ECM changes corresponded with decreased viscoelastic 
strain rate sensitivity in both murine OA ACLs, as well as decreased mechanical stiffness (tangent 
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modulus) and an increase in viscoelastic stress-relaxation in the post-traumatic OA ACL (Section 
3.3). ECM and cellular changes indicate that ligament structure was compromised during early 
stages of OA, opening the possibility that ligaments could play an active role in OA progression. 
This active role of ligaments needs further investigation. Viscoelastic changes in the OA ligaments 
further confirmed that ligament function and ECM viscoelasticity were affected and could 
likewise contribute to ligament and whole joint OA pathology. 
 
5.2 Extracellular matrix (ECM) changes in OA ligaments 
Changes in the OA ligament cellular morphology and ECM confirm the past work of Hasegawa 
et al. [129, 207], Quasnichka et al. [121], and Anderson-MacKenzie et al. [114]. Hasegawa et al. 
showed that ACL degeneration can precede cartilage changes in OA in humans, and that ACL 
degeneration corresponded with chondroid metaplasia, with SOX9, RUNX2 and COL2 
expression [129]. Our results in Chapter 2 confirmed these findings, but also showed that 
chondroid metaplasia occurred in the early stages of OA before ligament degeneration, 
particularly at the ACL-tibial enthesis. Furthermore, we showed that these changes cell markers 
and ECM occur not only in the spontaneous OA models [114, 121] (Section 2.3.1 and 2.3.4), but 
also in the post-traumatic OA model where ECM changes also included COL2 deposition and 
ASPN expression (Figure 2.22) in the mid-ligament region. Expression of ASPN expression in 
the same area of chondroid metaplasia was also seen in the STR/ort ACL (Figure 2.4), indicating 
a potential role of ASPN in OA ligaments. Overall, our results confirm previous findings seen in 
human OA also occur in murine OA at early stages of disease progression. In addition, our results 
indicate that both post-traumatic and spontaneous OA follow similar pathways of chondroid-like 
cells, therefore understanding the driving force of chondroid metaplasia, by chondrogenesis or 
endochondral ossification is important to understand both OA models. 
 
5.2.1 Proteoglycans 
As mentioned previously, proteoglycan composition in the ligament ECM is often overlooked but 
is particularly important for ligament fibre formation [29] and for water retention and viscoelastic 
properties [2, 122]. Deficiencies in decorin and biglycan have been shown to affect strain rate 
sensitivity and viscoelastic behaviour [69, 79]. Robinson et al. theorised that an increase in 
proteoglycan content (particularly GAGs) would increase strain rate sensitivity [69]. However, 
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this is the opposite of our findings, which found that strain rate sensitivity in OA ligaments 
decreased despite proteoglycan deposition seen with Toluidine blue staining (Section 2.3.1-4). 
This could indicate that individual proteoglycans (such as decorin or biglycan) or other ECM 
component, are responsible for strain rate sensitivity. It remains unclear how proteoglycans 
impede strain rate sensitivity and other viscoelastic properties and could provide further insights 
into the link between mechanics and cell response. Our study did not evaluate decorin or biglycan 
or quantify GAG content in OA ligaments, a limitation in this research which needs to be 
addressed. 
The only specific proteoglycan expression analysed in this study was ASPN, an SLRP lacking 
GAG chains necessary for water retention [193]. As previous mentioned, we identified ASPN as 
a potential marker of OA in the ACLs of post-traumatic (Section 2.3.3) and spontaneous OA 
murine models (Section 2.3.1). ASPN has been previously found in healthy ligament and tendons, 
usually surrounding fibroblasts [171]. Though the role of ASPN in the ligament remains unknown, 
it has been associated with a regulatory role in mineralisation [194] and its association with OA 
is not new. ASPN is upregulated in OA cartilage and involved in the TGF-β signalling pathway 
[356]. Our results showed ASPN colocalization in areas with changes in rounded cell morphology 
and COL2 deposition (Section 2.3.1 and 2.3.3). This is further evidence that ASPN plays a 
regulatory role in OA, particularly in ligaments and needs to be further explored. 
As previously mentioned, proteoglycan content has been shown to increase in the synovial fluid 
after trauma [108] and in the ACL before ligament rupture [125]. Therefore, proteoglycan 
deposition in OA is not a new concept and could allow for more water content and viscous 
behaviour, potentially as a protective effect from trauma or OA. The role of proteoglycans 
deposition in OA is still not well understood including the pathways that activate proteoglycan 
deposition and could be an important biomarker for disease progression. Our research theorised 
that rounded-cell morphology associated with COL2 deposition could be responsible for 
proteoglycan deposition. Potential proteoglycans of interest include ASPN and also ACAN, which 
was expressed in the L.F5 subpopulation (Figure 4.12), and is another proteoglycan previously 
associated with OA [177]. 
 
5.2.2 Collagen type II (COL2) 
Similarly the role of COL2 on ligament biology and mechanical properties remains relatively 
unknown. Collagen composition is essential for ligament stiffness and function [69], and is 
226 
 
considered the basic building block of ligament and tendon fibres [69]. Meanwhile, COL2 
deposition in tendons and ligaments has been associated with the fibrocartilaginous region and 
adaptation to compressive load [30, 357] as well as with disease and ageing [358], including in 
human OA ligaments [129] and guinea pig OA ligaments [121]. Our findings confirmed these 
results on COL2 deposition associated with OA disease progression, but also showed that this was 
not limited only to ligaments (ACL and MCL), but also to the fibrous region of the menisci 
(Section 2.3.1-4), reinforcing the idea that this is a whole joint pathology. 
COL2 could be involved in ligament ECM biomechanical properties and potentially OA 
progression. As previously mentioned, COL2 stiffness [232] could potentially account for the 
decrease in ligament stiffness seen in the post-traumatic OA ACLs (Figure 3.26). Furthermore, 
COL2 deposition was also seen in the mid-ligament region of 12-week-old CD1 spontaneous OA 
ACLs (Figure 2.33) and more importantly, COL2 deposition in 12-week-old mice preceded 
cartilage lesions (Figure 2.28). Therefore, if COL2 deposition affects ligament viscoelastic 
properties and biomechanical pathways, it could be an early trigger for spontaneous OA 
progression. Interestingly, COL2 denaturation is seen in early OA in articular cartilage as well as 
synthesis of damaged COL2 molecules [359]. It is possible, that the same pathways are initiating 
COL2 synthesis in the ligaments and menisci.  
Overall, COL2 deposition occurred in both the spontaneous and post-traumatic OA ligaments 
including at early stages of OA progression in both the ligament enthesis and mid-body regions 
associated to areas with rounded chondroid-like cells. Understanding COL2 synthesis in the 
ligament could provide further insights in OA pathology. 
 
5.2.3 Other collagens 
Other collagens could also affect ligament mechanical properties in OA. Collagen type III is 
another component of the healthy ligament ECM [2] which is upregulated in areas of ligament 
injury resulting in lower mechanical stiffness [357]. Moreover collagen V mutations also account 
for a decrease in ligament stiffness maximum load and resulted in secondary OA progression 
[141]. Collagen type I, III and V expression were not directly explored in this study. However, 
polarised PR staining demonstrated an increase in red collagen birefringence indicative of thicker 
collagen organisation [167] in the enthesis and epiligament layers of both the post-traumatic 
(Section 2.5) and spontaneous OA ACLs (Section 2.6). These changes in collagen organisation 
did not result in stiffer mechanical properties of the ACL as could be expected from thicker 
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collagen fibres (Section 3.3). Despite this, past studies have shown that collagens are important 
in ligament mechanics, therefore evaluating the full collagen blueprint in the healthy and diseased 
ligaments is necessary to determine the role of collagens in ligament mechanics and in OA.  
 
5.2.4 Mineralisation 
Other OA pathologies seen in OA ligaments included evidence of mineralisation. Mineralisation 
was found mainly in the MCL and the outer menisci regions in the late stages of OA development 
in all murine OA models except the post-traumatic non-invasive loading model (Section 2.3-2.6). 
Changes in the medial compartment during OA have been attributed to an increase in weight 
bearing forces [174]. Unfortunately, our study did not measure the mechanical properties of the 
MCL, however this is in line with past studies which found an increase in MCL stiffness in OA 
patients [140]. This could indicate that the MCL could also play an active role in OA progression, 
and deserves further consideration. 
Mineralisation of the joint space was quantified with µCT, a new but powerful methodology to 
quantify OA progression [165]. Mineralisation of joint space was quantified in the novel CD1 
spontaneous OA murine OA model and mineralisation increased from 12 to the 24-week-old knee 
joints (Figure 2.29). This mineralisation did not result in stiffer tangent modulus of the ACL 
between these two age groups (Figure 3.19), likely explained by the fact that increased 
mineralisation occurred mainly in the medial compartment (consisting of the medial menisci and 
MCLs) (Figure 2.29). Changes of cell morphology, SOX9 and RUNX2 expression, collagen 
birefringence and COL2 and proteoglycan deposition was always found in areas surrounding 
mineralisation (Section 2.3-2.6), therefore it is possible that these changes are associated, 
potentially through endochondral ossification pathways. More evidence is needed to confirm what 
is driving this increase in mineralisation, which likely have a major impact in knee stiffness and 
pain often associated with OA [6]. 
Overall, we can conclude that in the early stages of OA ligament ECM is severely affected and in 




5.3 Viscoelastic changes in OA ligaments 
In this study, mechanical testing of the ACL provided further evidence of ECM changes during 
OA. It is also important to note that differences in the strain rate sensitivity were found in the 
normalised tangent modulus-stress curves at higher strain rates (1%/s vs 10%/s) of both the 
spontaneous and post-traumatic OA models (Figure 3.21 and Figure 3.28). Changes at higher 
strain rates could be more physiologically relevant, strain rates of normal tendon function in 
horses exceeded 200%/s [360]. Normal strain rates in mouse tendons and ligaments have not been 
described. At higher strain rates, collagen fibril strain has been found to be more prevalent than 
global tissue strain, and this has been speculated to be due to less time for water content to 
dissipate and allow for viscous behaviour of non-collagenous ECM components [361]. Since 
strain rate sensitivity was lacking at higher strain rates of the OA ligaments, it is possible that 
collagen content could be responsible for this mechanical change. 
It is also worth mentioning that in our mechanical analysis no differences between healthy and 
OA ligaments were found in some viscoelastic properties including stress-strain curves and 
hysteresis (including hysteresis strain rate sensitivity) (Section 3.3.5-6). These results could be 
attributed to high standard deviation particularly in the stress-strain curves within our ACL 
samples discussed in Chapter 3 and could also be due to our testing methodology with varied from 
past studies on murine ligaments [114, 141, 148]. Similar to strain rate sensitivity, hysteresis is 
also believed to be regulated by proteoglycan content [73]. However, our results found no 
differences in hysteresis despite proteoglycan deposition in all OA ACLs. Furthermore, it is 
unclear why strain rate sensitivity was compromised in stress-strain curves but not in hysteresis 
strain rate sensitivity. This could in part be due to error in our mechanical analysis which resulted 
in negative hysteresis at higher strain rates (discussed in Section 3.4.3). These findings however 
also agree with several studies that showed that GAG depletion did not affect MCL viscoelastic 
behaviour (including hysteresis) [77] as well as canine ACL viscoelastic behaviour [61]. 
Therefore, it is possible that different ECM components are affecting hysteresis other than 
proteoglycans. The mechanical role of proteoglycans is currently under debate and could be tissue 
specific, as has been shown with collagen type V [204]. 
Mechanical testing of our murine OA ACLs did not find differences in the material strength as 
measured by in the ultimate load to failure in both murine OA models (Section 3.3.5-6). This does 
not concur with past studies on OA ligaments which found a decrease in ultimate load [114]. We 
theorised that this could be due to different OA models used and different timepoints in OA 
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progression. Our findings could suggest that viscoelastic properties are more prominent than 
material properties in these stages of OA and could be a useful diagnosis tool to measure OA 
progression. This also highlights the importance of understanding the underlying ECM 
components affecting viscoelastic behaviour, which can further elucidate OA pathology. 
The driving force of these ACL ECM compositional changes is likely due to the ligamentocytes. 
Hagesawa et al. postulated that the rounded chondrocyte-like cell types contribute to COL2 
deposition and abnormal ECM production [129], and therefore could consequently be driving 
changes in the ligament viscoelastic properties. Our findings confirmed the co-localisation of 
rounded-cell morphology with SOX9 and RUNX2 expression and COL2 and proteoglycan 
deposition (Section 2.3.1-4). This cartilage-like population has been previously seen in healthy 
and high-rupture risk canine ACLs [20, 122]. COL2 deposition was also seen in the 12-week-old 
CD1 ACLs (Figure 2.33), which could be a result of these chondrocyte-like fibroblasts similar to 
those seen in canine ligaments with a high-rupture risk [122]. These chondrocyte-like cells could 
be an important fibroblast subpopulation driving OA ECM changes and consequently viscoelastic 
properties. 
Overall, ligament viscoelastic properties, particularly normalised strain rate sensitivity at high 
strain rates, were affected in both the spontaneous and post-traumatic OA ACLs at the early stages 
of OA. This is evidence that ligament function is an important OA factor regardless of aetiology. 
The ECM changes mentioned previously, proteoglycan and COL2 deposition could be responsible 
for these viscoelastic properties. 
 
5.4 Ligament fibroblast subpopulations 
To understand these activated cellular pathways, a better understanding of the innate 
ligamentocytes during healthy ligament homeostasis is necessary. This includes identifying 
fibroblast subpopulations and their roles beyond ECM production. Fibroblasts roles have been 
shown to range from ECM production [2] to sensory [310], and even regulating differentiation 
[362]. However, fibroblasts heterogeneity [239], raises the question that not all fibroblasts are 
equal, and roles could be fibroblast-specific. To understand this, it is necessary to look at the 
single-cell level, including the spatial organisation and the encompassing ECM, which could also 
affect fibroblast phenotype. 
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To address this, our final goal was to categorise ligament fibroblast markers and subpopulations, 
the beginning of a ligament cellular atlas, which is fundamental to identify future biomarkers. It 
was hypothesised that distinct ligament fibroblast subpopulations could be identified using 
scRNA-seq. ScRNA-seq successfully identified nine distinct cell types including five ligament 
fibroblast subpopulations (L.F1-5) (Section 4.3.2). Interestingly, know tendon-ligament markers 
were mainly concentrated in one fibroblast subpopulation (L.F3) and markers included Scx, Tnmd, 
Mkx and Fmod (Figure 4.10). This would indicate that these markers are not as widespread in 
ligaments as previously thought and is similar to the findings in murine tendons [47]. Many of the 
other fibroblast subpopulations (L.F1-2, and L.F4) had a range of markers with relatively 
unknown functions within ligaments.  
The scRNA-seq approach used for this study was novel for murine ligaments, though it has 
previously been used to identify cell populations for mouse [236] and human tendon [235] and 
synovium [249]. Our results demonstrated many similarities in fibroblast heterogeneity between 
murine ligament and synovium tissue including subpopulations and markers (Section 4.3.5). This 
matches the similar pathological changes seen in the OA menisci and ligaments of all the murine 
OA models (Section 2.3-2.6), and could imply that connective tissues in the knee joint share 
similar fibroblast subpopulations, further evidence of the knee joint organ [6]. Fibroblast 
heterogeneity has revealed the true cellular complexity within these matrix-rich connective 
tissues, uncovering new markers and roles in healthy and subsequently in diseased tissue. 
Overall, we were able to identify distinct ligament fibroblast subpopulations with diverse markers 
which indicate diverse functions for each subpopulation. 
 
5.4.1 The L.F5 subpopulation 
Ligament fibroblasts also included a cartilage-like subpopulation (L.F5) that had a high 
expression of cartilage-associated markers (Acan, Col2a1 and Sox9) (Figure 4.12). While this is 
not novel, SOX9 and COL2 expression are present in the fibrocartilaginous insertion sites [318] 
and have been found in the mid-ligament region of canine ACLs [20, 122]. Our results, via a 
transgenic Acan-reporter mouse line, confirmed that ACAN expressing cells were found in the 
mid-ligament section of healthy murine ligaments (Section 4.3.4). Our scRNA-seq analysis not 
only confirms Acan-fibroblasts but indicates the presence of an entire cartilage-like fibroblast 
subpopulation with multiple cartilage-associated markers throughout the healthy ligament. These 
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findings question the definition of cartilage-specific markers, introduces a new dimension to 
fibroblast heterogeneity and potentially a new role to ligament fibroblasts. 
The L.F5 markers were remarkably similar to the markers expressed in the rounded-cell 
phenotype ligamentocytes seen in the post-traumatic and spontaneous OA ligaments (Sox9 and 
Col2a1) (Figure 4.12). It is possible that the L.F5 fibroblast subpopulation are the cells undergoing 
the rounded morphological change and are activated during OA resulting in SOX9 and COL2 
translation and expression. Understanding the underlying pathways of this native L.F5 
subpopulation is of particular importance for future therapeutic targets of OA. For example, SOX9 
has been shown to promote healing in the bone-tendon-junction [363], therefore activation of this 
gene could simply be a protective or healing effect. How this L.F5 ligamentocyte subpopulation 
contributes to healthy ligament homeostasis and to OA progression and interacts with other 
fibroblast subpopulations remains to be seen. Understanding this subpopulation, as well as the 
other relatively unknown subpopulations could reveal additional roles of the ligament fibroblasts 
in knee joint health. 
 
5.5 Future Directions 
Future research should continue to characterise the material and viscoelastic properties of all knee 
joint ligaments. This will allow for the creation of a comprehensive knee and ligament 3D model. 
Modelling the knee joint with all ligaments could give insights of whole knee mechanics and 
differences between healthy and diseased knee joints [364], which can be used to diagnose OA 
progression and ligament mechanical properties in patients without invasive procedures. In 
addition, finite element 3D modelling of the OA knee joint could predict areas of mechanical 
stress which trigger mechanotransduction pathways. This modelling has already been shown to 
be effective in articular cartilage [364]. 
There is also an emerging field of biomechanics focusing on revealing which aspects of the 
ligament ECM control specific mechanical properties [365]. This includes determining the role 
that proteoglycans play in ligament mechanics and can be revealed by characterising all 
proteoglycan content and other important matrix components (i.e. elastin) in healthy and OA 
ligaments. This would allow us to determine which ECM components are affecting strain rate 
sensitivity and give a better understanding of ECM biomarkers of OA progression. Furthermore, 
how the viscous ECM affects the biomechanical response of native ligament fibroblasts is a vital 
next step to finally expose elusive mechanotransduction pathways [224]. To do this, we must first 
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identify and characterise which cells in the ligament matrix can sense the ECM. In this study, 
scRNA-seq analysis potentially identified a sensory-related fibroblast subpopulation (L.F4). 
Confirming the role of this subpopulation could be key to determine if ligaments play an active 
role in OA pathology. Healthy sensory cells can be compared with those of less stiff or diseased 
ligaments to discover which factors govern the sensory switch between the two states. 
In the future, scRNA-seq could also be used in conjunction with machine learning to reveal OA 
progression and predict regulatory networks and signalling pathways in diseased ligaments [366]. 
Currently, scRNA-seq has predicted upstream regulators of synoviocytes and chondrocytes from 
OA tissue and revealed molecular crosstalk networks between the two tissues [367]. For a better 
understanding of these outcomes, in situ hybridization or spatial transcriptomics can also be used 
to analyse which regions of the ligaments are affected during OA progression, thus creating a 
detailed molecular map of cells and their surrounding ECM [368]. These techniques could allow 
for more in depth analysis of specific regions of interest, as has been done recently on 
inflammatory regions of synovial tissue from rheumatoid arthritis patients to analyse the immune 
response [369]. 
Since the aetiology of OA is complex and multifactorial [6], transcriptomics will only provide 
one layer of information about disease progression. For a more complete understanding of knee 
joint organ OA, a multi-omics data approach will most likely be necessary to understand the 
epigenome, proteome and metabolome mechanisms of disease [370]. Integrative analysis of 
multiple omics data could be used for a multimodal definition of cellular identity which improves 
cell type characterisation and function [371] and could allow for identification of more 
biologically relevant biomarkers.  
 
2.6 Conclusions 
The work detailed in this thesis demonstrated markers present in the ligament tissues in the early 
and late stages of post-traumatic (DMM and non-invasive loading) and spontaneous (STR/ort and 
CD1) murine OA models. This study confirmed changes in the ACL and MCL matrix including 
toluidine blue staining indicative of proteoglycan deposition, red collagen birefringence indicative 
of thicker collagen fibres and COL2 deposition occurring at the insertion sites and in some cases 
in the mid-ligament region. Furthermore, we also confirmed changes in the fibroblast cell 
phenotype including rounded-cell morphology with SOX9 and RUNX2 expression, as well as an 
increase in ASPN SLRP expression. Changes in ACL ECM composition associated with changes 
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of the ligament viscoelastic properties, particularly normalised tangent modulus-stress strain rate 
sensitivity which was reduced in both the murine spontaneous (CD1) and post-traumatic (non-
invasive loading) OA ACLs. Furthermore, post-traumatic OA also resulted in decreased 
viscoelastic stiffness and stress-relaxation, highlighting the important role of the ECM on 
viscoelastic properties. These findings confirm that OA pathological changes do affect ligament 
function (and potentially vice-versa). This study was also the first to use scRNA-seq to identify 
cell population in murine knee joint ligaments. Nine distinct cell types and five ligament 
fibroblasts subpopulations (L.F1-5) were successfully identified. Characterisation of these 
ligament fibroblast subpopulations and their role will be instrumental to discover ligament-related 
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Sup Fig 1 Load-elongation curves of the first ten preconditioning cycles from each murine group of all samples 
discarded from analysis. Samples were removed from the healthy ageing group 24-week-old ACLs (A), spontaneous 
OA 12 (B) and 24-week-old (C) ACLs, and the post-traumatic non loaded (D) and loaded (E) ACLs. Samples removed 
from analysis had a greater than 5% increase in elongation during preconditioning. This increase in elongation is due 




Sup Fig 2 Representative load-elongation curves during preconditioning from each murine group. Groups included the 
Healthy ageing group (A), spontaneous OA group (B) and post-traumatic OA group (C). These samples showed minimal 






#Synovial data file was created from matrices provided by 10X Genomics 
S2.raw <- Read10X(data.dir="S2_10000ec/outs/…") 
 
#Use Vlnplot to see raw data features and mitochondrial gene percentage 
> VlnPlot(S2.raw, features = c("nFeature_RNA", "nCount_RNA", "percent.mt"), n
col = 3) 
 
> #Filter cells, keep cells with <10% mit and >200 and <3000 features. 
> S2.flt4.norm <- subset(S2.raw, subset = nFeature_RNA > 200 & nFeature_RNA < 




> VlnPlot(S2.flt4.norm, features = c("nFeature_RNA", "nCount_RNA", "percent.
mt"), ncol = 3) 
> FeatureScatter(S2.flt4.norm, feature1 = "nCount_RNA", feature2 = "percent.
mt") 
> #Now normalize data 
> S2.flt4.norm <- NormalizeData(S2.flt4.norm, normalization.method = "LogNor
malize", scale.factor = 10000) 
> #Now, identify highly variable features 
> S2.flt4.norm <- FindVariableFeatures(S2.flt4.norm, selection.method = "vst
", nfeatures = 3000) 
> # Identify the 10 most highly variable genes 
> top10 <- head(VariableFeatures(S2.flt4.norm), 10) 
> # Plot variable features with and without labels 
> plot1 <- VariableFeaturePlot(S2.flt4.norm) 
> plot2 <- LabelPoints(plot = plot1, points = top10, repel = TRUE) 
> #Now scale the data 
> all.genes <- rownames(S2.flt4.norm) 
> S2.flt4.norm <- ScaleData(S2.flt4.norm, features = all.genes) 
> #Next run PCA 
> S2.flt4.norm <- RunPCA(S2.flt4.norm, features = VariableFeatures(object = S
2.flt4.norm)) 
> #Examine and visualize PCA results a few different ways 
> print(S2.flt4.norm[["pca"]], dims = 1:10, nfeatures = 5) 
> VizDimLoadings(S2.flt4.norm, dims = 1:10, reduction = "pca") 
> DimHeatmap(S2.flt4.norm, dims = 1:15, cells = 500, balanced = TRUE) 
> #Determining dimensionality 
> S2.flt4.norm <- JackStraw(S2.flt4.norm, num.replicate = 100) 
> S2.flt4.norm <- ScoreJackStraw(S2.flt4.norm, dims = 1:20) 
> JackStrawPlot(S2.flt4.norm, dims = 1:20) 
> #Significant dims chosen were dims 1 to 20 
> #Cluster cells 
> S2.flt4.norm <- FindNeighbors(S2.flt4.norm, dims = 1:20) 
> S2.flt4.norm <- FindClusters(S2.flt4.norm, resolution = 0.5) 
> #Run UMAP to visualize clusters 
> S2.flt4.norm <- RunUMAP(S2.flt4.norm, dims = 1:20) 
> DimPlot(S2.flt4.norm, reduction = "umap") 
 
> #Find markers of each cluster 
> cluster0.markers <- FindMarkers(S2.flt4.norm, ident.1 = 0, min.pct = 0.25) 
> write.csv(cluster0.markers, file = "S2flt4norm_cluster0.csv") 
> #Repeat with all clusters 
 
> #With markers of each cluster we can identify each cluster 
> #Now we can change cluster labels 
> new.cluster.ids <- c("Syn fibroblasts 1", "Syn fibroblasts 2", "Immune cel
ls 1", "Syn fibroblasts 3", "Syn fibroblasts 4", "Immune cells 2", "Immune c
ells 3", "Red blood cells", "Endothelial cells", "Immune cells 4", "Immune c
ells 5") 
> names(new.cluster.ids) <- levels(S2.flt4.norm) 
> S2.flt4.norm <- RenameIdents(S2.flt4.norm, new.cluster.ids) 
> DimPlot(S2.flt4.norm, reduction = "umap", label = TRUE, pt.size = 0.5) 
 
> #For each cluster, we can visualize expression using Dotplot, Heatmap, Vln 
plot, and others, see examples below 
> DotPlot(object, features = c(“marker name”)) 
> DoHeatmap(object, features = c(“marker name”)) 
> FeaturePlot(object, features = c(“marker name”)) 
> VlnPlot(object, features = c(“marker name”)) 
> RidgePlot(object, features = c(“marker name”)) 
 
> #Make a fibroblast subset 
> S2.flt4.Norm.fib <- subset(S2.flt4.norm, idents = c("Syn fibroblasts 1", "
Syn fibroblasts 2", "Syn fibroblasts 3", "Syn fibroblasts 4")) 
> #Rename clusters as S.F1 to S.F4 
> new.cluster.ids <- c("S.F1", "S.F2", "S.F3", "S.F4") 
> names(new.cluster.ids) <- levels(S2.flt4.Norm.fib) 
> S2.flt4.Norm.fib <- RenameIdents(S2.flt4.Norm.fib, new.cluster.ids) 
> DimPlot(S2.flt4.Norm.fib, reduction = "umap", label = TRUE, pt.size = 0.5) 
> #Now can do FindMarkers again this time with the Fib subset, same as above
, see above code for FindMarkers 
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> #Can visualize expression with plots same as above, see DotPlot, DoHeatmap
, FeaturePlot, VlnPlot, RidgePlot 
 
 
> #Find markers between multiple clusters (ex all fibroblasts vs all other c
lusters) 
> FibClusters.markers <- FindMarkers(S2.flt4.Norm, ident.1 = c("Syn fibrobla
sts 1", "Syn fibroblasts 2", "Syn fibroblasts 3", "Syn fibroblasts 4"), iden
t.2 = c("Immune cells 1", "Immune cells 2", "Immune cells 3", "Red blood cel
ls", "Endothelial cells", "Immune cells 4", "Immune cells 5"), min.pct = 0.2
5) 
> write.csv(SynFibClusters.markers, file = "S2FibClustersMarkers.csv") 
 
Sup Fig 3 Rscript used for single-cell RNA-seq downstream analysis. The standard Seurat workflow was followed 
(https://satijalab.org/seurat/v3.1/pbmc3k_tutorial.html) and adapted according to our data and markers. The same 
workflow was use for the ligament sample, except for changes in the initial filtering of cells, see methods (Section 4.2.5) 
for the parameters used. 
 
 
